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ABSTRACT OF THE DISSERTATION

Etv2/Myct1 axis in the regulation of tumor angiogenesis and anti-tumor immunity
by
Ashraf Ul Kabir

Doctor of Philosophy in Biology and Biomedical Sciences
Molecular Cell Biology
Washington University in St. Louis, 2021
Professor Kyunghee Choi, Chairperson

Angiogenesis is a critical determinant of neoplastic growth and metastatic spread. As such, antiangiogenic approaches have long been tried to throttle down tumor progression. However, current
anti-angiogenic treatments so far have produced modest clinical benefits. Further in-depth research
has provided rationales behind these disappointing and apparent perplexing clinical outcomes. It
is now established that VEGF (vascular endothelial growth factor) and other prominent current
angiogenic targets are neither specific to the vascular system nor the pathological conditions
explaining the sub-optimal angiogenic control following the existing treatments. This suggests that
anti-angiogenesis could still be a viable strategy for cancer patients should there are targets
exclusive for tumor angiogenesis. The goal for my Ph.D. dissertation has been to identify novel
angiogenic targets and their mechanism(s) of action in controlling tumor angiogenesis and growth.
In aim 1, I have demonstrated that ETS transcription factor Etv2, which is critical for the
endothelial and hematopoietic development exclusively in the developmental phase but stays silent
xii

in the adult phase, is reactivated in the endothelium of both the human cancers and mouse models
of tumors. Etv2 deficiency renders the tumor vasculature similar to normal vessels and reduces
tumor growth. Oxidative stress in the tumor environment is likely the driver to initiate Etv2
expression in the endothelial cells.
Despite being a promising and exclusive target for tumor angiogenesis, it is challenging to
utilize Etv2 as a therapeutic target because transcription factors are generally considered nondruggable. To address this, in aim 2, I have identified Myct1, a direct downstream target of Etv2,
as a novel and endothelial-specific angiogenic gene. MYCT1 is a cell membrane-localized protein
that makes it targetable by antibody-mediated approaches. Myct1 deficient endothelial cells lose
migratory angiogenic phenotype in vitro and demonstrate normalized vascular functions in the in
vivo tumor models. Moreover, Myct1 deficiency promotes an anti-tumor immune
microenvironment that leads to limited tumor growth. Combined Myct1 targeting drastically
improves the outcome of the anti-PD1 immunotherapy in the mouse models.
The data presented in this dissertation have collectively identified the Etv2-Myct1 axis as
a novel endothelial-specific regulator of tumor angiogenesis and tumor immunity. Myct1-targeted
anti-angiogenic treatment could provide significantly better outcomes compared to the existing
treatments, especially in combination with the immune checkpoint blockade immunotherapy.

xiii

Chapter 1: Introduction
1.1 Cancer
Cancer is not one, but a collection of pathological conditions characterized by uncontrolled cellular
growth. It has arguably been the most feared and devastating disease of the modern era. In 2020,
more than six hundred thousand Americans, and more than ten million people worldwide will die
from cancer(1). In the United States, approximately one in two males and one in three females will
develop cancer in their lifetime, and about one in five of both the males and females will die from
cancer(2). By 2040, yearly death from cancer would cross 16 million around the world(1). Unlike
many other diseases, cancer is not limited to any specific site; instead, it can develop in any tissue
and later metastasize to other distant tissues from the primary sites, contributing to the devastating
outcomes of this disease. Moreover, cancers in different tissues, even in the same tissue in certain
instances, present diverse phenotypical and pathological features, making the formulation of a
successful treatment strategy further complicated.
To defeat a disease, we need to understand the disease first. Although the history of
cancer goes well past a couple of millennia, the perception of the different aspects of cancer has
morphed rather radically in the modern medical sciences era. Rigorous investigations throughout
the twentieth century have led to our current understanding of cancer biology. Cancer, as we now
know, develops when a cell starts to grow uncontrollably. This apparently simple biologic of
cancer—unabated cellular proliferation—reside at the core of this fatal disease and exemplifies
the incredible power of cell division and growth. Cell division under physiological supervision, a
1

defining feature of the normal cells, allows the body to grow, survive, and repair; however, when
unleashed, it allows the cancer cells to flourish and outcompete the normal cells that leads to the
eventual fatal outcome. We now understand that the cancer cells acquire a defined set of traits to
unleash the power of cell growth for themselves and influence the neighboring cells to be the
accomplices in this process. These traits, commonly referred to as the hallmarks of cancer, are
discussed in the next sections.

1.2 Hallmarks of cancer
Organisms have machinery and mechanisms in-built to govern cellular differentiation, growth,
homeostasis, and demise appropriate to the body’s holistic needs. These cellular and extracellular
governing circuitries act as a barrier, and when broken, normal cells transform into neoplastic cells
and develop cancer. Throughout the transformation process, cancer cells acquire specific abilities
to break the cellular regulatory control, which constitute the hallmarks of cancer cells(3).

1.2.1 Sustained growth signaling
Growth signaling is essential for the proliferation and maintenance of normal cells. In response to
different positive growth signals under physiological conditions, normal quiescent cells enter into
an active cell division state. Conversely, negative or antigrowth signals act on the normal cells to
keep them in a non-proliferative state. One of the hallmarks of cancer cells is to go beyond the
control of this growth and antigrowth signals. The growth and antigrowth signaling work through
a plethora of growth factors and extracellular structural molecules in combination with different
transmembrane signaling receptors and very complex and highly intricate intracellular
downstream molecular effector pathways. It has been established that cancer cells can produce
2

various growth factors, for example, PDGF (platelet-derived growth factor), EGF (epidermal
growth factor), and TGFa (tumor growth factor a), to have a self-sustaining autocrine growth
control(4-6). Cancer cells can also change the expression of the transmembrane receptors, such as
EGFRs and PDGFRs, to hypersensitize or desensitize themselves for the growth or antigrowth
signals, respectively. Additionally, many transmembrane receptors rely on their tyrosine kinase
domain activation for relaying growth signals. Cancer cells often have structurally modified
transmembrane receptors capable of auto-activation even in the absence of the growth signals(79). Similarly, most of the cancer cells produce some form of irregular or altered hyperactive
molecular components of the intracellular pathways, such as Raf-MAPK and Akt/PKB, enabling
them to amplify and sustain the growth signaling for uncontrolled growth(10-13). Moreover, the
molecular pathways present in the normal cells to check and prevent the cell proliferation and
commonly referred to as tumor suppressor programs, RB and TP53 pathways, for example, are
also often downregulated and inactivated in the cancer cells, helping them to circumvent the
growth-suppressive mechanisms(14-18).

1.2.2 Replicative immortality
In addition to the regulation through the growth signaling, normal cells have in-built multi-layered
machinery to limit cell proliferation to prevent cancerous development. The replicative potential
of any cell is largely defined by the length of the telomere, a short segment of specialized DNA
sequences resided at the ends of the chromosomes. With each round of cell division, the telomere
length gets eroded; once the telomere becomes shortened beyond a critical level, the unprotected
DNA ends lead to abnormal chromosomal fusion and eventual cellular destruction(19-22). Cellular
senescence and apoptosis are among the in-built features of normal cells to prevent the cells from
getting into chromosomal abnormality and eradicate the cells with said abnormalities. Cellular
3

senescence mechanisms trigger once any cell passes certain proliferation cycles, which puts the
cell into a viable but non-proliferative state. If the cell fails to trigger senescence, ensuing genomic
instability or other critical cellular stresses induce programmed cell death or apoptosis, which is
regulated by the delicate balance between the survival signals and the death signals with their
respective ligands and receptors, to ensure the eradication of an abnormal cell(22-26). Cancer cells
are known to evade these mechanisms at multiple levels. For example, most cancer cells highly
upregulate telomerase expression, an enzyme that replenishes the eroding telomere length by
adding hexanucleotide repeats to the end of the telomere to achieve essentially replicative
immortality(22, 23). Cancer cells are also known to skew the balance between the proapoptotic
and antiapoptotic signals by the loss of the proapoptotic regulators like RB and TP53 tumor
suppressor and proapoptotic factors like Bax, Bak, Bim, and Puma or by the enhancement of
antiapoptotic regulators like BCL2 and BCLXL and survival pathways like PI3 Kinase-AKT/PKB
with IGF1/2(27-33).

1.2.3 Altered metabolism
Glucose is the preferred fuel for cells to maintain the energy demand of the body. During aerobic
respiration, normal cells utilize glucose, initially to produce pyruvate by glycolysis in the
cytoplasm and later to generate carbon dioxide by oxidative phosphorylation in the mitochondria
for the most efficient and maximum energy production. Under the anaerobic conditions, as often
observed in muscle tissue during strenuous exercises, for example, glycolysis is the predominant
process with very minimum mitochondrial oxidative phosphorylation, leading to a suboptimal but
much faster rate of energy production. The unrestricted proliferation of cancer cells requires a
substantial and continuous supply of energy and molecular building blocks. As first described by
Otto Warburg and colleagues, cancer cells, even in the presence of oxygen, heavily rely on
4

glycolysis with minimal oxidative phosphorylation, a phenomenon identified as aerobic
glycolysis(34-36). Although inefficient in energy production, a closer look at the byproducts of
aerobic glycolysis explains the rationale of this metabolic reprogramming of the cancer cells.
Molecular intermediate byproducts of aerobic glycolysis are utilized in the de-novo biosynthetic
pathways of the macromolecules, which are essential to sustain cancer cell growth(37-40). To
compensate for the lesser ATP generation per unit glucose, cancer cells upregulate glucose
transporters, such as GLUT1, to facilitate massive glucose influx into the cells(41, 42). The faster
rate of ATP production also provides a competitive advantage to cancer cells compared to their
neighboring normal cells. Moreover, aerobic glycolysis reduces the pH of the local tumor
environment, further supporting growth by inducing tumor-promoting inflammation, DNA
damage, and pro-survival pathways(40, 43, 44).

1.2.4 Genomic instability
Genome is the black box of life. All the information relevant to an organism’s existence is
imprinted in their DNA, which makes the genome. For the protection of this invaluable asset,
organisms have developed exceptional guarding mechanisms that are evident with every biological
process involving the DNA. During mitotic division, a cell makes an exact copy of its’ DNA to
pass on the genetic information to the progeny through an extraordinarily regulated and supervised
process. A precancerous cell, to acquire the hallmark cancer traits, invariably brings diverse
mutational changes to the DNA employing different strategies including, but not limited to,
reducing the fidelity of the DNA replication process, defecting the DNA damage recognition and
repair signaling machinery, impairing the damaged DNA repair activities, disarming the in-built
protective mechanisms against potential mutagens, and inactivating the surveillance system that
triggers apoptosis of the genetically damaged cells(45-51). Compared to a normal cell, a
5

transformed cancerous cell contains an exponentially higher mutational burden that enables the
cell to generate high levels of normal or hyperactivated versions of pro-growth and pro-survival
signals and to produce inactivated versions or lower levels of growth suppressor, proapoptotic, and
malignancy surveillance signals for the characteristic uncontrolled cancer growth. Moreover,
histone proteins constitute the core architecture around which DNA wraps around to form the
genome. Equipped with different post-translational modifications, for example, methylation and
acetylation, histone proteins differentially dictate chromatin accessibility for DNA replication and
transcription, and hence act as a hierarchical regulatory body of the genome(52-54). Cancer cells
exploit these regulatory processes, collectively known as epigenetic regulation, to enhance the prosurvival and pro-growth and to suppress the anti-tumor regulatory gene programs to their
advantage to sustain growth(55-57).

1.2.5 Angiogenesis, Immunity, and Metastasis
Following the transformation of normal cells into a population of cancer cells in the body, there
come several challenges for the cancer cells to develop into pathologically manifesting tumors.
First, depending on the site of development, the growth of the cancerous mass is limited by the
availability of nutrients. As normal vasculature is not designed to support uncontrolled cellular
growth, instead acts as a barrier, cancer cells circumvent this by inducing angiogenesis.
Angiogenesis is the generation of new vessels from the preexisting vasculature in the surrounding
tissue and under physiological conditions observed in the female reproductive cycle and tissue
repair following an injury such as wound healing. Cancer cells hijack this process to create new
vessels to perfuse the developing tumor mass and ensure continuous blood and nutrients supply
for sustained growth(58). Next, different components of the immune system act as a barrier to
tumorigenesis by killing infected or damaged or any other cells with foreign antigens. For survival,
6

cancer cells employ a myriad of strategies—selective expansion of less immunogenic cancer
clones, recruiting pro-tumor immune components, inactivating anti-tumor cytotoxic immune
components, and inducing tumor-supportive immune-protective stromal tumor environment—
aimed at evading immune destruction(59-61). Lastly, following the successful development of the
tumor mass, cancer cells emanate from the local site to other distant sites through a coordinated
process known as tissue invasion and metastasis. Colonizing distal secondary sites is the most
devastating aspect of cancer development and the cause of the majority of cancer-related deaths.
Cancer cells produce different enzymes and factors to degrade the surrounding stroma and
influence the neighboring cells to pave ways for their invasion into the surrounding tissue and the
vasculature that eventually leads to disseminating the cancer cells into distant tissues(62-65).

1.3 Tumor angiogenesis and anti-angiogenics in cancer
treatment
As mentioned above, tumor angiogenesis makes up new blood vessels to perfuse the developing
tumor mass for sustained growth. Research in the last fifty years has firmly established tumor
angiogenesis as one of the defining features of solid tumors. Ensuing the cancerous
transformation of normal cells in a tissue site, the vasculature in the surroundings goes through a
significant change commonly known as an angiogenic switch: normal quiescent vessels acquiring
an activated state where the endothelial cells actively proliferate and migrate towards the tumor.
Different tumor types show different levels of neovascularization following the angiogenic switch.
Various lines of evidence suggested that this angiogenic switch is a determining factor in tumor
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growth, which led to a very promising avenue of treatment: anti-angiogenesis strategy in
cancer(58, 66).
Courtesy of the relentless investigations done by numerous researchers worldwide,
different regulators of angiogenesis has been identified and evaluated as the potential treatment
modalities. Under physiological demands, where angiogenesis is transient, a balance between
pro-angiogenic and anti-angiogenic signals controls the outcome. Vascular endothelial growth
factors (VEGFs), fibroblast growth factors (FGFs), platelet-derived growth factors (PDGFs),
angiopoietin (Ang), insulin-like growth factors (IGFs), and hypoxia-inducible factors (HIFs) are
among the most common and potent inducer of angiogenesis, whereas Thrombospondin-1(TSP1), angiostatin, and endostatin are among the inhibitors of angiogenesis(58, 67-70). These soluble
angiogenesis regulatory factors work through different combinations of transmembrane kinase
receptors to keep endothelial cells in a quiescent state or transitorily push them into an activated
state. Various environmental cues, such as oxidative stress and injury, and neighboring cells,
such as pericytes and circulating leukocytes, generate these angiogenic signals, and different
regulatory transcriptional networks in both the neighboring cells and in the endothelial cells dictate
the response and regulation of the signals(71-73). Cancer cells induce deregulation of this
balanced process by a variety of means, including overproduction of angiogenic promoters like
VEGFs and FGFs, influencing stromal cells to support vascular growth, and recruiting
inflammatory cells that stimulate angiogenic outgrowth.
The regulators of angiogenesis provided a unique opportunity to target tumor
neovascularization. Different small molecule inhibitors and monoclonal antibodies of the proangiogenic growth factors and their cognate tyrosine kinase receptors have been developed and
tested in both pre-clinical and clinical settings. Most prominent among these are the therapeutics
that target VEGFs and VEGF receptors. Anti-VEGF approaches produced promising results in
the pre-clinical mouse models with both the autochthonous and transplanted tumors in restricting
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tumor growth(74-78). However, anti-VEGF or other anti-angiogenics resulted in modest clinical
benefits in cancer patients(79, 80). This disappointing outcome has promoted two fundamental
changes in approaching angiogenesis-directed therapy in cancer for better clinical outcomes.
First, as most of the currently utilized anti-angiogenics targets, including the VEGFs and VEGF
receptors, are not limited to the tumor but also crucial for homeostasis, finding novel molecular
targets specific for tumor angiogenesis would be beneficial. Moreover, the VEGF pathway is not
even specific to endothelial cells. As such, endothelial-specific angiogenic regulators would
provide the opportunity for a direct anti-vascular approach. Second, instead of starving off the
cancer cells to death with anti-angiogenics, which was the intended approach of this class of
therapeutics at the beginning, influencing the tumor microenvironment by an adjuvant antivascular strategy to restrict the tumor growth and to prime for the tumoricidal treatment
approaches would be more effective. Research in the last decade has shed light on the promise
of this new take on the anti-angiogenic strategies in both the mouse models of tumor and cancer
patients in the clinic.

1.4 Combined immunotherapy and anti-angiogenic
treatment in cancer
Both the innate and adaptive components of the immune system are the body’s defense system
against tumorigenesis. As discussed earlier, cancer cells deploy various measurements to evade
immune destruction, such as promoting less immunogenic tumor clones, fostering an immune
protective tumor-stromal environment, inactivating cytotoxic T cells, and an overall skewing of
the tumor immune microenvironment to favor cancerous growth(59-61). Immunotherapy in cancer
treatment aims to boost the immune system to negate the measures taken by the cancer cells.
9

Different immunotherapeutic approaches target different aspects of the cancer-immune-evasion
biology, such as blocking antibodies targeting immune checkpoints (like PD1, PDL1, CTLA4,
etc.) to unleash the power of endogenous cytotoxic T cells, chimeric receptor antigen T cells (CAR
T cells) for artificial cytotoxic T cell response against the tumor, anti-cancer vaccines to render
cancer clones to more immunogenic and responsive to cytotoxic T cells(81-83). Although these
diverse immunotherapeutic approaches, such as PD1 and CTLA4 blockade therapies, have
generated unprecedented clinical responses in cancer patients, in terms of both regression and
durability, different tumor types show differing response against immunotherapy; even in the most
sensitive cancer types, a significant portion of the patients who receive treatment do not respond
to immunotherapy(84, 85). Recent investigations have proposed potential mechanisms behind the
suboptimal immunotherapy response, which has also opened up avenues for combination
treatment approaches to improve clinical outcomes.
The immunological status of the tumor dictates the outcome of the immunotherapy.
Tumors are commonly classified as hot or cold, characterized by the higher presence or lack of
infiltrating immune cells, respectively. Additionally, there are tumors that are almost immune
excluded, presumably, among other reasons, due to the lack of neoantigens to activate cytotoxic T
cells through a process called immunoediting(85-88). As evident from the clinical outcomes, the
success of the immune checkpoint blockade therapies relies on the abundance of the cytotoxic T
cells in the tumor parenchyma, and they are very effective against the hot tumors(89). Because
infiltration of the T cells in the tumor mass is dependent on the efficient vascular coverage and
functioning, and as tumor vasculature is known to be discontinuous, tortuous, leaky, and
inefficient, one auspicious way to turn cold tumors into hot is to normalize tumor vasculature by
utilizing an angiogenic-directed approach(90-92). Moreover, the hypoxic tumor core fosters an
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immunosuppressive microenvironment, further suggesting the vascular normalization approaches
to improve immune responses against the tumor(93-97). Recent studies have demonstrated the
potential of this strategy of combined vascular normalization with checkpoint blockade
immunotherapy in pre-clinical mouse models using currently available anti-angiogenic
treatments(98-100). Further studies are warranted to fully explore the promises and mechanisms
of combined anti-angiogenic and immunotherapy in cancer treatment.

1.5 Summary
Tumor angiogenesis is a critical event in the progression of solid tumors. Throughout the last fifty
years now, it has become more and more evident that this event, also known as the angiogenic
switch, can be a viable therapeutic target for cancer. Recent understanding of the relationship
between tumor microenvironment and anti-tumor immunity has fueled massive interest in the
potential for the combined immune checkpoint blockade and anti-angiogenic treatment approach.
However, the modest clinical impact of the current anti-angiogenic treatments in cancer patients
underscores the need to develop novel and more effective anti-angiogenic strategies.
Here, in my dissertation research, with my colleagues and our collaborators, I have
investigated novel anti-angiogenic molecular targets that would ideally be endothelial-specific and
exclusive to tumor angiogenesis. I have also explored the premises and potential cellular-level
mechanisms for the combined immune checkpoint blockade and anti-angiogenic therapy using the
anti-PD1 treatment with an anti-Myct1 approach.
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2.2 Abstract
Angiogenesis, new blood vessel formation from preexisting vessels, is critical for solid tumor
growth. As such, there have been efforts to inhibit angiogenesis as a mean to obstruct tumor
growth. However, anti-angiogenic therapy faces major challenges to selectively target tumor13

associated-vessels, as current anti-angiogenic targets also disrupt steady-state vessels. Here, we
demonstrate that the developmentally critical transcription factor Etv2 is selectively upregulated
in both human and mouse tumor associated endothelial cells (TAECs) and is required for tumor
angiogenesis. Two-photon imaging revealed that Etv2 deficient tumor-associated-vasculature
remained more like steady-state vessels. Etv2 deficient TAECs displayed decreased Flk1 (Vegfr2)
expression, FLK1 activation, and proliferation. Endothelial tube formation, proliferation, and
sprouting response to vascular endothelial growth factor (VEGF), but not to fibroblast growth
factor2 (FGF2), was reduced in Etv2 deficient ECs. Reactive oxygen species (ROS) activated Etv2
expression in ECs, and ROS blockade inhibited Etv2 expression in TAECs in vivo. Systemic
administration of Etv2 siRNA nanoparticles potently inhibited tumor growth and angiogenesis
without cardiovascular side effects. These studies highlight a link between vascular oxidative
stress, Etv2 expression, and VEGF response that is critical for tumor angiogenesis. Targeting the
ETV2 pathway might offer a unique opportunity for more selective anti-angiogenic therapies.

2.3 Introduction
Angiogenesis is an important process for successful embryogenesis, injury-mediated tissue repair
and regeneration, and progression of many pathologic conditions, including cancer. Thus, while
promotion of angiogenesis is critical to tissue repair and regeneration, inhibition of angiogenesis
is important to obstruct pathologic conditions such as tumor. Currently, it remains as a challenge
to selectively target tumor angiogenesis, as many of the factors and pathways presently targeted in
therapies are shared between normal and tumor vessels(3, 101, 102). For example, prevalent antiVEGF therapies, although considered to be the major venue in inhibiting tumor angiogenesis, have
14

severe shortcomings in specifically targeting tumor-associated vessels undergoing neoangiogenesis(103, 104) as VEGF is also required for physiological steady-state vessels(105, 106).
Considering these limitations, it would be crucial to identify molecular marker(s) and signaling
pathways uniquely functioning in tumor-associated vessels that can be exclusively targeted.
ETS transcription factors have emerged as critical regulators of angiogenesis(107-109). A
winged helix-turn-helix motif formed by the ETS domain can bind a consensus sequence
(GGAA/T) to regulate target gene expression(110). Many ETS factors are redundantly expressed
in hematopoietic and endothelial cells in the developing embryo(111, 112). Consistently, mice or
zebrafish deficient in any of these Ets factors display varying degrees of hematopoietic and
vascular defects(113), probably reflecting the redundant expression pattern of these Ets factors in
hematopoietic and endothelial cells. Distinct from these ETS factors, Etv2 (aka Er71, Etsrp) is
transiently expressed in the primitive streak, yolk sac blood islands and large vessels of the dorsal
aorta during embryogenesis(114-117). Etv2 deficient mice display a complete block in blood and
blood vessel formation, demonstrating that ETV2 performs a non-redundant and indispensable
function in hematopoietic and vessel development. We recently established that ETV2 activates
other Ets transcription factors in hematopoietic cell and endothelial cell (EC) lineage development.
Moreover, hematopoietic and EC program induced by ETV2 is maintained by other ETS factors
through an ETS switching mechanism in the face of transient Etv2 expression(118). Importantly,
ETV2 function is evolutionary conserved, as mouse or human Etv2 can induce hematopoietic and
vascular development in zebrafish(119). Notably, ECs can be efficiently generated from mouse
and human pluripotent stem cells by enforced Etv2 expression(116, 120, 121). Moreover, Etv2 can
efficiently reprogram somatic cells to ECs(122-125). These studies have established that Etv2 is
necessary and sufficient for EC generation and function.
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While Etv2 function in the developmental context has been extensively investigated(126,
127), studies on this gene in adults are greatly lacking. Previous studies have established that Etv2
expression becomes silent once hematopoietic cells and ECs have been generated(116, 128-130).
However, it becomes reactivated upon injury and is required for hematopoietic and EC
regeneration(131, 132). Since developmental programs are often reactivated in pathological
conditions and regulate disease progression, we investigated whether developmentally critical
factor Etv2 is also reactivated in tumor endothelium and is required for tumor angiogenesis. Our
data demonstrates that ETV2 is expressed in human and mouse tumor-associated-endothelial-cells
(TAECs). Endothelial Etv2 is required for tumor angiogenesis. While Etv2 deficient TAECs failed
to elevate Flk1 expression and had defective response to VEGF, they displayed normal response
to FGF. We identify reactive oxygen species (ROS), which were readily elevated in TAECs, as
upstream activators of Etv2 expression. Systemic Etv2 siRNA nanoparticle delivery effectively
inhibited tumor growth and angiogenesis without cardiovascular side effects. Our results indicate
that Etv2 is a novel marker for TAECs and that targeting Etv2 maybe a valid choice for blocking
tumor angiogenesis.

2.4 Materials and Methods
2.4.1 Animals
Tie2-Cre;Etv2 CKO, VECadherin-Cre;Etv2 CKO, and Vav-Cre;Etv2 CKO mice were generated
as described previously(131, 132). C57BL/6J mice were used as wild-type mice. Tie2-Cre;
Etv2flox/- or Tie2-Cre; Etv2flox/flox were used as Tie2-Cre;Etv2 CKO mice. VECadherin-Cre;Etv2flox/or VECadherin-Cre; Etv2flox/flox were used as VECadherin-Cre; Etv2 CKO mice. Vav-Cre;Etv2flox/16

or VECadherin-Cre;Etv2flox/flox were used as Vav-Cre;Etv2 CKO mice Littermate subjects were
used as control with the CKO mice. Both male and female mice were used in an equal quantity in
any given experiment. The ages of the experimental animals were between 10-12 weeks. Animals
were randomly distributed into groups when different treatments, such as Etv2 shRNA or Gfp
shRNA treatment, NAC+APO or vehicle treatment, and Etv2 siRNA or scrambled siRNAnanoparticles treatment, were employed. A group of technicians was in charge of distributing and
codifying the experimental animals. The investigators were not aware of the group allocation until
the treatment, data collection, and data analysis were done.

2.4.2 Cell lines
LLC-GFP cells were obtained from Alexander S Krupnick , Washington University in St. Louis
(St. Louis, MO). B16F10 melanoma cells were purchased from ATCC. YSE cells were obtained
from Laurence A. Lasky (Genentech, South San Francisco). All cell lines have been tested negative
for mycoplasma contamination.

2.4.3 Human tumor samples
De-identified patient-derived formalin-fixed paraffin embedded (FFPE) malignant and matched
non-malignant breast, lungs, prostate, and colon tissue specimens were collected from Tissue
Procurement Core (TPC)-Siteman Cancer Center at Washington University School of Medicine in
St. Louis. TPC performs pathological reviews to determine the malignant vs non-malignant status
of the tissues following standard procedures before disseminating the tissue for downstream
applications. According to TPC definition, any section associated with equal to or more than 1
neoplastic cells were considered malignant. However, most of our samples had more than 50%
neoplastic cells in any given section.
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2.4.4 Tumor transplantation studies
GFP expressing Lewis lung carcinoma (LLC) cells (LLC-GFP) were cultured in growth medium
consisting of DMEM (Gibco) supplemented with 10% (v/v) FBS, 100 unit/ml penicillin and 100
μg/ml streptomycin. For tumor transplantation studies, 1 ml of growth factor reduced Matrigel:
Matrix protein HC (Cat: 354248; Corning) was mixed with 1 ml of tumor cell suspension (2
x106/ml in PBS); 100µl of tumor cell-Matrigel mixture was injected to the back of mice
subcutaneously. Tumor growth was measured by a digital slide calipers (VWR International) at
indicated days after tumor cell injection. Tumor volume was calculated by the equation,
Volume=(largest diameter) x (smallest diameter)2 x 0.5.

2.4.5 Immunofluorescence
FFPE human tissue sections were processed for antigen retrieval using DIVA Decloaker (Cat:
SKU: DV2004, Biocare Medical), blocked using freshly made blocking buffer (3% essentially IgG
free BSA (Cat: A9085, Millipore Sigma), 0.3% Triton X-100, and Fc blocker (Cat: 422301,
Biolegend)) to prevent non-specific binding, incubated overnight at 4°C with mouse anti-human
CD31 (1:100) (Cat: MA5-13188, ThermoFisher Scientific) and rabbit anti-human ETV2 (1:300)
(Cat: ab181847, Abcam) primary antibodies, and finally visualized with Alexa Flour 594 labeled
goat anti-mouse (1:400) (Cat: R37121, ThermoFisher Scientific) and Alexa Fluor 647 labeled goat
anti-rabbit (1:500) (Cat: A-21245, ThermoFisher Scientific) secondary antibodies for 2h at room
temperature. Later, the sections were processed to counterstain nuclei with DAPI (Cat: D1306,
ThermoFisher scientific), cured with ProLong Diamond Antifade mountant (Cat: P36970,
ThermoFisher scientific) for 24h, and finally sealed with nail polish for preservation. No primary
antibody control, Isotype control (Mouse IgG1 Isotype Control, Cat: ab91353, Abcam and Rabbit
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IgG Isotype Control, Cat: ab172730, Abcam), and Absorption control (using ETV2 Antibody
Blocking Peptide at a 5 to 1 ratio with employed ETV2 antibody, Cat: LS-E910, LifeSpan
Biosciences) were performed as negative controls for immunofluorescence staining. The stained
sections were examined using the Olympus Fluoview 1200 confocal microscope and minimally
processed with Imaris (Bitplane) software to prepare the figures. At least 6 pictures from every
section were processed using ImageJ software (NIH) to quantify CD31 and ETV2 positive areas.
In mouse tumor transplantation studies, before harvesting the tumors, the mice underwent transcardiac whole-body perfusion of 10% buffered formalin. Harvested tumors were thin sliced and
fixed in 10% buffered formalin for 36h, immersed in 30% (w/v) sucrose solution for 48h to cryoprotect the tissue, frozen in NEG-50 frozen section medium (Cat: 6502, ThermoFisher scientific)
using liquid nitrogen and 2-methylbutane, and sectioned in 16 µm thickness using a Cryostat
Cryocut Microtome (Leica, CM1850, Nussloch, Germany). Tissue sections were first blocked
using freshly made blocking buffer (3% essentially IgG free BSA (Cat: A9085, Millipore Sigma),
0.3% Triton X-100, and Fc blocker (Cat: 101301, Biolegend)) to prevent non-specific binding,
then incubated overnight at 4°C with hamster anti-mouse CD31 (1:400) (Cat: MA3105,
ThermoFisher Scientific), along with either rabbit anti-mouse ETV2 (1:200) (Cat: orb156791,
Biorbyt) or rabbit anti-mouse pFLK1 (Y951) (1:200) (Cat: 4991S, Cell Signaling Technology) or
rabbit anti-mouse Ki67 (1:200) (Cat: Ab15580, Abcam) primary antibodies, and finally visualized
with Alexa Fluor 568 labeled goat anti-hamster (1:500) (Cat: A-21112, ThermoFisher Scientific)
and Alexa Fluor 647 labeled goat anti-rabbit (1:500) (Cat: A-21245, ThermoFisher Scientific)
secondary antibodies for 2h at room temperature. Later, the sections were processed to counterstain
nuclei with DAPI (Cat: D1306, ThermoFisher scientific), cured with ProLong Diamond Antifade
mountant (Cat: P36970, ThermoFisher scientific) for 24h, and finally sealed with nail polish for
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preservation. No primary antibody control, Isotype control (Armenian Hamster IgG Isotype
Control, Cat: 14-4888-85, ThermoFisher scientific and Rabbit IgG Isotype Control, Cat:
ab172730, Abcam), and Absorption control (using ETV2 Antibody Blocking Peptide in a 5 to 1
ratio with employed ETV2 antibody, Cat: LS-E910, LifeSpan Biosciences) were performed as
negative controls for immunofluorescence staining. The stained sections were examined using the
Olympus Fluoview 1200 confocal microscope system and minimally processed with Imaris
(Bitplane) software to prepare the figures. At least 5 pictures from every section were processed
using ImageJ software (NIH) to quantify CD31, ETV2, pFLK1, and Ki67 positive areas.
To further confirm the specificity of the ETV2 antibody staining, we employed iEtv2
embryonic cell (ES) cell system by using our previously described A2 ES cell line that express
ETV2-V5 in a doxycycline (DOX)-inducible manner, following protocol described
previously(118). Briefly, DOX-treated iEtv2 ES cells (cultured on Matrigel coated coverslips)
were fixed with ice cold methanol for 10 minutes at room temperature. After fixation, the ES cells
were first blocked using freshly made blocking buffer (10% Normal Goat Serum (Cat: 5425S, Cell
Signaling Technology) in 1X TBS), to prevent non-specific binding, then incubated overnight at
4°C with rat anti-V5 antibody (1:1000) (Cat: ab206571, Abcam) and rabbit anti-mouse ETV2
(1:1000) (Cat: orb156791, Biorbyt), and finally visualized with Alexa Fluor 488 labeled goat antirabbit (1:500) (Cat: ab150077, Abcam) and Alexa Fluor 568 labeled goat anti-rat (1:500) (Cat:
ab11077, Abcam) secondary antibodies for 1h at room temperature. Later, the cells were processed
to counterstain nuclei with DAPI (Cat: D1306, ThermoFisher scientific), cured with ProLong
Diamond Antifade mountant (Cat: P36970, ThermoFisher scientific) for 12h, and finally sealed
with nail polish for preservation. The stained cells were examined using the Olympus Fluoview
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1200 confocal microscope system and minimally processed with Imaris (Bitplane) software to
prepare the figures.

2.4.6 Lung endothelial cells (LEC) isolation
Lungs were harvested from the mice, dissociated into single cell suspension by using a digestion
buffer

consisting

of

Collagenase-II

(Cat:

17101-015,

ThermoFisher

scientific)

and

Deoxyribonuclease 1 (Cat: LS002139, Worthington) solution for 30 minutes, stained with rat antimouse CD31 (Cat: 102501, Biolegend) conjugated magnetic sheep anti-rat IgG Dynabeads (Cat:
11035, ThermoFisher scientific), and CD31+ cells were sorted using MACS. Afterwards, sorted
CD31+ endothelial cells were either cultured with M199 medium containing 20% (v/v) FBS and
endothelial cell growth supplement (Cat: E2759, Millipore Sigma) or directly processed for total
RNA isolation by RNeasy mini kit (Cat: 74104, Qiagen), following manufacturer’s instructions.

2.4.7 Tumor associated endothelial cells (TAEC) isolation
Tumors were harvested from the mice, dissociated into single cell suspension using a digestion
buffer consisting of Collagenase IV (Cat: LS004188, Worthington), Dispase (Cat: 17105-041,
ThermoFisher scientific), and Deoxyribonuclease 1 (Cat: LS002139, Worthington) for 90 minutes
at 37oC and stained with PE-Cy7 anti-mouse CD31 (Cat:102418, Biolegend) and APC anti-mouse
CD45 (Cat:103112, Biolegend) antibodies. GFP-CD45-CD31+ endothelial cells were FACS sorted
using BD FACSAria II (BD Bioscience). Sorted endothelial cells were processed for total RNA
isolation by RNeasy mini kit (Cat: 74104, Qiagen) following manufacturer’s instructions. At least
five independent tumors per group were used for gene expression analysis.
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2.4.8 Quantitative real time-reverse transcription PCR (qRT-PCR)
RNA and cDNA were prepared according to manufacturer’s protocol. Gene expression was
measured by quantitative real-time RT-PCR using primers detailed in the table 2.1.

Table 2.1: qRT-PCR primer sequences used in the study
Gene

Forward primer

Reverse primer

Etv2

CTGGGAGCGGAATTTGGTTTC

GTAAAGCGGGGTTCCAGTCC

Flk1

TTTGGCAAATACAACCCTTCAGA

GCAGAAGATACTGTCACCACC

Fgfr1

GCAGAGCATCAACTGGCTG

GGTCACGCAAGCGTAGAGG

Fgfr2

GCCTCTCGAACAGTATTCTCCT

ACAGGGTTCATAAGGCATGGG

Fgfr3

GCCTGCGTGCTAGTGTTCT

TACCATCCTTAGCCCAGACCG

Fli1

ATGGACGGGACTATTAAGGAGG

GAAGCAGTCATATCTGCCTTGG

Ets1

ACAGACTACTTTCGGATCAAGCA

ACGCTCTCAAAAGAGTCCTGG

Ets2

CCTGTCGCCAACAGTTTTCG

TGGAGTGTCTGATCTTCACTGA

Elk3

TCCTCACGCGGTAGAGATCAG

GTGGAGGTACTCGTTGCGG

Erg

ACCTCACCCCTCAGTCCAAA

TGGTCGGTCCCAGGATCTG

Vegfa

GCACATAGAGAGAATGAGCTTCC

CTCCGCTCTGAACAAGGCT

B-actin

GGCTGTATTCCCCTCCATCG

CCAGTTGGTAACAATGCCATGT

2.4.9 Two-photon (2P) imaging and analysis of vessel morphology
For 2P imaging experiments, tumor cells were implanted in the ear pinna (and in some cases the
hind flank) by injecting 10ul of LLC-GFP (2 x 106 / ml)-Matrigel mixture. Twenty-one days after
tumor implantation, mice were anesthetized with isofluorane and placed in a custom chamber for
imaging. 2PM was performed non-invasively through skin. Blood vessels were labeled with a retro
orbital injection of either 70 kDa Rhodamine-Dextran (50 µl, ~1µg; Cat: D1824, ThermoFisher
scientific) or 655nm Q-dots (15µl; Cat: Q21321MP, Invitrogen). Multiple images were collected
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near the tumor margin using a custom-built 2PM system equipped with a Chameleon Vision II
Ti:Sapp laser and a 20x 1.0 NA Olympus water dipping objective. Each 3D image consisted of 31
z-slices taken in 2.5µm steps. Z-stacks were rendered in 3D and morphometric analysis was
performed to assess vessel diameter, the number of discontinuous segments in the tumor associated
vessel network and the volume of each vessel segment. Imaris (Bitplane) was used to generate 3D
contour surfaces to identify vessels (Supplemental movie 1). Surface quality was optimized using
background subtraction and thresholding and common settings used across all images. Vessel
complexity was determined by counting the number of discrete vessel segments in each image.
The volume of each vessel segment in an image was measured and compared across groups by
using a linear mixed effects model where the fixed effects are the treatment groups themselves and
the random effects are due to intra-image correlation. Normality of the outcome variable was
achieved after a log10 transform and all tests were performed on the transformed data. After the
model was fitted, pairwise statistical contrasts were used to assess pairwise group differences.
Vessel leak was variable and was often observed in discreet regions of an image. Therefore, to
minimize selection bias in our analysis, we quantified leak by averaging histograms of maximum
intensity projections for all images in each group and then plotting average pixel intensity counts
for each group.

These plots were analyzed by fitting them to an exponential probability

distribution function using maximum likelihood estimation methods to extract the rate of decay
for each group. When extravascular leak was present, it resulted in an increase in the intermediate
intensity red pixels (10 to 80 gray levels) and thus lower rate of decay for the plot. Maximum
likelihood estimates were obtained for each curve and the estimates compared by generating a
null-hypothesis estimate and a likelihood ratio test to assess a goodness of fit. Vessel integrity was
assessed using a standard kymograph analysis on representative images.
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2.4.10
pLKpuro

Lentiviral Etv2 shRNA production
lentiviral

Etv2

shRNA

clones,

TRCN0000084284

(NM_007959.1-93s1c1),

TRCN0000084285 (NM_007959.1-52s1c1), TRCN0000084286 (NM_007959.1-887s1c1) and
TRCN0000084287 (NM_007959.1-888s1c1), constructed and distributed by the RNAi
Consortium (TRC) at Broad Institute (http://www.broadinstitute.org/rnai/trc/lib), were obtained
from the McDonnell Genome Institute at Washington University School of Medicine and funded
in part by the Children’s Discovery Institute of Washington University in St. Louis. 293T cells
were transfected with pLKpuro Etv2 shRNA constructs, pCAG-HIVgp and pCMV-VSV-G-RSVRev (4:3:1) by using Calcium Phosphate method. Sixteen hours after transfection, media was
changed, and cells were then grown for additional 48h. Subsequently, supernatant was harvested
and concentrated by Lenti-X-Concentrator (Clontech). The virus titer was determined using the
Lenti-X™ p24 Rapid Titer Kit (Clontech). For the intratumor injection, IFU was around 3 x107/ml.
In a preliminary screening with this panel of Etv2 shRNA lentivirus, we identified lentiviral
shRNA clone TRCN0000084284 (NM_007959.1-93s1c1) to be most effective in restricting tumor
growth, and hence used for all subsequent experiments (data not shown). Lentiviral Gfp shRNA
was used as control treatment.

2.4.11

Endothelial cell proliferation assay

Lung endothelial cells, previously sorted from wild-type and Tie2-Cre;Etv2 CKO mice, were
cultured in growth medium consisting of M199 medium (Gibco), 10% (v/v) FBS, 100 unit/ml
penicillin and 100μg/ml streptomycin. For proliferation assay, cells were plated in 96 well plates
(3,000 cells/well). One day later, medium was changed to 0.5% serum-containing medium. After
24h, vascular endothelial growth factor (VEGF, 50ng/ml) or fibroblast growth factor 2 (FGF2,
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50ng/ml) was added to the culture. After three days, 10μL of CCK-8 (Cat: 96992, Millipore Sigma)
solution was added to each well and the plates were incubated for 3h at 37°C. Absorbance at 450
nm (A450) for each well was measured.

2.4.12

Aortic ring assay

Aorta was retrieved from control or Tie2-Cre;Etv2 CKO mice, cut into rings ~0.5 mm in width,
and cultured for 24h in serum free culture medium. Subsequently, aortic rings were embedded into
Matrigel (Cat: 356231, Corning) and culture medium containing 2.5% FBS and VEGF (50ng/ml)
or FGF2 (50ng/ml) was added. Medium was changed on days 3, 5, and 7. Aortic rings were fixed
with 4% PFA on day 8 and sprout number and sprout length were measured using ImageJ image
analysis software (NIH).

2.4.13

Tube formation assay

Wild type yolk sac derived endothelial cells (YSE) and lentiviral Etv2 shRNA infected YSE cells,
cultured in growth medium consisting of M199 medium (Gibco), 10% (v/v) FBS, 100 unit/ml
penicillin and 100μg/ml streptomycin, were kept in 24h hypoxia (<1% oxygen), followed by 24h
normoxia with overnight serum starvation (0.5% serum). Afterwards, cells were plated on Matrigel
(Cat: 96992, Corning) coated 24-well plate with either VEGF (50ng/ml) or FGF2 (50ng/ml) and
incubated at 37°C for 5h before taking picture with a Leica DFC 310 FX microscope system.

2.4.14

ROS induction, measurement, and scavenger treatment

For ROS induction, wild-type or Etv2 shRNA infected YSE cells were plated in 6-well culture
plate (1.5 x 105 cells/well). The following day, cells were treated with either H2O2, or BSO, or
hypoxic condition (<1%O2) for 24h or hypoxia-reoxygenation (24h <1%O2 followed by 24h
nomoxia). For ROS measurement, YSE or tissue-derived endothelial cells were incubated with
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PBS containing 2.5µM DCFDA (Cat: D399, ThermoFisher scientific) for 10 min at 37°C. Tissuederived cells were stained with PE-Cy7 anti-mouse CD31 (Cat:102418, Biolegend) and APC antimouse CD45 (Cat:103112, Biolegend) antibodies. ROS levels in YSE cells or in CD45-CD31+
cells from the tissues were measured by BD LSRFortessa (BD Bioscience). For in-vitro ROS
scavenger treatment, N-acetyl cysteine or NAC (dissolved in water; 5mM) (Cat: A9165, Millipore
Sigma) and Apocynin or APO (dissolved in DMSO and later diluted with water; 100mM) (Cat:
178385EMD, Millipore Sigma) were added to the YSE cells at the beginning of re-oxygenation
period for next 24h. For the in-vivo treatment, NAC (200mg/kg, dissolved in water) and APO
(50mg/kg, dissolved in DMSO and later diluted with water) were intraperitoneally injected into
the mice.

2.4.15

Preparation of Etv2 siRNA-peptide nanoparticle

For siRNA nanoparticle treatment study, Etv2 siRNA was made from the Millipore Sigma against
the sequence “GAGCGGAATTTGGTTTCTATT” (the sequence of the lentiviral shRNA clone
TRCN0000084284 (NM_007959.1-93s1c1) that was used for the shRNA studies). MISSION®
siRNA Universal Negative Control #1 (Cat: SIC001, Millipore Sigma) was used as scrambled
siRNA control. For tracking the distribution of the siRNA, a special batch of siRNA was also
prepared using a fluorescence dye, Quasar705, tagged with the siRNA sequence. 100µM siRNA
solution was prepared by dissolving in 1x siRNA buffer (Cat: B-002000-UB-100, Dharmacon)
and incubating on an orbital mixer (~500rpm) at 37°C for 70-90minutes; this stock siRNA was
stored in 10µL aliquot at -80°C until use. To prepare the nanoparticle complex, 10µL of the siRNA
suspension was mixed with 5µL of 20mM p5RHH peptide solution and 185µL of 1x HBSS
(Gibco), and incubated on ice for ~7minutes for the siRNA and peptide to conjugate at a siRNA
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to peptide ratio of 1:100. The resultant 200µL siRNA-peptide nanoparticle was immediately
injected to the mouse through tail vein to deliver a siRNA dose of 1nmol/mouse/day.

2.4.16

IVIS imaging

To track the siRNA distribution after nanoparticles injection, in vivo fluorescence images were
acquired and analyzed with a Xenogen IVIS Spectrum imaging system (Caliper Life-Sciences).
Mice were kept under isoflurane inhalation anesthesia during the whole-body image acquisition
process. Tumor and other major organs were harvested immediately after that and processed for
imaging as well. A fixed protocol (excitation, 640 nm; emission, 700 nm; exposure time, 2 s;
binning factor, 8; f value, 2; field of view, 12.9) was used for image acquisitions at 24hours after
tail vein injection of nanoparticles containing Quasar705 labeled Etv2 siRNA to tumor-bearing
wild-type mice. For the non-injected subjects, HBSS was injected through tail vein, and images
were taken following the same protocol.

2.4.17

Blood pressure measurement and compliance studies

Arterial blood pressure and arterial compliance measurements were performed after 5 consecutive
injections (every other day) of vehicle or Etv2 siRNA, or scrambled siRNA nanoparticles to
healthy wild-type mice following standard protocol. Briefly, for blood pressure, mice were
anesthetized with 1.5% isoflurane and kept on a heating pad to maintain normal body temperature,
monitored via a rectal thermometer. A 2- to 3-mm midline incision was made in the neck; the lobes
of the thymus were separated to expose the right common carotid artery. After clamping and
making a small nick in the right common carotid artery, a Millar pressure transducer (model SPR671) was introduced and advanced to the ascending aorta. Systolic blood pressure, diastolic blood
pressure, and heart rate were recorded and analyzed using the PowerLab data acquisition system
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and LabChart 7 for Mac software, respectively (ADInstruments). For compliance studies,
following the blood pressure measurement, mice were euthanized under isoflurane anesthesia, and
the ascending aorta and the left common carotid artery were excised and placed in physiology
saline (PSS) at 37°C. After cleaning the fatty tissues, vessels were placed on a pressure
arteriograph (Danish Myo Technology), maintained in PSS at 37°C, and examined with an inverted
microscope attached to a CCD camera and a computerized system that allows continuous recording
of the vessel diameter measurement.

2.4.18

Echocardiography

Mouse Cardiovascular Phenotyping Core at Washington University School of Medicine performed
noninvasive cardiac ultrasound examination of healthy wild-type mice under light anesthesia, after
5 consecutive injections of vehicle or Etv2 siRNA, or scrambled siRNA nanoparticle (every other
day). VisualSonics Vevo-2100 cardiac echocardiography system (FUJIFILM, VisualSonics Inc.)
was used to characterize the structure and function of the heart and great vessels.

2.4.19

Histological analysis

Heart, lungs, kidneys, and liver were harvested after 5 injection (every other day) of vehicle or
Etv2 siRNA, or scrambled siRNA nanoparticles to healthy wild-type mice and fixed in 10%
buffered formalin for 48 hours. The tissues were decalcified in EDTA solution, embedded in
paraffin, and cut as 5μm sections. Finally, the sections were stained with H&E. Digital images of
4 random areas per H&E-stained organ-section were acquired at 20x magnification, and checked
by a double blinded histologist/pathologist.
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2.4.20

Single-dose siRNA nanoparticle administration, blood sampling, high

performance liquid chromatograph (HPLC), and pharmacokinetic analysis
Five wild-type mice (C57BL/6J; ~17 weeks old) received a single IV dose of siRNA nanoparticle
and underwent PK measurements. A carotid artery catheter was inserted before the siRNA
nanoparticle dosing for blood sampling. Blood samples were taken prior to, and at 10, 40, 90 and
180 min after the IV administration of p5RHH- Cy3 siRNA nanoparticle. Blood drawn was
replaced with 80µl of heparinized saline (5 U/mL) after each collection to avoid volume depletion.
Plasma was separated by centrifugation and then stored at -80oC until analyzed for siRNA.
Individual plasma samples (~ 60µl) were added with 0.4 mL of Clarity OTX lysis-loading
buffer (Phenomenex Inc. Torrance, CA). The mixture was vortex-mixed for 30 seconds and then
loaded onto the solid-phase extraction (SPE) cartridge. The siRNA nanoparticles were extracted
from individual plasma samples using Clarity OTX SPE cartridges with polymeric sorbent
(100mg/3mL; Phenomenex Inc., Torrance, CA). Sorbent was conditioned with 1.0mL of methanol
and equilibrated with 1mL of 150mM NaH2PO4 buffer (pH 5.5) containing 2mM NaN3. For
plasma samples, following sample loading, the cartridge was washed with 4.0mL of washing
buffer (50mM NaH2PO4 buffer (pH 5.5) containing 50% acetonitrile). The siRNA nanoparticles
were eluted with 1mL of elution buffer (100mM NH4HCO3 containing 10% tetrahydrofuran and
40% acetonitrile). The eluent was evaporated to near dryness using a Savant SC110 SpeedVac
concentrator. Samples were reconstituted with 100µL of HPLC-grade water and a 25μL aliquot
was injected into the HPLC column. The HPLC assay was carried out using an Agilent series 1200
high-performance liquid chromatography system equipped with a binary pump, autosampler and
degasser coupled to an Agilent 1260 fluorescence detector. Separation was achieved on an Acquity
UPLC oligonucleotide BEH C18 column (50 × 2.1 mm, 1.7 µm particle size; Waters Corporation,
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Milford, MA). The analyte was eluted using acetonitrile/100mM hexylammonium acetate (HAA)
(48: 52, v/v) as the mobile phase with a flow rate of 0.1 mL/min. The column temperature was set
at 60°C. The siRNA nanoparticle was detected by use of an excitation wavelength of 548 nm and
an emission wavelength of 566 nm. A 1-compartment open model with 1st order elimination (𝐶 =
𝐶 ! 𝑒 "#$ ) was used to characterize drug disposition in plasma, where C0 is siRNA concentration at
time 0, k is the 1st order elimination rate constant. Elimination half-life was calculated as 𝑡%/' =
!.)*+
#

.

2.4.21

Statistics

GraphPad Prism 7 software was used for performing statistical analysis and generating
graphs/plots. Data are presented as mean with standard deviation for all the measurements. All
experimental data were reliably reproduced in two or more individual biological replicates.
Comparison between two independent samples was performed using a two-tailed Student’s t-test.
In case of comparing more than two groups, One-way ANOVA with either post-hoc Dunnett’s or
Tukey’s or Bonferroni’s multiple-comparison test, or Two-way ANOVA with either post-hoc
Tukey’s or Sidak’s multiple-comparison test was used, whichever appropriate. Tumor volume data
was analyzed using or Two-way repeated measures ANOVA with either post-hoc Tukey’s or
Sidak’s multiple-comparison test. A p<0.05 was considered statistically significant.

2.4.22

Study Approval

Animal husbandry, generation, handling, and experimentation were done in accordance with
protocols approved by the Institutional Animal Care and Use Committee of Washington
University School of Medicine in St. Louis.
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2.5 Results
2.5.1 Etv2 is upregulated in both human and mice tumor associated
endothelial cells (TAEC)
As Etv2 was required for ECs undergoing active angiogenesis(131), we assessed if Etv2 also plays
a role in tumor angiogenesis. We first examined human malignant and matched non-malignant
specimens from lung, breast, prostate, and colon cancer patients and found that ETV2 is expressed
in the tumor vessels, but not in the non-malignant tissues (Figures 2.1A-D).
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Figure 2.1: Etv2 is upregualted in the vasculature of cancer patients. (A-D), Representative images for ETV2
(green) and CD31 (red) immunofluorescence of malignant and matched non-malignant specimens from (A) lung, (B)
breast, (C) colon, and (D) prostate cancer patients. DAPI (blue) is used to counterstain nuclei. Associated graphs show
the quantification of %ETV2 expressing CD31+ vessels in malignant vs non-malignant tissues. Every cancer type had
malignant and non-malignant tissue specimen pairs collected from at least 3 patients; at least 3 sections from each
tissue type were subjected to immunofluorescence. Scale bars: 100µm (50µm for zoomed-in sections). Data are
presented as mean with standard deviation for all measurements. Statistical significances were analyzed by either a
two-tailed Student’s t-test.
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To determine the kinetics of Etv2 expression in tumors, we next utilized a mouse tumor
transplantation model using Lewis lung carcinoma (LLC)-GFP tumor cells. In this tumor
transplantation model, palpable tumor mass is detected by days 4-5 post tumor-cell transplantation,
followed by robust tumor growth. Etv2 expression was detected in the tumor mass from day 4
post-transplantation, with its expression highly upregulated from day 10 post-transplantation. We
analyzed the FACS sorted ECs from the tumor by qRT-PCR and found that TAECs expressed high
levels of Etv2 (Figure 2.2A). Immunofluorescence of the mouse tumor sections also revealed that
ETV2 is present primarily in TAECs (Figure 2.2B). Intriguingly, ETV2 was also detected in some,
not all, hematopoietic cells (Figure 2.2C). Since tumor cells and ECs in non-malignant vessels do
not express Etv2, we conclude that Etv2 expression is induced in TAECs.

Figure 2.2: Etv2 is upregualted in tumor endothelial cells in mice. (A) qRT-PCR analysis on Etv2 expression in
tumor cells (LLC, n=4), lung endothelial cells (LEC, n=4), and tumor endothelial cells (CD31+CD45-) (TAEC, n=6
or more/time point). Tumors were collected on 4, 7, 10 and 13 days post tumor transplantation. (B, C) Representative
images for ETV2 (green) and CD31 (red) (B) or CD45 (red) (C) immunofluorescence of mouse tumor and lung
sections, processed after 20 days of tumor transplantation. LLC-GFP cells (blue) and nuclei counterstained with DAPI
(grey) are shown. Scale bars: 50µm. Data are presented as mean with standard deviation for all measurements.
Statistical significances were analyzed by either a two-tailed Student’s t-test (B, C) or One-way ANOVA with Tukey’s
multiple-comparison test (A).
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2.5.2 Endothelial Etv2 is required for optimal tumor growth
To determine whether the re-activation of Etv2 expression in TAECs reflected its functional
requirement in tumor angiogenesis, we transplanted LLC-GFP cells into Tie2-Cre;Etv2f/f (Tie2Cre;Etv2 CKO: lacks Etv2 in ECs and hematopoietic cells) and VECadherin-Cre;Etv2f/f (VECCre;Etv2 CKO: lacks Etv2 in ECs) mice(131, 132). Efficient deletion of Etv2 was confirmed in
ECs of both models (Figure 2.3A). Etv2 expression in TAECs and tumor growth were significantly
reduced in the Etv2 CKO mice (Tie2-Cre or VEC-Cre) compared to littermate control wild-type
mice (Figures 2.3B and 2.3C). Similar tumor growth defects were observed with another wellstudied B16-melanoma tumor model (Figure 2.3D). Capillary densities within tumors were also
significantly decreased (Figure 2.3E), suggesting that endothelial Etv2 is required for efficient
tumor angiogenesis and growth. Ets transcription factors are redundantly expressed in ECs(111,
112). Notably, Etv2 deficient TAECs had elevated expression of Fli1, Erg, and Ets1 (Figure 2.3F),
suggesting that there might be possible compensatory roles played by the other Ets factors in the
absence of the Etv2, which could have contributed to the residual tumor growth in the Etv2 CKO
mice. Hematopoietic Etv2 also appears to contribute to tumor progression, as Tie2-Cre;Etv2 CKO
mice displayed more severe reduction in tumor growth than the VEC-Cre;Etv2 CKO mice. Indeed,
Vav-Cre;Etv2f/f (Vav-Cre;Etv2 CKO; Etv2 deletion in hematopoietic cells) mice showed a mild,
but significant, reduction in tumor growth and angiogenesis compared to littermate control mice
(Figure 2.3G and 2.3H). Importantly, tumor associated hematopoietic cells in the Vav-Cre;Etv2
mice had diminished expressions of angiogenic growth factors Vegf-a, Vegf-b, Fgf-2, Igf-1, and
Igf-2 (Figure 2.3I), which could explain why mice with deleted hematopoietic Etv2 displayed
defective tumor angiogenesis.
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Figure 2.3: Endothelial Etv2 is required for tumor growth and angiogenesis. (A) Genomic DNA PCR analysis
with the lung CD31+CD45- endothelial cells of control, VEC-Cre;Etv2, and and Tie2-Cre; Etv2 CKO mice. (B) qRTPCR analysis of Etv2 expression in TAECs of control(n=5), Tie2-Cre;Etv2 CKO(n=7), and VEC-Cre;Etv2 CKO(n=7)
mice, on day 13 post tumor-cell transplantation. (C) Tumor growth in control, VEC-Cre;Etv2, and Tie2-Cre;Etv2
CKO mice. Tumor voulme was measured on days 6, 9, 12, 15, 18, and 21 post-translation; n=7/group (*p<0.05,
**p<0.01, ***p<0.001). (D) Tumor growth in littermate control, VEC-Cre;Etv2 and Tie2-Cre;Etv2 CKO mice using
B16 melanoma cells. n=8(control), 7(Tie2-Cre), and 5(VEC-Cre); *P<0.05. (E) Representative images for CD31 (red)
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immunofluorescence and quantifiaction of CD31+ vessel density of the tumor sections (n= at least 10/group). LLCGFP cells (blue) and nuclei counstained with DAPI (grey) are shown. Scale bars: 100µm. (F) qRT-PCR analysis of
Fli1, Erg, and Ets1 expression in TAECs of littermate control (WT) and Tie2-Cre;Etv2 CKO mice, on day 15 posttransplantation (n=4/group). (G) Tumor growth in littermate control, Vav-Cre;Etv2 CKO mice using LLC-GFP cells.
n=7(control) and 6(Vav-Cre); *P<0.05 (H) Representative images for CD31 (red) immunofluorescence and
quantification of CD31+ vessel density of the tumor sections, processed after 21 days of transplantation (n=10/group).
LLC-GFP cells (green) and nuclei counterstained with DAPI (blue) are shown. Scale bars: 50µm. (I) qRT-PCR
analysis of Vegfa, Vegfb, Fgfr2, Igf1, and Igf2 expression in CD45+CD31- hematopoietic cells of littermate control
(WT) and Vav-Cre;Etv2 CKO mice, on day 16 post-transplantation (n=4/group).
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2.5.3 2PM analysis reveals that Etv2 deficient tumor vessels are similar to
steady-state vessels
We examined the effect of Etv2 loss on the morphology and function of the tumor-associated
vasculature in vivo using Two-photon microscopy (2PM). 2PM induces less photo-damage than
confocal microscopy and has higher spatiotemporal resolution (~30fps and <0.5 µm/pixel) than
magnetic resonance imaging, computed tomography and positron emission tomography(133). To
assess Etv2 deficient tumor vessels, we transplanted LLC-GFP into the ear pinna of Etv2 CKO
mice, performed in-vivo 2PM, and assessed vessel morphology. In wild type mice, tumorassociated vessels, compared to steady-state vessels, had distinct tortuous morphology, larger
diameter, and functional abnormalities including sluggish blood flow and increased leakiness, as
previously observed(134). However, tumor associated vessels in Etv2 CKO mice resembled those
of steady-state vessels (Figures 2.4A-C). It is important to note that the vessels of the control and
Etv2 CKO mice were similar in steady state (Figure 2.4D). Next, to better assess tumor-associated
changes to the vascular network, we created 3D-contour surfaces of all vessels in the images
including capillaries and larger venules and arterioles to quantify the number of discontinuous
vessel segments, as a measure of network complexity, and the volume of each vessel segment.
Tumors growing in wild-type mice showed increased vessel complexity and decreased average
vessel-segment volume, compared to steady-state vessels, suggesting the expansion of tumorcapillaries via angiogenesis (Figures 2.4E and 2.4F). However, tumors growing in Etv2 CKO mice
had similar vessel complexity and average vessel-segment volume compared to steady-state
vessels (Figures 2.4E and 2.4F), suggesting that new capillary formation requires Etv2. Finally,
we evaluated vessel integrity in the tumor bearing mice by plotting the average pixel-intensitycounts and identified extravascular leakage by the increased intermediate intensity-pixel-counts in
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the red channel (10 to 80 gray levels, zoomed inset) and, when fitted to an exponential curve, a
lower rate of decay. Tumor associated vessels were significantly leakier than steady-state vessels
in wild-type mice, whereas the leakage was significantly reduced in Etv2 CKO mice (Figures 2.4G
and 2.4H). We additionally performed a kymograph analysis on representative images to further
validate vessel integrity of the Etv2 deficient tumor vessels. While tumor associated vessels in
wild-type mice showed noticeable broadening of the intensity profile and higher extravascular
dextran signal, tumor associated vessels in the Etv2 CKO mice had sharp well delineated vessel
edges and little extravascular dextran signal (Figure 2.4H and 2.4I). These data suggested that Etv2
deficient tumor vessels, in the absence of new angiogenesis, remained similar to steady state.
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Figure 2.4: In vivo assessment of tumor-associated vessel morphology in Etv2-CKO mice. 2PM was performed
on anesthetized mice to assess vessel morphology in (A) wild-type (WT, WT+LLC) and (B) Tie2Cre Etv2 CKO
(Tie2Cre, Tie2Cre+LLC) tumor bearing mice. Images show LLC tumor (green) is associated with vascular remodeling
and the growth of larger tortuous and irregular capillaries (red), collagen fibers (second harmonic generation signal,
blue); Scale bar, 10µm. (C), Average capillary diameter in steady-state vessels (WT, black bar) and tumor associated
capillaries in littermate control (WT+LLC, blue bar) and CKO (Tie2-Cre+LLC, red bar) mice (n=5mice/group;
*p<0.5). (D) Representative images from Tie2-Cre;Etv2f/f CKO and VEC-Cre;Etv2f/f CKO mice showing steady-state
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capillaries (red) and collagen fibers (second harmonic generation signal, blue); Scale bar, 10µm. (E, F) Vessel
complexity in (E) tumor vessels and (F) steady-state vessels was analyzed by generating 3D contour surfaces to
identify vessels and counting the number of discrete vessel segments in each image. Vessel volume is plotted for each
group with each dot representing the average volume of vessel segments in an image (n=5 or more/group; *p<0.05,
***p<0.001 and n.s.=not significant). (G) A plot of average pixel intensity counts for each group fitted to an
exponential probability distribution function using maximum likelihood estimation methods to extract the rate of
decay for each group (n=4/group; *p<0.05, n.s.=not significant). (H) Representative images of vessel integrity
analyzed using kymographs. Intensity profiles were measured for the boxed regions in the images. (I) Images of blood
vessels focusing on the tumor margin in littermate control wild-type and Tie2-Cre;Etv2f/f CKO mice. BV=Blood
vessels, SHG=second harmonic generation, LLC=tumor cells. Data are presented as mean with standard deviation for
all measurements. Statistical significances were analyzed by One-way ANOVA with Dunnett’s multiple-comparison
test (C,E,F) or Two-way repeated-measures ANOVA with Tukey’s multiple-comparison test (G).
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2.5.4 ETV2 regulates VEGF response in TAECs
VEGF is crucial for tumor angiogenesis. Previous studies have established a positive feedback
regulation between Etv2 and Flk1 expression in development(118, 135). We therefore determined
if Etv2 deficiency might lead to defects in VEGF responsiveness in TAECs. Flk1 expression was
similar in steady-state ECs from both wild-type and Etv2 CKO mice. However, while Flk1
expression was readily upregulated in TAECs in the wild-type mice, Flk1 expression in the Etv2
deficient TAECs remained similar to steady-state ECs (Figure 2.5A). As expected, intra-tumoral
lentiviral Etv2 shRNA injection significantly inhibited Etv2 expression in the TAECs, reduced
TAEC proliferation, and restricted tumor growth and angiogenesis (Figures 2.5B-E). Importantly,
tumor-associated vessels, but not the non-tumor vessels, had reduced activating-phosphorylation
of FLK1(136) after Etv2 shRNA injection, suggesting that Etv2 regulates Flk1 expression and
activation in a TAEC-specific manner (Figures 2.5F and 2.5G).
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Figure 2.5: Etv2 regulates tumor endothelial cell-specific Flk1 in mice. (A) qRT-PCR analysis of Flk1 expression
in lung ECs (LECs) and tumor ECs (TAECs) obtained from littermate control (WT) and Tie2-Cre;Etv2 CKO mice,
on day 15 post-translation (n=5/group). (B) qRT-PCR analysis of Etv2 expression in CD31+CD45- ECs obtained from
tumors of Gfp shRNA (control) and Etv2 shRNA treated mice, on day 15 post-translation. Data are shown as %relative
expression of control shRNA group (n=4/group). (C) Tumor growth in Gfp shRNA (control) and Etv2 shRNA treated
mice; n=6(control), 7(Etv2 shRNA); *p<0.05,**p<0.01,***p<0.001. (D-G), Representative images and
quantification for (D) CD31 (red), (E) Ki67 (green), and (F,G) pFLK1 (Y951) (green) immunofluorescence of the
tumor sections (D-F) and lung sections (G). LLC-GFP cells (blue) and nuclei counstained with DAPI (grey) are shown.
White arrows indicate the expression of Ki67(E) and pFLK1(F) in tumor vessels. Scale bars: 100µm(D) and 50µm(EG). Data are presented as mean with standard deviation for all measurements. Statistical significances were analyzed
by either a two-tailed Student’s t-test (B, D, E, F, G) or Two-way ANOVA with Sidak’s (A) or Tukey’s (C) multiplecomparison test.
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Notably, Etv2 deficiency does not appear to disturb FGF (fibroblast growth factor) signaling as
Frgfr1, Fgfr2, and Fgfr3 expression in both TAECs and non-tumor ECs were similar in wild-type
and Etv2 CKO mice (Figure 2.6A). Etv2 deficient lung-ECs showed reduced proliferation to VEGF
stimulation, but not FGF2, compared to controls (Figure 2.6B). Additionally, Etv2 deficient aortas
displayed diminished VEGF-induced, but not FGF2-induced, sprouting in aortic ring assay (Figure
2.6C)(137). Moreover, lenti-Etv2 shRNA infected YSE (yolk sac-derived endothelial) cells
displayed defective tube formation in response to VEGF, but not FGF2, compared to wild-type
YSE cells (Figure 2.6D). These results indicate that Etv2 regulates VEGF singling in TAECs.
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Figure 2.6: Etv2 regulates VEGF signaling in angiogenic endothelial cells. (A) qRT-PCR analysis of Fgfr1, Fgfr2,
and Fgfr3 expression in CD31+CD45- ECs obtained from the tumor and lungs of wild-type littermate control and Tie2Cre;Etv2 CKO mice, 15 post-transplantation (n=3 or more/group). (B) Lung-ECs of littermate-control (WT) or Tie2Cre;Etv2 CKO mice were sorted and subjected to cell proliferation assay. Data is shown as a percentage of control
(0.5% serum) (n=4/group). (C) Aortas from the controls (WT) and Tie2-Cre;Etv2 CKO mice were subjected to
angiogenic sprouting assay, and the mean sprout number and length were measured 8 days later. VEGF; vascular
endothelial growth factor. FGF2; fibroblast growth factor 2. Scale bars: 100µm. (n=5 or more/group). (D)
Representative images from tube formation assay with wild type yolk sac derived endothelial cells (YSE) and lentiviral
Etv2 shRNA infected YSE cells to probe VEGF and FGF responsiveness. Scale bars: 200µm. Data are presented as
mean with standard deviation for all measurements. Statistical significances were analyzed by either a two-tailed
Student’s t-test (A), or Two-way ANOVA with Sidak’s (B,C) multiple-comparison test.
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2.5.5 Reactive Oxygen Species (ROS) activate Etv2 expression
Developmental angiogenesis is controlled by changes in O2 tension(138, 139). Moreover,
oxidative stress underlies many of the characteristics of cancer(140). Particularly, reactive oxygen
species (ROS), increased in response to ischemia, hypoxia, inflammation, or growth factors such
as VEGF and angiopoietin-1, play a critical role in angiogenesis(141). Thus, we determined if
ROS could trigger Etv2 expression in TAECs. Higher ROS levels were detected in TAECs
compared to steady-state lung or hindlimb ECs (Figure 2.7A). Remarkably, Etv2, Flk1, or Vegf
expression was greatly upregulated by H202 or L-buthionine-S,R-sulfoximine(BSO) in YSE cells
(Figures 2.7B and 2.7C). ROS also increased the expression of other Ets factors including Ets1,
Ets2, and Elk3 in YSE cells (Figure 2.7D). Additionally, 24h hypoxia followed by 24h
reoxygenation (H/R), which mimics the patho-physiological ischemic injury-reperfusion
condition(142, 143), or even 24h hypoxic exposure alone increased ROS and upregulated Etv2
expression in YSE cells; ROS scavengers inhibited this Etv2 expression (Figures 2.7E and 2.7F).
Remarkably, systemic ROS scavenger treatment reduced Etv2 expression in the TAECs and
reduced tumor growth in vivo (Figure 2.7G and 2.7H).
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Figure 2.7: ROS trigger Etv2 expression. (A) ROS levels in ECs obtained from lung (LEC), hindlimb tissue (HLEC)
or tumor (TAEC) (n=3 or more/group). (B-D) qRT-PCR analysis of (B,C) Etv2, Flk1, Vegf, and (D) Ets factors Elk3,
Ets1, and Ets2 expression in (B, D) H2O2 and (C) BSO treated YSE (yolk sac derived endothelial) cells (n=4 or
more/group). (E) ROS level and Etv2 expression in YSE cells underwent with 24h hypoxia (<1% oxygen) followed
by 24h normoxia (H/R) with/without ROS scavengers N-Acetyl cysteine (NAC; 5mM) and Apocynin (APO; 100mM)
(NAC) (n=4 or more/group). (F) qRT-PCR analysis of Etv2 expression in YSE cells following 24h hypoxia (<1%
oxygen) (n=4/group). (G) Etv2 expression in TAECs isolated from untreated and NAC+APO treated mice, on day 14
post-transplantation. (H) LLC tumor growth in untreated and NAC+APO treated mice. Mice were treated with daily
i.p. injections of vehicle or combination of NAC (200mg/kg) and APO (50mg/kg) for 10 days, from day 4 to day 13
post-transplantation. n=5(vehicle), 7(NAC+APO). **P<0.01,***P<0.001. Data are presented as mean with standard
deviation for all measurements. Statistical significances were analyzed by either a two-tailed Student’s t-test (F,G), or
One-way ANOVA with Dunnett’s (B-E) or Two-way repeated-measures ANOVA with Sidak’s multiple comparisontest (H).
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2.5.6 Etv2 siRNA nanoparticles effectively inhibit tumor angiogenesis and
tumor growth
As Etv2 expression is silent in steady-state ECs, we speculated that systemic anti-Etv2 strategy
could effectively block Etv2 expression in TAECs, without causing any potential vascular adverse
effects. To test this idea, we first determined if the Etv2 shRNA used was specific for inhibiting
Etv2, but not other Ets factors. Particularly, YSE cells infected with Etv2 shRNA, upon H2O2
treatment, greatly suppressed Etv2 upregulation, whereas upregulation of other Ets genes including
Fli1, Ets1, Ets2, and Elk3 were not affected, establishing the selectivity of Etv2 shRNA in
inhibiting Etv2 (Figure 2.8A). Next, we formulated nanoparticles composed of Etv2 siRNA (using
the same sequence as the shRNA) and a self-assembling peptide carrier (“p5RHH”), which has
been previously described(144) and used to deliver p65NF-kB siRNA to inhibit experimental
arthritis(145, 146). The p5RHH-siRNA nanoparticles (~55nm diameter) protect the siRNA from
serum deactivation, while avoiding reticuloendothelial system uptake, and deliver functional
oligonucleotides to selected inflammatory targets(147). We injected Etv2 siRNA-peptide
nanoparticles through tail-vein to the tumor-bearing mice, from days 9-17 post-transplantation,
every other day, for a total of five dosage. The nanoparticles reached the tumor effectively within
24hours of the injection (Figure 2.8B and 2.8C). Etv2 expression in TAECs, and tumor growth and
tumor angiogenesis were dramatically reduced, starting from 2 days after the first nanoparticle
injection (Figures 2.8D-F). An extended treatment scheme (days 5-23 post-transplantation, every
other day, for a total of ten dosage) continuously attenuated the tumor progression until the end of
the study (Figure 2.8G). Importantly, proliferation and FLK1 activation were inhibited in the
TAECs of Etv2 siRNA- peptide nanoparticles treated mice (Figures 2.8H and 2.8I).
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Figure 2.8: Systemic treatment with Etv2 siRNA peptide nanoparticle restricts tumor growth and angiogenesis.
(A) qRT-PCR analysis of Etv2, Fli1, Ets1, Ets2, and Elk3 expression in wild type YSE cells (WT) and lentiviral Etv2
shRNA infected YSE cells (shRNA) with/without 10µM H2O2 treatment (n=3/group; n.s.=not significant). (B) IVIS
imaging of whole-body and isolated tumor at 24h after the injection of Quasar705-tagged Etv2 siRNA-peptide
nanoparticles through tail-vein. (C) Representative images from fluorescence microscope for Quasar705-tagged Etv2
siRNA-nanoparticles (purple) in the tumor sections at 24h after the injection. (D) qRT-PCR analysis of Etv2
expression in TAECs isolated from scrambled and Etv2 siRNA nanoparticles treated mice, on day 15ptt (n=5/group).
(E) Tumor growth in the scrambled and Etv2 siRNA nanoparticles treated mice. Scrambled and Etv2 siRNA
nanoparticles were injected through the tail-vein of the mice on days 9, 11, 13, 15, and 17ptt; n=8(scrambled), 10(Etv2
siRNA); **p<0.01,***p<0.001. Right, representative images of mice with tumor from the treatment and control
groups. (F), Representative images and quantification for CD31 (red) immunofluorescence of the tumor sections (n=7
or more/group). LLC-GFP cells (blue) and nuclei counstained with DAPI (grey) are shown. Scale bars: 200µm. (G)

48

(B) Tumor growth in mice treated with scrambled and Etv2 siRNA nanoparticle for an extended period. Line fitted to
the bars showing the trend of the growth curve. Scrambled and Etv2 siRNA nanoparticles were injected through the
tail-vein of the mice on the indicated days (n=8/group; *p<0.05,**p<0.01,***p<0.001). (H,I) Representative images
and quantification for (H) Ki67 (green), and (I) pFLK1 (Y951) (green) immunofluorescence of the tumor sections
(n=7 or more/group). LLC-GFP cells (blue) and nuclei counstained with DAPI (grey) are shown. White arrows
indicate the expression of (H) Ki67 and (I) pFLK1 in tumor vessels. Scale bars: 50µm. Data are presented as mean
with standard deviation for all measurements. Statistical significances were analyzed by either a two-tailed Student’s
t-test (D,F,H,I) or One-way ANOVA with Bonferroni’s multiple-comparison test (A), or Two-way repeated-measures
ANOVA with Sidak’s multiple-comparison test (E,G).
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2.5.7 Etv2 siRNA nanoparticles do not elicit cardiovascular side-effects
Anti-angiogenic therapies like anti-VEGF treatments often have systemic and vascular side effects
that complicate and, at times, diminish the outcome of the treatment(103), as commonly targeted
VEGF is also required for vascular homeostasis(105, 106). Prior work has shown that the p5RHHbased nanoparticles exert no untoward immune stimulation, complement activation, and
appreciable toxicity toward blood components or major organs after multiple systemic doses(145).
To assess the safety profile of our employed Etv2 siRNA-peptide nanoparticle treatment in
cardiovascular systems, we injected the Etv2 siRNA nanoparticles into wild-type mice (every other
day, for a total of five dosages). Following the treatment, systolic, diastolic, and mean blood
pressures(148) were similar in the treated and control groups (Figure 2.9A). Pressure-diameter
measurements, commonly used to evaluate vessel mechanics(149), showed that the compliances
of the ascending aorta and carotid artery were equivalent for the treated and control groups (Figures
2.9B and 2.9C). Clinically relevant cardiac functions, including left ventricular interior and
posterior wall diameters following systole and diastole, relative wall thickness, mass index, and
fractional shortening, were found normal and equivalent across treated and control groups in
echocardiogram analysis (Figure 2.9D). Additionally, histological inspection of the H&E stained
samples of major vascular organs revealed no pathological abnormalities (Figure 2.9E).
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Figure 2.9: Etv2 siRNA peptide nanoparticle treatment does not adversely affect cardiovascular system and
functions. Wild-type mice were intravenously treated with vehicle, or scrambled siRNA, or Etv2 siRNA nanoparticles
for 5 times, every other day. (A) Systolic, diastolic, and mean blood pressure measurements in control (vehicle and
scrambled siRNA-nanoparticles) or Etv2 siRNA-nanoparticles treated mice. (n=5/group; n.s.=not significant). (B,C),
Pressure-diameter measurements of the (B) ascending aorta and (C) carotid artery over a range of pressures from 0 to
175 mmHg. (n=5/group; n.s.=not significant). (D) Heart rate, left ventricular mass, left ventricular mas index, relative
wall thickness, left ventricular posterior wall end diastole, left ventricular posterior wall end systole, left ventricular
internal diameter end diastole, left ventricular internal diameter end systole, intraventricular septal end diastole,
intraventricular septal end systole, and %fractional shortening in control (vehicle and scrambled siRNA-nanoparticles)
or Etv2 siRNA-nanoparticles treated mice, measured by echocardiogram analysis (n=5/group; n.s.=not significant).
(E) Representative images of H&E stained sections of heart, lungs, kidney, and liver harvested from control or Etv2
siRNA-nanoparticles treated mice; 20X magnification. Data are presented as mean with standard deviation for all
measurements. Statistical significances were analyzed by either One-way ANOVA with Bonferroni’s multiplecomparison test (A,D) or Two-way ANOVA with Tukey’s multiple-comparison test (B,C).
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To better understand the pharmacokinetics of the Etv2 siRNA nanoparticles, we injected a separate
group of mice with a single dose of the siRNA nanoparticles and performed HPLC on the blood
samples. After the IV administration of 0.5nmol of the siRNA nanoparticles to each wild-type
mouse, the siRNA nanoparticle plasma concentrations were still detectable at 3h (Figure 2.10A).
The mean elimination half-life of siRNA nanoparticle was calculated as 43 ± 27 min (Figure
2.10B). Together, these data suggest that Etv2 siRNA nanoparticle-based drugs can be considered
in the future to inhibit tumor angiogenesis without any obvious cardiovascular side effects.

Figure 2.10: Pharmacokinetics of Etv2 siRNA peptide nanoparticle. (A) Systemic disposition kinetics of siRNA
delivered by i.v. injection of p5RHH-siRNA nanoparticles to wild-type mice. Blood samples were collected at 10, 40,
and 180 minutes after the nanoparticles injection (n=4 or more/time point). Data is presented as Mean with standard
deviation. (B) Representative chromatograms of siRNA standard curve (left) and siRNA in plasma samples (right)
collected from siRNA-nanoparticle inected subjects (n=4 or more).
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2.6 Discussion
ETS factors are implicated to play a role in tumorigenesis(150). However, most studies are
restricted to tumor cell intrinsic effects. Thus, despite their prominent roles in developmental
angiogenesis(112, 126, 127), there have been limited studies on ETS factors in tumor
angiogenesis(151, 152). Herein, we show that while Etv2 expression is silent in adult steady-state
ECs, it is induced in TAECs in both human and mice. Importantly, Etv2 deficient mice supported
reduced tumor growth and angiogenesis. Etv2 deficient tumor vessels remained similar to
physiological steady-state vessels. Previous studies have established that tumor angiogenesis is
sensitive to oxygen tension. Particularly, tumor environment is known to be hypoxic, and hypoxia
induces angiogenesis through activating HIF1a and VEGF production(139, 141). Importantly,
developmental angiogenesis is also regulated by oxygen tension(138, 153). Our data suggest that
Etv2 is a redox-sensitive transcription factor, which is induced by ROS in TAECs. We show that
ROS levels were elevated in TAECs. ROS scavenging inhibited Etv2 upregulation in TAECs.
These studies enforce the notion that the genetic programs regulating developmental processes are
recapitulated in the pathologic disease processes.
Recent studies have established that the interplay among ETV2, VEGF and its receptor
VEGFR2/FLK1 is essential for hematopoietic and vascular development(118, 135). We have
recently demonstrated that the VEGF-FLK1 pathway is also required downstream of ETV2 in EC
regeneration(131). As in development and EC regeneration, the VEGF-FLK1 pathway seems to
be the target of ETV2 in tumor angiogenesis. In particular, while Flk1 expression levels were
elevated in wild-type TAECs compared to steady-state vessels, Flk1 expression levels in Etv2
deficient TAECs were similar to steady-state vessels. Moreover, Etv2 deficient ECs showed
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decreased endothelial proliferation, tube formation, and sprouting response to VEGF, not FGF,
compared to wild-type ECs. Thus, an important implication of our study is that VEGF targeting in
TAECs maybe selectively achieved through Etv2 inhibition. Intriguingly, other Ets genes were
greatly upregulated in Etv2 deficient TAECs. However, upregulation of other Ets genes was not
apparently sufficient to overcome Etv2 deficiency in tumor angiogenesis. Potential compensatory
mechanisms involving FGF signaling and other Ets factors in the residual tumor growth in Etv2
deficient mice need to be investigated in the future.
Currently, many RNAi-based drugs, including Vegf, Epha2, Vegfr1, are in clinical trials,
phase I or II to inhibit tumor angiogenesis(154-156). In the present work, we sought to define the
utility of a novel siRNA delivery approach using nanoparticles targeted to the Etv2. The
nanoparticle construct is composed of a self-assembling peptide (p5RHH)-siRNA complex that
serves to protect the siRNA from serum deactivation, while avoiding reticuloendothelial system
uptake and delivering functional oligonucleotides to selected inflammatory targets(144-146). Key
features of the complex that promote sequentially coordinated endosomal uptake, endosomal lysis,
and siRNA release depend on specific molecular features of the carrier peptide, which is derived
through modification of the bee venom peptide melittin(147). Selected amino acid truncations and
substitutions mitigate the undesirable pore-forming capacity of peptide, yet retain its ability to
condense siRNA and facilitate endosomal escape, as previously reported(157). A simple mixing
procedure of only 10 minutes yields a complex that is small enough (~55nm) to passively diffuse
rapidly into inflamed tissues, where it is retained, yet avoids hepatic sequestration(147). Using a
mouse tumor transplantation model, we demonstrated that systemic Etv2 siRNA-p5RHH
nanoparticle delivery can effectively inhibit tumor angiogenesis, without eliciting any
cardiovascular side effects. Future investigations on p5RHH-siRNA nanoparticles as a safe and
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effective clinical tool instead of viral vectors for delivering siRNA are warranted. Optimizing antiEtv2 strategy and delineating Ets factor redundancy and potential compensatory pathways in Etv2
deficient TAECs would be critical for improved and selective clinical anti-angiogenic
interventions. Potentially, combined chemotherapy and/or immunotherapy with Etv2 blockade
leading to vessel normalization could be beneficial for future treatment of solid tumors. Moreover,
Etv2 role in proangiogenic function of hematopoietic tumor microenvironment should also be
addressed in the future studies. In summary, we have demonstrated that Etv2 is a novel and critical
molecular marker specific for activated endothelial cells and that targeting Etv2 is a valid approach
for inhibiting tumor angiogenesis.
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Chapter 3: Dual role of endothelial Myct1 in
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3.2 Abstract
The crosstalk between angiogenesis and immunity within the tumor microenvironment (TME) is
critical for tumor prognosis. While pro-angiogenic and immunosuppressive TME promote tumor
growth, anti-angiogenic and immune stimulatory TME inhibit tumor progression. Therefore, there
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is a great interest in achieving vascular normalization to improve drug delivery and enhance antitumor immunity. However, anti-vascular endothelial growth factor (VEGF) mechanisms to
normalize tumor vessels have offered limited therapeutic efficacies for cancer patients. Herein, we
report that Myct1, a direct target of ETV2, was nearly exclusively expressed in endothelial cells.
In preclinical mouse tumor models, Myct1 deficiency reduced angiogenesis, enhanced high
endothelial venule formation, and promoted an anti-tumor immune environment, leading to
restricted tumor progression in Myct1 knockout mice. Analysis of The Cancer Genome Atlas
(TCGA) datasets revealed a significant (p<0.05) correlation between MYCT1 expression,
angiogenesis, and anti-tumor immunity in human cancers, as suggested by the decreased FOXP3
expression and increased anti-tumor macrophages in patients with low MYCT1 expression.
Mechanistically, MYCT1 interacted with tight junction protein ZO1 and regulated Rho GTPasemediated actin cytoskeleton dynamics, thereby promoting endothelial motility in the angiogenic
environment. Myct1-deficient endothelial cells facilitated trans-endothelial migration of cytotoxic
T lymphocytes and polarization of M1 macrophages. Myct1 targeting combined with anti-PD1
treatment significantly (p<0.05) increased complete tumor regression and long-term survival in
anti-PD1-responsive and -refractory tumor models in mice. Our data collectively support a critical
role for Myct1 in controlling tumor angiogenesis and reprogramming tumor immunity. Myct1targeted vascular control, in combination with immunotherapy, may become an exciting
therapeutic strategy.
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3.3 Introduction
Tumor vessels are abnormal, as characterized by irregular, tortuous, and leaky structures.
Malfunctioning vessels lead to a hypoxic environment where tumors thrive and eventually
metastasize to secondary sites. Following the initial report on the vasculature-dependent nature of
solid tumor progression 50 years ago(101), the notion of preventing new vessel formation created
a substantial interest in treating cancers. Extensive research has discovered several critical proangiogenic factors, including vascular endothelial growth factors (VEGFs) and fibroblast growth
factors, as potential targets for anti-angiogenic therapies(3, 153). However, despite impressive
potential shown in the preclinical studies, anti-angiogenic strategies like anti-VEGF treatment
generated modest clinical outcomes in cancer patients, possibly due to temporary vascular
normalization, angiogenic adaptive responses, and/or acquired resistance by the tumor(102, 158).
Pro-angiogenic factors like VEGFs are also required for physiological vascular maintenance,
contributing to the related toxicities and poor clinical outcomes of the anti-VEGF therapies(103,
105, 159). As such, new targets are required to develop anti-angiogenic approaches that may
empower cancer management.
Immunotherapies such as the immune checkpoint blockers and adoptive immune cell
transfer have revolutionized the field of oncotherapy by enabling the regression and long-term
control of previously incurable and aggressive tumors. However, they fail to produce clinical
benefits in a staggering proportion of patients, warranting in-depth studies focusing on the
functional crosstalk between different immunotherapeutic approaches and the constituents of the
tumor microenvironment. Accumulating data show that the abnormal nature of the tumor vessels
also profoundly influences the outcome of different immunotherapeutic strategies(160, 161).
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Moreover, several recent preclinical studies have shown that a combination of immunotherapy
with anti-angiogenic treatment could result in an improved outcome(162, 163). Better
understanding of the crosstalk between the angiogenic determinants and immunotherapies may
lead to more effective clinical strategies.
In this study, we identified Myct1 as a direct target of ETS transcription factor ETV2, which
we previously established to be a deterministic factor for vascular development, regeneration, and
tumor angiogenesis(116, 118, 131, 132, 164). According to Human Protein Atlas and
Immunological Genome Project databases, Myct1 expression is mainly restricted to hematopoietic
stem and progenitor cells and endothelial cells (ECs)(165, 166). We found Myct1 to be an
angiogenic gene by analyzing The Cancer Genome Atlas (TCGA) datasets from thirteen different
cancer types. Using five different preclinical mouse models of cancer, we established that Myct1
is required tumor angiogenesis and tumor growth. We show that although Myct1 is dispensable for
vascular development and homeostatic functions, it is crucial for the angiogenic responses elicited
by ECs that involve coordinated actin cytoskeletal activity. By analyzing both the human cancer
datasets using the CIBERSORT deconvolution algorithm(167) and mouse tumors from the
preclinical models, we observed a high correlation between endothelial Myct1 expression and the
immune output in the tumor microenvironment. Moreover, endothelial Myct1 regulates T cell
transendothelial migration and macrophage polarization, thereby shaping the tumor immune
environment. Finally, genetic ablation, both global and EC-specific, and siRNA-peptide
nanoparticle-mediated systemic targeting of Myct1 in combination with anti-PD1 immunotherapy
in preclinical mouse tumor models restricted tumor growth and significantly improved the longterm survival. These data establish a critical role for Myct1 in modulating the tumor vasculature
and remodeling of immune constituents of the tumor microenvironment.
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3.4 Materials and Methods
3.4.1 TCGA cancer patient dataset analysis for novel angiogenic regulator
genes, angiogenic score, differential gene expression, and immune
microenvironment
a. Mixture file generation
Manifests containing fragments per kilobase per million (FPKM) normalized RNA-Seq data from
14 TCGA cohorts—Breast Invasive Carcinoma (TCGA-BRCA), Lung Adenocarcinoma (TCGALUAD), Lung Squamous Cell Carcinoma (TCGA-LUSC), Kidney Renal Clear Cell Carcinoma
(TCGA-KIRC), Kidney Renal Papillary Cell Carcinoma (TCGA-KIRP), Head and Neck
Squamous Cell Carcinoma (TCGA-HNSC), Stomach Adenocarcinoma (TCGA-STAD), Ovarian
Serous Cystadenocarcinoma (TCGA-OV), Prostate Adenocarcinoma (TCGA-PRAD), Pancreatic
Adenocarcinoma (TCGA-PDAC), Sarcoma (TCGA-SARC), Colon Adenocarcinoma (TCGACOAD), Bladder cancer (TCGA-BLCA), and Testicular Germ Cell Tumors (TCGA-TGCT)—
were downloaded. Gzipped files from individual cohorts were then transferred to a central Excel
file using a python script. GDC.h38 GENCODE v22 GTF annotation was used to map Ensembl
stable protein ID’s to HGNC symbols in mixture files. Patients were then sorted by increasing
MYCT1 expression in each cohort.
b. Top Angiogenic regulator gene identification:
Similar genes detection function in GEPIA2(168) was used for building a co-expression network
to identify novel angiogenic regulators using a seed signature of genes implicated in the process
of angiogenesis. Briefly, the ‘seed gene signature’ were generated from the Hallmark
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Angiogenesis gene set and a similar core angiogenic gene signature used previously by taking the
genes that are common in the datasets(169-171). Genes with greatest co-expression with the ‘seed
genes’ were identified as potential regulators of angiogenesis. Genes from the signature gene set
were excluded in the top 100 gene list. The top 20 co-expressed genes are depicted in Table 1 and
the top 100 genes are depicted in Supplementary Table 1.
c. Angiogenesis Score Enrichment
A master angiogenesis signature list containing 56 genes upregulated in the process of
angiogenesis was curated using 20 genes from a core primary tumor angiogenesis signature(169)
and 36 genes in the Hallmark Angiogenesis gene set derived from the molecular signatures
database(170). Using the curated signature, single sample gene-set enrichment analysis (ssGEA)
was conducted using Gene Set Variation Analysis (GSVA) for each patient in the 13 TCGA
cohorts to generate an enrichment score, which we term as the “Angiogenic Score”(172). A
correlation was calculated between angiogenesis scores and MYCT1 expression in each TCGA
cohort to identify if MYCT1 may play a role in the process of angiogenesis/tumor vasculature.
d. FOXP3 and FASLG expression
Patients within the 25th percentile of MYCT1 expression were grouped in the “LOW expression”
subgroup, while patients above the 75th percentile of MYCT1 expression were grouped in the
“HIGH expression” subgroup. Expressions of FOXP3 and FASLG were compared between the
two sub-groups. Grubbs test was used to identify outliers in the data, and a Mann-Whitney test
was used to calculate statistical significance with an alpha value of 0.05.
e. Immune Cell Fraction Deconvolution
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CIBERSORT, which uses a nu-support vector regression algorithm to estimate cell fractions in
inputted mixture files, was used to depict immune cell fractions from bulk RNA-Seq data as
previously described(167). Briefly, the leukocyte signature matrix, LM22, containing the
expression of 547 genes across 22 immune cell subtypes, was used to deconvolute immune cell
fractions for each patient in all cohorts. CIBERSORT was run on the R environment (version 3.61)
using 100 permutations to generate leukocyte fractions for each patient in a given cohort. An alpha
value of 0.05 was used to filter nonsignificant deconvolution results. Patients within the 25th
percentile of MYCT1 expression were grouped in the “LOW expression” subgroup, while patients
above the 75th percentile of MYCT1 expression were grouped in the “HIGH expression”
subgroup. The ratio between pro-tumoral macrophages (M2) and anti-tumoral macrophages (M1)
was computed for high and low expression MYCT1 groups. Moreover, the abundance of activated
natural killer cells and activated dendritic cells were calculated for high and low expression
MYCT1 groups. Patients with inconclusive deconvolution results for any of the aforementioned
immune cell subtypes were excluded from the analysis. The Grubbs test was used to identify
outliers in the data, and a Mann-Whitney test was used to calculate statistical significance with an
alpha value of 0.05.

3.4.2 Animals
C57BL/6 mice were used as wild-type mice in this study. Myct1-/- (Myct1 KO) mice were generated
at the Genome Engineering and iPSC Center (GEIC), Washington University in St. Louis by
utilizing the CRISPR/CAS9 technology. Briefly, the gRNA SM767.Myct1.g1 was selected for
oocyte microinjection. The resulted F0 mosaic pups were genotyped with targeted deep sequencing
to identify pups with the majority of the reads being out-of-frame. Next, the selected pup
(ID#9129) was crossed with C57BL/6 wild-type mice to get the F1 heterozygous mice. Finally,
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sibling mating of the sequence-verified F1 heterozygous mice (Myct1+/-) produced F2 Myct1 KO
mice with a 2bp insertion and 6bp deletion in the first exon of the Myct1 gene, which generated an
early stop codon and resulted in knocking out of the gene. Cdh5-Cre;Myct1f/f mice were generated
at the Emory University. Briefly, to generate Myct1f/f mice, the loxP sequences were inserted in
front of exon 2 and immediately after the termination codon of Myct1 (Cyagen, Santa Clara, CA).
After confirming the germ line transmission, the NeoR selection cassette was deleted, and Myct1f/+
mice were crossed with Myct1f/+ mice to generate Myct1f/f mice. Subsequently, Myct1f/f mice were
crossed with Cdh5-Cre mice (The Jackson Laboratory, Bar Harbor, ME) to generate Cdh5Cre;Myct1f/f conditional KO mice (EC specific Myct1 KO). The resulting mice were born alive,
fertile, and do not show any phenotypic defect. MMTV-PyMT mice were a gift from Mikala
Egeblad, Cold Spring Harbor Laboratory, and crossed with Myct1 KO mice to generate Myct1 KO
in the presence of MMTV-PyMT transgene (MMTV-PyMT Myct1-/-). VECadherin-Cre;Etv2 CKO
(VECadherin-Cre; Etv2flox/flox) mice were generated as described previously(131). Littermate
subjects were used as a control with the different knockout mice. Both male and female mice were
used in an equal quantity in any given experiment except experiments utilizing both the genetic
and orthotopic breast tumor models, where only female mice were used. The ages of the
experimental animals were between 10 and 12 weeks.

3.4.3 Bone marrow (BM) chimeric mice generation
As described previously, wild-type recipient mice (CD45.1) were lethally irradiated with 950rad
irradiation(173). Donor BM from the control (CD45.2) and Myct1 KO (CD45.2) mice were
transplanted into the recipient mice retro-orbitally the next day. Flow cytometric analysis of the
peripheral blood after 5-months of transplantation confirmed the successful BM reconstitution and
generation of ‘hematopoietic Myct1 KO BM chimeric’ mice. Alternatively, lethally irradiated
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wild-type (CD45.2) and Myct1 KO (CD45.2) recipient mice received BM transplantation from
wild-type (CD45.1) donors and generated ‘stromal Myct1 KO BM chimeric’ mice.

3.4.4 Arterial blood pressure, heart rate, and pressure-diameter
measurement
Myct1 KO and wild-type littermates were secured under 1.5% isoflurane anesthesia. A Millar
pressure catheter (Cat: SPR-671, Millar, Inc.) was introduced to the ascending aorta and heart rate,
arterial systolic, diastolic, and mean blood pressures were recorded using the PowerLab data
acquisition system (ADInstruments, Inc.). The ascending aorta and left common carotid artery of
the mice were dissected and mounted on metal cannulae in a pressure myograph (Danish Myo
Technology). Intravascular pressure was increased from 0 to 175 mmHg in 25 mmHg increments,
and the vessel diameter was recorded at each pressure point. The average of 3 measurements at
each pressure was reported.

3.4.5 Doppler echocardiography
The Mouse Cardiovascular Phenotyping Core at Washington University School of Medicine
performed a noninvasive cardiac Doppler ultrasound examination of the Myct1 KO and littermate
control mice under light anesthesia. VisualSonics Vevo-2100 cardiac echocardiography system
(FUJIFILM, VisualSonics Inc.) was used to examine and illustrate the structures and functions of
the heart and the great vessels.

3.4.6 Zebrafish morpholino injection and rescue experiments
The zebrafish embryos used in this study were Tg(flk1:EGFP)s843(174). For knockdown of
myct1, myct1 translation blocking ATG morpholino (myct1 MO) was purchased from Gene-Tools,
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LLC and injected into 1–2-cell-stage embryos(175). For rescue experiments, In vitro synthesis of
myct1 mRNA was performed using the mMESSAGE mMACHINETM T7 ULTRA kit (Cat:
AM1345, Ambion). myct1 mRNA were injected into 1-cell embryos. For live imaging, embryos
were anesthetized with 0.03% Tricaine (Cat: E10521, Millipore Sigma) and mounted in 0.8% lowmelting-point agarose (SeaPlaque GTG agarose, Cat: 50111, Lonza) on glass-bottomed 35-mm
dishes (MatTek). Afterward, embryos were imaged using a Nikon A1si laser-scanning confocal
microscope. Images were processed using NIS-Elements AR Analysis 4.30 (Nikon) software.

3.4.7 Mammary tumorigenesis
MMTV-PyMT transgenic mice were utilized to generate a spontaneous model of breast cancer,
where MMTV-LTR drives the expression of mouse mammary gland-specific polyomavirus
middle T-antigen(176). Palpable tumors in the mammary gland of the MMTV-PyMT Myct1-/(Myct1 KO) mice were measured every week until 21-weeks of age to track the development and
progression of tumorigenesis. Tumor volume was calculated by the equation, Volume=(largest
diameter) x (smallest diameter)2 x 0.5.

3.4.8 Tumor transplantation studies
1 ml of growth factor reduced Matrigel (Cat: 354248; Corning) was mixed with 1 ml of cultured
LLC-GFP or B16F10 tumor cell suspension (2 x106/ml in PBS); 100μl of the mixture was
subcutaneously injected to the back of the mice. 1956-sarcoma cells were subcutaneously injected
as 1x106 cells in 150μl PBS per mouse to the back of the mice. PyMT-BO1 cells were
orthotopically injected as 1x105 cells in 50μl PBS per mouse to the mammary fat pad of the mice,
as described previously(177). For tumor explant transplantation experiments, chunks of tumor
harvested from both the WT and Myct1 KO MMTV-PyMT transgenic mice were minced, digested
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using Collagenase-III (for breast tumors) (Cat: LS004182, Worthington), along with Dispase-II
(Cat: D4693, Millipore Sigma) and Deoxyribonuclease 1 (Cat: LS002139, Worthington), finally
injected into the 1x10^6 cells in 50μl PBS per mouse to the mammary fat pad of the recipient mice.
Palpable tumors started to develop by 4-5 days after transplantation, and tumor growth were
measured until the end of the study. For overexpression studies, relevant lentiviral particles were
intra-tumor injected as 15ml/injection for a viral content of 2x10^6 TU/injection, as many times
as indicated in the relevant figures. For in vivo checkpoint blockade treatment studies, rat IgG2ak
anti-mouse PD1 antibody (Cat: P372, Clone: RMP1-14, Leinco Technologies) was injected
intraperitoneally at a dose of 200µg/day(178). For different immune compartment neutralizing
treatment modalities, rat IgG2bk anti-mouse CD4 (Cat: C2838, Clone: GK1.5, Leinco
Technologies), rat IgG1 anti-mouse CD8b.2 (Cat: C2836, Clone: 53-5.8, Leinco Technologies),
and hamster IgG anti-mouse IFNg (Cat: I-1190, Clone: H22, Leinco Technologies) antibodies were
intraperitoneally injected at a weekly dose of 250µg/mouse(179). Rat IgG2a, rat IgG2b, and
hamster IgG1 (PIP) (Leinco technologies) isotype controls at similar doses were used as control.
IFNg cytokine (Cat: 315-05, Peprotech) was injected at a weekly dose of 500IU/g.

3.4.9 Preparation of Myct1 esiRNA-p5RHH peptide nanoparticle
For esiRNA nanoparticle treatment study, MISSION® esiRNA targeting mouse Myct1 (Cat:
EMU033761) was purchased. MISSION® siRNA Universal Negative Control #1 (Cat: SIC001)
was used as scrambled siRNA control. 100µM esiRNA solution was prepared by dissolving in
siRNA buffer (Cat: B-002000-UB-100, Dharmacon). 10µL of the esiRNA suspension was mixed
with 5µL of 20mM p5RHH peptide solution and 185µL of 1x HBSS (Gibco) to prepare the
nanoparticle complex and immediately injected into the mouse through the tail vein.
67

3.4.10

Flow cytometric analysis of tumor microenvironment

Tumor tissues were harvested, minced into fine pieces, and dissociated into single-cell suspensions
with an enzymatic digestion buffer consisting of Collagenase-II (for subcutaneous tumors) (Cat:
LS004176, Worthington) or Collagenase-III (for breast tumors) (Cat: LS004182, Worthington),
along with Dispase-II (Cat: D4693, Millipore Sigma) and Deoxyribonuclease 1 (Cat: LS002139,
Worthington). Next, the cell suspensions were incubated with LIVE/DEAD™ Fixable Blue Dead
Cell Stain Kit (Cat: L34961) along with different panels of fluorophore-conjugated antibodies for
macrophage and T cell populations, as detailed below. For subsequent intracellular staining, cell
suspensions were fixed and permeabilized using either Foxp3/Transcription Factor Staining Buffer
Set (Cat: 00-5523-00, ThermoFisher Scientific) or Intracellular Fixation & Permeabilization
Buffer Set (Cat: 88-8824-00, ThermoFisher Scientific) and subsequently stained with intracellular
antibodies. Samples were analyzed using either BD LSRFortessa™ X-20 (BD Biosciences) or BD
FACSymphony™ A3 (BD Biosciences) and later processed with FlowJo software (BD Life
Sciences). T cell and macrophage cell populations were expressed as % of CD3+ and F4/80+
population, respectively. The “Treg/CD8” and “M2/M1” values were generated by taking the
ratios of the abundance of indicated cell types in individual samples.
a. T cell panel: Anti-mouse antibodies
Surface staining: APC CD45 (Cat: 103112, Clone: 30-F11), PE CD3 (Cat:100206, Clone: 17A2),
BV650 CD4 (Cat: 100469, Clone: GK1.5), PerCP/Cy5.5 CD8a (Cat: 100734, Clone: 53-6.7), and
BV711 CD25 (Cat: 102049, Clone: PC61)
Intracellular staining: BV421 FOXP3 (Cat: 126419, Clone: MF-14)
b. Macrophage panel: Anti-mouse antibodies
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Surface staining: BV605 CD45 (Cat: 103155, Clone: 30-F11), BV421 CD11b (Cat: 101235,
Clone: M1/70), PerCP/Cy5.5 Gr1 (Cat: 108428, Clone: RB6-8C5), BV650 F4/80 (Cat: 123149,
Clone: BM8), APC CD206 (Cat: 141708, Clone: C068C2), and PE CX3CR1 (Cat: 149006, Clone:
SA011F11)
Intracellular staining: PE-Cy7 iNOS (NOS2) (Cat: 25-5920-80, Clone: CXNFT)

3.4.11

Immunofluorescence studies

Harvested tumors were thin sliced and fixed in 10% buffered formalin (Cat: 16004-112, VWR),
immersed in 30% (w/v) sucrose solution for 48 hours to cryo-protect the tissue, frozen in NEG-50
frozen section medium (Cat: 6502, ThermoFisher scientific) using liquid nitrogen and 2methylbutane system, and sectioned in 8µm thickness using a Leica Cryostat microtome (Cat:
CM1850, Germany). Afterward, tissue sections were blocked using freshly made blocking buffer
(3% essentially IgG free BSA (Cat: A9085), 0.3% Triton X-100 (Cat: X100), and Fc blocker (Cat:
101301)). Next, sections were incubated with different primary antibodies for 16h at 4°C, followed
by visualization with appropriate secondary antibodies. Finally, the sections were counterstained
for nuclei with DAPI, cured with ProLong Diamond Antifade mountant, and sealed with nail
polish for preservation. For the detection of intra-tumoral hypoxia in mice, Hypoxyprobe-1
solution (Cat: HP6-100Kit) was intraperitoneally administered 90 minutes prior to sacrifice as
100mg/Kg bodyweight. FITC-conjugated anti-pimonidazole mouse IgG1 monoclonal antibody
was used to detect the extent of hypoxia. For the vascular leakage and perfusion experiments,
FITC-conjugated 70KD Dextran (60mg/Kg bodyweight) (Cat: 46945) and FITC-conjugated
Lectin (8mg/Kg bodyweight) (Cat: L9381), respectively, were injected through tail-vein 15
minutes prior to sacrifice the mice. Hamster anti-mouse CD31 (Clone: 2H8, Cat: MA3105), rabbit
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anti mouse NG2 (Clone: Polyclonal, Cat: ab129051), rat anti-mouse CD8a (Clone: 53-6.7, Cat:
100701), and rat anti mouse MECA-79 (Clone: MECA-79, Cat: 120801) were used as primary
antibodies. AF568 goat anti-hamster (Cat: A-21112), AF488 goat anti-rat (Cat: A-11006), and
AF647 goat anti-rabbit (Cat: A-21245) were utilized as secondary antibodies. No-primaryantibody control and isotype controls (Armenian Hamster IgG (Cat: 14-4888-85), Rabbit IgG (Cat:
ab172730), and Rat IgM,k (Cat: 400801)) were performed as negative controls. The sections were
examined using the Olympus Fluoview 1200 confocal microscope system and minimally
processed with Imaris (Bitplane) software. At least five pictures from every section were processed
using ImageJ software (NIH) for quantification purposes.

3.4.12

Hindlimb ischemia injury

Hindlimb ischemia injury was inflicted by permanent ligation of the femoral artery, as described
before(131). Surface blood perfusion, as an indicator of vascular recovery, was measured using a
laser doppler perfusion imager (Moor Instruments, Devon, UK) as indicated. Images were
analyzed by the moorLDI Laser Doppler Imager Review software to quantify the blood perfusion
around and below the injured region. Adductor muscles from the injury-surrounding area were
harvested 28-day post-injury and processed for immunofluorescence investigation as described
above.

3.4.13

Cell lines

Mouse cardiac endothelial cells (MCEC) were purchased from CELLutions Biosystems Inc. (Cat:
CLU510). Myct1 overexpressing MCEC cell lines were generated by transducing parental MCEC
cells with either HA-Myct1 or Myct1-FLAG overexpressing lentiviral particles followed by
blasticidin selection (Cat: A1113903, ThermoFisher Scientific). As a rule of thumb, the
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knockdown cells were generated using a set of 5 shRNA clones for any specific gene as described
below. Myct1 KD, Etv2 KD, Zo1 KD, and Rhoa KD cell lines were generated by transducing the
parental MCEC cells with Myct1, Etv2, Zo1, and Rhoa shRNA lentiviral particles with puromycin
selection (Cat: A1113802, ThermoFisher Scientific). Overexpressing lentiviral particles of Myct1,
MYCT1, Zo1, and Rhoa were used to further transduce different knockdown cells with either
blasticidin or G418 selection (Cat: 10131027, ThermoFisher Scientific) for the generation of
different gene overexpression systems in the context of the different knockdown systems. MCEC
Myct1 KD Arhgdia KD cell line was developed by further transduction of MCEC Myct1 KD cell
line with Arhgdia shRNA lentiviral particles. Immortalized HUVEC (iHUVEC) cells were
generated by transfecting the HUVEC cells with pCDH-(LB12-FLAG-TERT)-EF1-NEO plasmid
using Lipofectamine 3000 (Cat: L3000001, ThermoFisher Scientific) following manufacturer’s
instruction, with subsequent G418 selection. iHUVEC MYCT1 KD cell line was developed by
transducing iHUVEC cell line with MYCT1 shRNA lentiviral particles followed by puromycin
selection. iHUVEC MYCT1 KD Myct1 overexpressing line was generated by further transducing
the iHUVEC MYCT1 KD cell line with Myct1 overexpressing lentiviral particles followed by
blasticidin selection. GFP expressing Lewis lung carcinoma (LLC cells; Cat: ATCC® CRL1642™) cells (LLC-GFP) were a gift from Alexander S Krupnick, University of Virginia. 1956
sarcoma cells, PyMT-BO1 cells, and human fibroblast cells BJ-5ta (Cat: ATCC® CRL-4001™)
were obtained from Robert D Schreiber, Katherine N Weilbaecher, and Andrew Yoo, respectively,
at Washington University in St. Louis. B16F10 melanoma cells (Cat: ATCC® CRL-6475™),
mouse fibroblast NIH/3T3 cells (Cat: ATCC® CRL-1658™), HUVEC cells (ATCC® CRL1730™), and HEK293T cells (Cat: ATCC® CRL-3216™) were purchased from ATCC. All cell
lines have been tested negative for mycoplasma contamination.
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3.4.14

Cell culture and treatment

LLC-GFP cells, B16F10 cells, PyMT-BO1, HEK293T cells, NIH/3T3 cells, and BJ-5ta cells were
cultured in DMEM high glucose (Cat: 11965092, ThermoFisher Scientific) growth medium
supplemented with 10% (v/v) FBS (Cat: 12103C, Millipore Sigma), 100 unit/ml penicillinstreptomycin (Cat: 15140122, ThermoFisher Scientific). 1956 sarcoma cells were cultured in
RPMI 1640 growth medium supplemented with 10% (v/v) FBS, 100 unit/ml penicillinstreptomycin, 1% (v/v) L-glutamine (200mM) (Cat: BW17-605E, ThermoFisher Scientific), 1%
(v/v) Sodium Pyruvate (100mM) (Cat: BW13-115E, ThermoFisher Scientific), 0.5% (v/v) Sodium
Bicarbonate (7.5%w/v stock) (Cat: BW17-613E, ThermoFisher Scientific), and 0.1% (v/v) 2Mercaptoethanol (Cat: M-6250, Millipore Sigma). All MCEC cell lines were maintained in M199
growth medium (Cat: 11150067, Gibco), supplemented with 20% (v/v) FBS, 100 unit/ml
penicillin-streptomycin, and 10mM HEPES (Cat: 15630106, ThermoFisher Scientific). Parental
and immortal HUVEC cell lines were cultured in Endothelial Cell Growth Medium (Cat: C-22010,
Promocell) supplemented with 100 unit/ml penicillin-streptomycin. For assays utilized endothelial
cell activation, parental and Myct1 KD MCEC cells were treated with either with TNFa (20ng/ml)
(Cat: 315-01A, Peprotech) for 12h or VEGF165 (50ng/ml) for 12h, as indicated.

3.4.15

Lentiviral shRNA and overexpression particle production

pLKpuro lentiviral mouse Myct1 shRNA clones TRCN0000246636 (NM_026793.2-680s21c1),
TRCN0000246635 (NM_026793.2-213s21c1), TRCN0000246634 (NM_026793.2-2456s21c1),
TRCN0000246633

(NM_026793.2-268s21c1),

459s21c1);

Zo1

mouse

shRNA

clones

and

TRCN0000257743

TRCN0000091618

(NM_026793.2-

(NM_009386.1-5678s1c1),

TRCN0000091619 (NM_009386.1-4410s1c1), TRCN0000091620 (NM_009386.1-1925s1c1),
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TRCN0000091621

(NM_009386.1-3986s1c1),

5003s1c1);

Rhoa

mouse

shRNA

clones

and

TRCN0000091622

TRCN0000068201

(NM_009386.1-

(NM_016802.3-733s1c1),

TRCN0000311121 (NM_016802.4-524s21c1), TRCN0000304743 (NM_016802.4-682s21c1),
TRCN0000302388

(NM_016802.4-733s21c1),

and

TRCN0000304744

(NM_016802.4-

605s21c1); mouse Arhgdia shRNA clones TRCN0000106162 (NM_133796.3-579s1c1),
TRCN0000106161 (NM_133796.3-858s1c1), TRCN0000106163 (NM_133796.3-651s1c1),
TRCN0000316502 (NM_133796.6-680s21c1), TRCN0000316589 (NM_133796.6-401s21c1);
mouse Etv2 shRNA clones TRCN0000084284 (NM_007959.1-93s1c1), TRCN0000084285
(NM_007959.1-52s1c1), TRCN0000084286 (NM_007959.1-887s1c1), and TRCN0000084287
(NM_007959.1-888s1c1); human MYCT1 shRNA clones TRCN0000137125 (NM_025107.1323s1c1), TRCN0000136533 (NM_025107.1-305s1c1), TRCN0000135843 (NM_025107.1262s1c1), TRCN0000423596 (NM_025107.2-60s21c1), and TRCN0000423608 (NM_025107.2996s21c1) were purchased from Millipore Sigma. HEK293T cells were transfected with the
mentioned

shRNA,

or

pCSII-EF1-(HA-mouseMYCT1)-IRES2-Bsr,

or

pCSII-EF1-

(mouseMYCT1-FLAG)-IRES2-Bsr, pcDNA3-EGFP-RHOA-wt, or pCB6-ZO1-myc, or pCSIIEF1-humanMYCT1-IRES2-Bsr constructs, along with pCAG-HIVgp and pCMV-VSV-G-RSVRev (with a ratio of 4:3:1) by using Calcium Phosphate method. Sixteen hours after transfection,
media was changed, and cells were then grown for additional 48h. Subsequently, supernatant was
harvested and concentrated by Lenti-X-Concentrator (Cat: 631232, Clontech). The virus titer was
determined using the Lenti-X™ p24 Rapid Titer Kit (Cat: 632200, Clontech).

3.4.16

Chromatin Immunoprecipitation (ChIP)-qPCR Assay

As described previously, differentiated iFLAG-ETV2 mESC (1x107 cells/IP) at day 3.5 were
cross-linked with 1% formaldehyde and lysed with cell membrane lysis buffer followed by further
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incubation with nuclear membrane lysis buffer(116). The lysate was incubated with anti-FLAG
antibody (Cat: 14793S, Cell Signaling Technology Inc.) followed by protein A/G sepharose beads
(Cat: sc-2002, Santa Cruz Biotechnology). The beads were washed to isolate immunoprecipitated
DNA fragments that were later subjected to qPCR.

3.4.17

Luciferase reporter assay

Three different sizes of Myct1 promoter regions and four different mutated ETS binding sequences
in the -383 bp fragment were cloned into pGL3vector. HEK293T cells were co-transfected with
pGL3 control vector and wild-type or mutant Myct1 promoter luciferase reporter constructs,
together with Renilla luciferase vector in the presence or absence of Etv2 expression plasmid
(pIRES-FLAG-ETV2) or Erg expression plasmid (pIRES-FLAG -ERG) or Fli1 expression
plasmid (pIRES-FLAG-FLI1), by lipofectamine 2000 (Cat: 11668027, Invitrogen). Forty-eight
hours later, cells were harvested, and luciferase activity was measured using the Dual-Luciferase
reporter assay system (Cat: E1910, Promega) according to the manufacturer’s instructions.

3.4.18

Flow cytometric analysis of MYCT1 localization

Parental, HA-Myct1, and Myct1-FLAG overexpressing MCEC cells were surface stained
following standard procedures utilizing APC conjugated anti-FLAG (Cat: 637307, Biolegend) and
PE tagged anti-HA (Cat: 901517, Biolegend) antibodies. Groups of cells selected for intracellular
staining were further fixed and permeabilized using BD Cytofix/Cytoperm™ Kit (Cat:
BDB554714, ThermoFisher Scientific) following manufacturer’s protocol and later incubated with
the same antibodies. Finally, the cells were washed and resuspended in flow cytometry staining
buffer (Cat: 00-4222-26) and analyzed with BD LSRFortessa™ X-20 (BD Biosciences).
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3.4.19

Endothelial cell proliferation assay

Overnight serum-starved parental and Myct1 KD MCEC cells were plated on a 6-well plate (6x104
cells/well) and incubated with APC BrdU (10µM) (Cat: 557892, BD Pharmingen) in 5%
FBS/DMEM medium for 3 hours and subjected to BrdU staining according to the manufacturer’s
instruction.

3.4.20

Tube formation assay

Overnight serum-starved endothelial cells were plated on Matrigel (Cat: 96992, Corning) coated
24-well plates (3x104 cells/well) and incubated at 37°C for 6 hours before taking pictures with a
Leica DFC 310 FX microscope system. Angiogenesis analyzer module of ImageJ software (NIH)
was used to quantify total tube length, number of loops, and number of branches.

3.4.21

Tumor spheroid endothelial cell co-culture

Tumor spheroids were generated using the hanging-drop method, as described previously(180).
Briefly, 50μl of LLC tumor cells suspension (4x105 cells/ml in complete media) was added to the
top of a petri dish and hanged upside down carefully. An adequate amount of sterile PBS was
added to the bottom of the petri dish to keep the inside hydrated. Hanging drops of tumor cells
were incubated for 3-4 days until spheroids of defined shape and structure were formed. Using a
wide bore pipette, spheroids were carefully transferred to a flat bottomed 96-well plate coated with
50μl of growth factor reduced Matrigel. Complete growth media with parental or Myct1 KD
MCEC cells were added to the wells and incubated at 37°C for 36 hours. A Leica DFC 310FX
brightfield microscope system was used to examine the tube structures and capture images.
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3.4.22

Fibrin gel bead sprouting angiogenesis assay

As described previously(181), parental and modified endothelial cells were coated on Cytodex 3
microcarrier beads (Cat: 17-0485-01, GE Healthcare). Coated beads were then resuspended in
Fibrinogen solution (Cat: F8630, Millipore Sigma), supplemented with Aprotinin (Cat: A1153,
Millipore Sigma). 500μl of this bead suspension is transferred to each well of a 24-well plate
containing 20μl of Thrombin (50 unit/ml in DPBS) (Cat: T3399, Millipore Sigma). After the gel
solidifies, either NIH/3T3 mouse fibroblast cells or BJ-5ta human fibroblast cells were added to
the wells. The wells were monitored for the sprouting using a bright-field microscope, and pictures
were taken using a Leica DFC 310 FX microscope system. ImageJ software (NIH) was used to
count the number of sprouts/bead and average sprout lengths. For competition assay, parental and
Myct1 KD MCEC cells were labeled with PKH26 red fluorescent dye (Cat: PKH26GL, Sigma)
and PKH67 green fluorescent dye (Cat: PKH67GL, Sigma), respectively, prior to the bead coating
step following manufacturers instruction. The wells were examined using the Nikon A1Rsi
scanning confocal microscope and minimally processed with Imaris (Bitplane) software to prepare
the figures.

3.4.23

Migration assay

Overnight serum-starved endothelial cells were seeded on the PET membrane (8µm pore size) of
an insert (Cat: 351152, Corning) as described previously(182). The inserts were hanged on a 24well support plate (Cat: 353504, Corning), which had a 75% confluent monolayer of cultured LLCGFP tumor cells. Alternatively, the wells had complete growth media with 50ng/ml VEGF-A165
(Cat: 450-32, Peprotech). After 12 hours of incubation at 37°C, the inserts were washed with PBS
and transferred to a different plate to fix with 4% paraformaldehyde and counterstained with DAPI
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(Cat: D1306, ThermoFisher Scientific). The membranes were excised and mounted with ProLong
Diamond Antifade mounting media (Cat: P36965, ThermoFisher Scientific). Images were
captured by Olympus Fluoview 1200 confocal microscope and processed with ImageJ software
(NIH) to count the DAPI+ cells.

3.4.24

Wound closure assay

Parental and Myct1 KD MCEC cells were cultured overnight to reach a confluent layer in a well
separated by an insert (Culture–Insert 2 Well, Cat: 81176, iBidi). Subsequently, the insert was
removed to generate a cell-free gap, and 1 ml of medium with 0.5% FBS was added into the wells.
The area of the gap was captured by a phase-contrast microscope and calculated by ImageJ.

3.4.25

Cell motility PCR array

RT2 PCR array kit (Cat: PAMM-128Z, Qiagen) was utilized to profile expressions of 84 key genes
implicated in endothelial cell motility. RNA from parental and Myct1 KD MCEC cell sprouts in
the fibrin gel sprouting assay was isolated using Trizol (cat: 15596026, ThermoFisher Scientific).
Briefly, first, fibroblasts were removed using 0.25% Trypsin with 1μM EDTA (Cat: 25200056,
Gibco). Next, the fibrin gel was digested through an extended incubation with 0.25% Trypsin with
1μM EDTA in a conical tube at 37°C with constant agitation for 30 minutes. Isolated RNA was
converted to cDNA and used for PCR in accordance with the manufacturer’s protocol.

3.4.26

Immunocytochemistry studies

In both 2D and 3D systems, cells were fixed with 4% paraformaldehyde, permeabilized with 0.3%
Triton X-100, and blocked with 5% normal goat serum (Cat: 5425S, Cell Signaling Technology
Inc.). The samples were then incubated with mouse anti-FLAG (Cat: 701629), rabbit anti-HA (Cat:
PA1-985), mouse anti-HA (Cat: ab130275), rabbit anti-mouse GM130 (Cat: G-7295), rabbit anti77

mouse GIANTIN (Cat: 924302), and rabbit anti-mouse ZO1 (Cat: 61-7300) primary antibodies,
as required. AF488 Phalloidin (Cat: A12379) was used to visualize the actin cytoskeleton.
Otherwise, the cells were finally visualized with AF568 goat anti-rabbit (Cat: A-11011), AF568
goat anti-mouse (Cat: A-11004), AF488 goat anti-rabbit (Cat: A-11008), and AF488 goat antimouse (Cat: A-11001) secondary antibodies, as required, counterstained for nuclei with DAPI, and
finally mounted with ProLong Diamond Antifade mountant. The samples were examined with
Olympus Fluoview 1000, Nikon A1Rsi, Zeiss LSM 880 Airyscan confocal microscope system, as
required, and minimally processed with Imaris (Bitplane) or ImageJ software (NIH) software.

3.4.27

Co-Immunoprecipitation assay

After HA-Myct1 overexpressing MCEC cells were transfected with pCB6-ZO1-MYC tag
(Addgene Plasmid #30317) or pcDNA3.1-CKAP4-FLAG (GenScript), whole cells were lysed
with immunoprecipitation (IP) lysis buffer and centrifuged at 13,500×g. The supernatant was
incubated overnight with anti-FLAG (Cat: 14793S, Cell Signaling Technology Inc.), anti-HA (Cat:
ab9110, Abcam), and anti-MYC tag (Cat: ab32, Abcam) primary antibodies and precipitated with
protein A/G agarose beads. The beads were washed and resuspended in 50μl SDS gel-loading
buffer and performed western blot analysis.

3.4.28

Primary endothelial cell isolation

Endothelial cells from the lungs, heart, mammary gland, and tumor tissues (both transplanted and
mammary) were processed by standard enzymatic digestion consisting of Collagenase-I (for lungs)
(Cat: LS004196, Worthington), Collagenase-II (for heart and for subcutaneous tumors) (Cat:
LS004176, Worthington), and Collagenase-III (for mammary gland and breast tumors) (Cat:
LS004182, Worthington), along with Dispase-II (Cat: D4693, Millipore Sigma) and
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Deoxyribonuclease 1 (Cat: LS002139, Worthington). Next, samples were incubated with PE-Cy7
CD31 (Cat:102418) and APC CD45 (Cat:103112) antibodies. CD45-CD31+ endothelial cells were
FACS sorted using BD FACSAria II (BD Bioscience). Sorted endothelial cells were processed for
downstream applications like single-cell RNA sequencing utilizing 10x genomics platform and
total RNA isolation using RNeasy mini kit (Cat: 74104, Qiagen) or Trizol reagent (Cat: 15596026,
ThermoFisher Scientific) by following the manufacturer’s instructions.

3.4.29

T cells transendothelial migration assay

T cell migration potential across an endothelial barrier in vitro was assessed using a QCM™
Leukocyte Transendothelial Migration Colorimetric Assay kit (Cat: ECM557, Millipore Sigma)
following the manufacturers’ instruction. T cells used in the study were isolated from the spleens
harvested from 1956 sarcoma subcutaneous tumor-bearing wild-type mice with the APC CD45
(Cat: 103112, Clone: 30-F11), PE CD3 (Cat:100206, Clone: 17A2), BV650 CD4 (Cat: 100469,
Clone: GK1.5), PerCP/Cy5.5 CD8a (Cat: 100734, Clone: 53-6.7), and BV711 CD25 (Cat: 102049,
Clone: PC61) antibodies. Cytotoxic T cells and Treg cells were sorted using BD FACSAria™ II
(BD Biosciences) as CD45+CD3+CD8+ and CD45+CD3+CD4+CD25+ populations, respectively.
For TNFa and/or Rac1-inhibitor treated groups, endothelial monolayers were treated with either
TNFa (20ng/ml) for 12hours and/or Rac1-inhibitor NSC23766 (100 M) (Cat: ENZ-CHM1160010, Enzo Life Sciences) for 2hours and washed with PBS before placing the harvested T cells
on the endothelial monolayer. The relative abundance of migrated T cells was calculated by
measuring the absorption of the samples at 450nm following the WST-1 reagent staining.
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3.4.30

Monocyte polarization in endothelial cell co-culture assay

Peripheral blood was collected from 1956 sarcoma subcutaneous tumor-bearing wild-type mice
and surface stained for APC/Cy7 CD45 (Cat: 103116, Clone: 30-F11), BV421 CD11b (Cat:
101235, Clone: M1/70), PE/Cy7 F4/80 (Cat: 123114, Clone: BM8), PE CD115 (Cat: 135505,
Clone: AFS98), BV650 Ly-6G (Cat: 127641, Clone: 1A8), BV510 anti-mouse Ly-6C (Cat:
128033, Clone: HK1.4), and APC CX3CR1 (Cat: 149007, Clone: SA011F11) antibodies. Classical
monocytes were sorted as CD45+CD11b+F4/80+CD115+Ly-6G-Ly-6C+CX3CR1low population
using BD FACSAria™ II (BD Biosciences) and plated on a monolayer of either parental or Myct1
KD MCEC cells (pre-activated with TNFa), along with either LPS (20ng/L) (Cat: L2637,
Millipore Sigma) and IFNg (10ng/L) (Cat: 315-05, Peprotech) for M1 polarization or IL-4
(20ng/L) (Cat: 214-14, Peprotech) for M2 polarization. Finally, the cells were stained with
APC/Cy7 CD45 (Cat: 103116, Clone: 30-F11), BV421 CD11b (Cat: 101235, Clone: M1/70),
PE/Cy7 F4/80 (Cat: 123114, Clone: BM8), BV605 CD206 (Cat: 141721, Clone: C068C2), and
AF488 iNOS (NOS2) (Cat: 25-5920-82, Clone: CXNFT) antibodies and analyzed using BD
FACSymphony™ A3 (BD Biosciences). FlowJo (BD Life Sciences) software was used to process
the data.

3.4.31

Quantitative real-time reverse transcription PCR (qRT-PCR)

cDNA was prepared with qScript™ cDNA SuperMix (Cat: 101414-106, VWR) according to the
manufacturer’s protocol. Gene expression was measured by quantitative real-time RT-PCR using
primers detailed in table 3.1.
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Table 3.1: Sequences of primers used in the study.
ChIP-qPCR= Chromatin Immunoprecipitation combined with quantitative Polymerase Chain
Reaction.
qRT-PCR = Reverse transcription quantitative real-time polymerase chain reaction
Gene

Forward sequence

Reverse sequence

Description

Myct1

GCACTTAGCAACGAGGGAGG

TTTCACGCAACCCCACGTA

ChIP-qPCR

Negative control

TGGGCATATCCCTGGAGCTT

GGCCATCCCACAGTCACAAC

ChIP-qPCR

Myct1 promoter (-

CAATCGGTACCGCATTGCACTCAGGT

CAATCAAGCTTAATGTCCACAAGA

Luciferase construct

383)

GAAGCT

AAAAGAAGCCA

cloning

Myct1 promoter (-

CAATCGGTACCGCCTAGAGATGAAT

CAATCAAGCTTAATGTCCACAAGA

Luciferase construct

899)

TTTACT

AAAAGAAGCCA

cloning

Myct1 promoter (-

CAATCGGTACCGAGGAACCCTACCTT

CAATCAAGCTTAATGTCCACAAGA

Luciferase construct

1445)

TGCTT

AAAAGAAGCCA

cloning

Myct1 promoter

GAGGGAGGAAATGACGTTAAGGAAA

CACAAAACTATTTCCTTAACGTCA

Site directed

mutant 1

TAGTTTTGTG

TTTCCTCCCTC

mutagenesis

Myct1 promoter

GTGTCTGAGAGCCATGTTTAATTTTA

CTGTTTTTCTTATCTTAAAATTAAA

Site directed

mutant 2

AGATAAGAAAAACAG

CATGGCTCTCAGACAC

mutagenesis

Myct1 promoter

CGAGTATAAAAGCATTAAACATGAT

GTAAGTGTATCATGTTTAATGCTTT

Site directed

mutant 3

ACACTTAC

TATACTCG

mutagenesis

Myct1 promoter

GGAAACATGATACACTTACTTTTTTT

CTTGTGTTTACATAAAAAAAAGTA

Site directed

mutant 4

TATGTAAACACAAG

AGTGTATCATGTTTCC

mutagenesis

Myct1 WT

TAATAACACCAC GAGCTT AGG

ATGCCAGCCAAGCTGTATATG

Genotyping

Myct1 KO

TAATAACACCAC CA AGG

ATGCCAGCCAAGCTGTATATG

Genotyping

Myct1

ATGGCTAATAACACCACGAGC

CAGCGCCCAGAGAAATCCT

qRT-PCR

Arhgdia

AAGGACGATGAAAGCCTCCG

GGTCAGTCGAGTCACAATGACA

qRT-PCR

B2m

TTCTGGTGCTTGTCTCACTGA

CAGTATGTTCGGCTTCCCATTC

qRT-PCR

TERT

CCGATTGTGAACATGGACTACG

CACGCTGAACAGTGCCTTC

qRT-PCR

MYCT1

CAATCGGGCTGGTACTTGGAG

CGTGGGTGTAAGAAGACCTAGA

qRT-PCR

B2M

GAGGCTATCCAGCGTACTCCA

CGGCAGGCATACTCATCTTTT

qRT-PCR

Zo1

GCCGCTAAGAGCACAGCAA

TCCCCACTCTGAAAATGAGGA

qRT-PCR

Rhoa

AGCTTGTGGTAAGACATGCTTG

GTGTCCCATAAAGCCAACTCTAC

qRT-PCR

Sele

ATGCCTCGCGCTTTCTCTC

GTAGTCCCGCTGACAGTATGC

qRT-PCR
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Selp

CATCTGGTTCAGTGCTTTGATCT

ACCCGTGAGTTATTCCATGAGT

qRT-PCR

Icam1

GTGATGCTCAGGTATCCATCCA

CACAGTTCTCAAAGCACAGCG

qRT-PCR

Vcam1

AGTTGGGGATTCGGTTGTTCT

CCCCTCATTCCTTACCACCC

qRT-PCR

Rac1

GAGACGGAGCTGTTGGTAAAA

ATAGGCCCAGATTCACTGGTT

qRT-PCR

Trio

AGTCTGAGCACATTGTGTCCG

GCACGATGCACATGACTTCTA

qRT-PCR

Tiam

GAAGCACACTTCACGCTCC

CTCCAGGCCATTTTCAGCCA

qRT-PCR

Rhog

GCGCACCGTGAACCTAAAC

GTGGACTGGCAATGGAGAAAC

qRT-PCR

Faslg

TCCGTGAGTTCACCAACCAAA

GGGGGTTCCCTGTTAAATGGG

qRT-PCR

Nos2

GTTCTCAGCCCAACAATACAAGA

GTGGACGGGTCGATGTCAC

qRT-PCR

Nos3

GGCTGGGTTTAGGGCTGTG

CTGAGGGTGTCGTAGGTGATG

qRT-PCR

Pecam1

CTGCCAGTCCGAAAATGGAAC

CTTCATCCACCGGGGCTATC

qRT-PCR

Kdr

TTTGGCAAATACAACCCTTCAGA

GCAGAAGATACTGTCACCACC

qRT-PCR

Ifit1

CTGAGATGTCACTTCACATGGAA

GTGCATCCCCAATGGGTTCT

qRT-PCR

Il1a

CGAAGACTACAGTTCTGCCATT

GACGTTTCAGAGGTTCTCAGAG

qRT-PCR

Il6

TAGTCCTTCCTACCCCAATTTCC

TTGGTCCTTAGCCACTCCTTC

qRT-PCR

Il10

GCTCTTACTGACTGGCATGAG

CGCAGCTCTAGGAGCATGTG

qRT-PCR

Mx1

GACCATAGGGGTCTTGACCAA

AGACTTGCTCTTTCTGAAAAGCC

qRT-PCR

Isg15

GGTGTCCGTGACTAACTCCAT

TGGAAAGGGTAAGACCGTCCT

qRT-PCR

Irgm1

TGCTCCACTACTCCCCAACAT

GCTCCTACTGACCTCAGGTAAC

qRT-PCR

Irf1

ATGCCAATCACTCGAATGCG

TTGTATCGGCCTGTGTGAATG

qRT-PCR

Ccl1

GGCTGCCGTGTGGATACAG

AGGTGATTTTGAACCCACGTTT

qRT-PCR

Ccl4

TTCCTGCTGTTTCTCTTACACCT

CTGTCTGCCTCTTTTGGTCAG

qRT-PCR

Ccl17

TACCATGAGGTCACTTCAGATGC

GCACTCTCGGCCTACATTGG

qRT-PCR

Cxcl9

TCCTTTTGGGCATCATCTTCC

TTTGTAGTGGATCGTGCCTCG

qRT-PCR

Cxcl10

CCAAGTGCTGCCGTCATTTTC

GGCTCGCAGGGATGATTTCAA

qRT-PCR

Lif

ATTGTGCCCTTACTGCTGCTG

GCCAGTTGATTCTTGATCTGGT

qRT-PCR

Vegfa

GCACATAGAGAGAATGAGCTTCC

CTCCGCTCTGAACAAGGCT

qRT-PCR

Csf3

ATGGCTCAACTTTCTGCCCAG

CTGACAGTGACCAGGGGAAC

qRT-PCR

Tgfb

CTCCCGTGGCTTCTAGTGC

GCCTTAGTTTGGACAGGATCTG

qRT-PCR

Pdl1

GCTCCAAAGGACTTGTACGTG

TGATCTGAAGGGCAGCATTTC

qRT-PCR

Etv2

CTGGGAGCGGAATTTGGTTTC

GTAAAGCGGGGTTCCAGTCC

qRT-PCR

Gapdh

AGGTCGGTGTGAACGGATTTG

TGTAGACCATGTAGTTGAGGTCA

qRT-PCR
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3.4.32

Single-cell RNA sequencing

Cellular suspensions were loaded on a Chromium Single Cell Instrument (10X Genomics) to
generate single-cell GEMs. Single-cell RNA-seq libraries were prepared using version 2
Chromium Single-cell 3′ Library, Gel Bead & Mutiplex Kit (10X Genomics). Sequencing was
performed on Illumina NextSeq2500 and mapped to the mouse genome (build mm10) using
CellRanger software (10x Genomics, version 2.1.1). Sequencing data is available as GSE157879
and GSE146819.

3.4.33

Single-cell RNA-seq data QC and Normalization

Seurat was used for single-cell analysis(183). Single cells were filtered based on the following
criteria: mitochondrial gene expression less than 8% of total count number and cells with <95,000
counts. Regularized negative binomial regression using the SCTransform function in the Seurat
v3 package was used for normalization(184). Percentage mitochondrial gene expression was
regressed out in the process.

3.4.34

Previously published single-cell RNA sequencing datasets for analysis

Quality control of single cell RNA-sequencing of mice heart tissue and COLO205 tumor tissue
was conducted as described by authors(185). Briefly, cells with mitochondrial gene expression of
less than 10% and total counts between 3,000 and 40,000 were included for analysis. Seurat
package was used for downstream analysis.

3.4.35

Integration, Dimensionality Reduction, and Clustering

Pearson residuals generated using SCTransform function were used to integrate and remove batch
effects across conditions using Seurat v3(186). Forty principal components were computed and
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analyzed for significance using Jack Straw plots. Significant principal components were further
used to generate t-distributed stochastic neighbor embedding (t-SNE) and uniform manifold
approximation and projection (UMAP) plots. Unsupervised clustering using the Leiden algorithm
was completed using Seurat v3 and cell types were assigned using expression of characteristic
markers.

3.4.36

Single-Cell rEgulatory Network Inference and Clustering (SCENIC)

Normalized expression matrix from the Seurat object was inputted to run SCENIC and data was
scored using the 24453-motif database that searched 500bp upstream of the transcription start site
as previously described(187). Transcriptional activity for WT and Cdh5-cre Myct1fl/fl endothelium
were compared.

3.4.37

Gene Set Enrichment Analysis (GSEA)

Enrichment of mouse orthologous gene sets from the C5 and C2 gene set collections from the
molecular signatures database were calculated using GSEA(188). Normalized counts and
phenotype labels delineating genotype and cell cluster were inputted to generate enrichment results
for individual clusters and the WT vs Cdh5-cre Myct1fl/fl tumor endothelium comparison.

3.4.38

Gene Set Variation Analysis (GSVA)

GSVA was conducted to analyze the enrichment of biological activities within endothelial
cells(172). Endothelial cells were sorted and grouped by the expression of Myct1, and biological
activity, as represented by enrichment scores, were plotted and compared between cells expressing
low and high levels of Myct1.

84

3.4.39

Statistics

GraphPad Prism 8 software was used for performing statistical analysis and generating
graphs/plots. Data are presented as mean with standard deviation for all the measurements.
Statistical significance was determined by two-tailed unpaired Student’s t-test (for two groups)
and One-way ANOVA with Tukey’s multiple comparison test (for more than two groups). Nonparametric tests were used for non-log transformed gene expression data from the TCGA database.
p<0.05 was considered statistically significant.

3.4.40

Ethics statement

Animal husbandry, generation, handling, and experimentation were done in accordance with
protocols approved by the Institutional Animal Care and Use Committee of Washington University
School of Medicine in St. Louis.
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3.5 Results
3.5.1 Myct1 is a direct target of ETV2 and is an angiogenic regulator gene.
We first analyzed the expression profiles of more than 8,000 human cancer patients (from thirteen
different cancer types) from the TCGA database. We generated a list of the top 20 potential
angiogenesis regulatory genes (Table 3.2), whose expression correlates with “seed genes” that are
well characterized in angiogenesis and EC biology (Table 3.3)(169-171). Comparing this list with
the ETV2 transcriptional target genes(118), we found Flt1, Myct1, Ptprb, and S1pr1 as top
potential angiogenesis regulatory genes downstream of ETV2. Unlike the other genes, Myct1 has
never been implicated in angiogenesis; hence, we identified Myct1 as a potential novel angiogenic
gene. Consistent with this idea, we found that Myct1 expression is mostly restricted to ECs (Figure
3.1A).
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Table 3.2. Top 20 regulators of Angiogenesis identified by their correlated expression with seed genes
Rank

Gene Symbol

Full name

PCC

1

GPR4

G Protein-Coupled Receptor 4

0.92

2

LDB2

LIM Domain Binding 2

0.91

3

CXorf36

Chromosome X open reading frame 36

0.91

4

ADGRL4

Adhesion G Protein-Coupled Receptor L4

0.91

5

FLT1

Fms Related Tyrosine Kinase 1

0.9

6

CLEC14A

C-Type Lectin Domain Containing 14A

0.9

7

ECSCR

Endothelial Cell Surface Expressed Chemotaxis and Apoptosis Regulator

0.9

8

RP11-389C8.2

RP11-389C8.2

0.9

9

ESAM

Endothelial Cell Adhesion Molecule

0.9

10

MYCT1

Myc Target 1

0.9

11

CD93

Cluster of Differentiation 93

0.9

12

PLVAP

Plasmalemma Vesicle Associated Protein

0.89

13

S1PR1

Sphingosine-1-Phosphate Receptor 1

0.89

14

PTPRB

Protein Tyrosine Phosphatase Receptor Type B

0.89

15

ARHGEF15

Rho Guanine Nucleotide Exchange Factor 15

0.89

16

GIMAP8

GTPase, IMAP Family Member 8

0.89

17

PCDH12

Protocadherin 12

0.88
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18

EXOC3L2

Exocyst complex component 3-like 2

0.88

19

ZNF366

Zinc Finger Protein 366

0.88

20

GIMAP6

GTPase, IMAP Family Member 6

0.88

PCC = Pearson Correlation Coefficient
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Table 3.3: List of genes (termed as “seed genes”) to identify angiogenic regulatory genes
Gene Symbol

Full name

TEK

TEK receptor tyrosine kinase

CDH5

cadherin 5

DLL4

delta like canonical Notch ligand 4

EGFL7

EGF like domain multiple 7

KDR

kinase insert domain receptor

ROBO4

roundabout guidance receptor 4

VWF

von Willebrand factor

VEZF1

vascular endothelial zinc finger 1

EDIL3

EGF like repeats and discoidin domains 3

PECAM1

platelet and endothelial cell adhesion molecule 1

CD34

CD34 molecule

ENG

endoglin

ESM1

endothelial cell specific molecule 1

ADGRF5

adhesion G protein-coupled receptor F5

SELE

selectin E

PROM1

prominin 1

VEGFA

vascular endothelial growth factor A

RAMP2

receptor activity modifying protein 2

RGS5

regulator of G protein signaling 5

AGGF1

angiogenic factor with G-patch and FHA domains 1

ITGB3

integrin subunit beta 3

ITGAV

integrin subunit alpha V

ITGB5

integrin subunit beta 5

ANGPTL4

angiopoietin like 4
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Figure 3.1: Myct1 expression in heterogenous cell population from different mouse organs. (A) tSNE scRNAseq
projections and feature plots for different cell population and Myct1 expression, respectively, in different mouse organ.
These data are acquired from the Tabula Muris portal: https://tabula-muris.ds.czbiohub.org/
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Next, we performed a gene set variation analysis with the TCGA-derived patient datasets using a
signature of genes upregulated during angiogenesis to generate an “Angiogenic score” for every
patient (Table 3.4)(172). We found that MYCT1 expression was significantly (p<0.05) correlated
with the “Angiogenic score” in all of the cancers analyzed (Figure 3.2A).

Table 3.4: List of genes used to generate the “Angiogenic score” for patient datasets
across different cancer types
Symbol

Full Name

CDH5

cadherin 5, type 2 (vascular endothelium)

ELTD1

EGF, latrophilin and seven transmembrane domain containing 1

CLEC14A

C-type lectin domain family 14, member A

LDB2

LIM domain binding 2

ECSCR

endothelial cell-specific chemotaxis regulator

RHOJ

ras homolog gene family, member J

VWF

von Willebrand factor

TIE1

tyrosine kinase with immunoglobulin-like and EGF-like domains 1

KDR

kinase insert domain receptor (a type III receptor tyrosine kinase)

ESAM

endothelial cell adhesion molecule

CD93

CD93 molecule

PTPRB

protein tyrosine phosphatase, receptor type, B

GPR116

G protein-coupled receptor 116

SPARCL1

SPARC-like 1 (hevin)

EMCN

endomucin

ROBO4

roundabout homolog 4

ENG

endoglin

TEK

TEK tyrosine kinase, endothelial
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S1PR1

sphingosine-1-phosphate receptor 1

APOH

apolipoprotein H

APP

amyloid beta precursor protein

CCND2

cyclin D2

COL3A1

collagen type III alpha 1 chain

COL5A2

collagen type V alpha 2 chain

CXCL6

C-X-C motif chemokine ligand 6

FGFR1

fibroblast growth factor receptor 1

FSTL1

follistatin like 1

ITGAV

integrin subunit alpha V

JAG1

jagged canonical Notch ligand 1

JAG2

jagged canonical Notch ligand 2

KCNJ8

potassium voltage-gated channel subfamily J 8

LPL

lipoprotein lipase

LRPAP1

LDL receptor related protein associated protein 1

LUM

lumican

MSX1

msh homeobox 1

NRP1

neuropilin 1

OLR1

oxidized low density lipoprotein receptor 1

PDGFA

platelet derived growth factor subunit A

PF4

platelet factor 4

PGLYRP1

peptidoglycan recognition protein 1

POSTN

periostin

PRG2

proteoglycan 2

PTK2

protein tyrosine kinase 2

S100A4

S100 calcium binding protein A4

SERPINA5

serpin family A member 5

92

SLCO2A1

solute carrier organic anion transporter family member 2A1

SPP1

secreted phosphoprotein 1

STC1

stanniocalcin 1

THBD

thrombomodulin

TIMP1

TIMP metallopeptidase inhibitor 1

TNFRSF21

TNF receptor superfamily member 21

VAV2

vav guanine nucleotide exchange factor 2

VCAN

versican

VEGFA

vascular endothelial growth factor A

VTN

vitronectin
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Figure 3.2: Correlation between angiogenic scores and MYCT1 expression in TCGA cancer patient datasets.
(A) Correlation between angiogenic score and MYCT1 expression in TCGA derived datasets for breast cancer (TCGABRCA), LSCC (TCGA-LUSC), sarcoma (TCGA-SARC), prostate cancer (TCGA-PRAD), and CCRCC (TCGAKIRC), stomach adenocarcinoma (TCGA-STAD), bladder cancer (TCGA-BLCA), head-and-neck squamous cell
carcinoma (TCGA-HNSC), colon adenocarcinoma (TCGA-COA), ovarian cancer (TCGA-OV), pancreatic cancer
(TCGA-PDAC), PRCC (TCGA-KIRP), and testicular (TCGA-TGCT) cancer patients.
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Moreover, we found increased Myct1 expression in the tumor-ECs compared to the non-tumorECs in the mouse models (Figure 3.3A). In line with this, our analysis of a recently published
single-cell RNA sequencing dataset (GSE110501)(185) on the heterogeneous mouse tumor
stromal population revealed that Myct1 expression is observed exclusively in the tumor-ECs
(Figures 3.3B-D). Additionally, in the same dataset, compared to the EC population from a healthy
heart, tumor-EC population had a higher number of cells that expressed Myct1 (Figure 3.3E).
Together, these observations suggest that Myct1 plays a role in tumor angiogenesis/vasculature in
both human cancer and mouse tumor.

Figure 3.3: Exclusive pattern of Myct1 expression in the endothelial cells of tumor stromal compartment. (A)
Myct1 mRNA expression in CD31+CD45- ECs isolated from the (left) mammary glands of healthy WT mice, and the
lungs and mammary tumors of WT MMTV-PyMT mice at 21 weeks of age and (right) lungs and tumors of the tumorbearing WT mice at 14-days post LLC tumor transplantation. n=6/group. (B) tSNE scRNAseq projection of stromal
components with a total of 1266 cells isolated from mouse COLO205 tumor tissue (GSE110501 datasets). (C) Feature
plots depicting expression levels of Pecam1, and Myct1 genes. (D) Violin plot of Myct1 expression across cell types
in stromal compartment. (E) Relative proportion of endothelial cells expressing Myct1 in heart (838 cells) and tumor
(1266) endothelial cell population. Data is presented as mean with SD. Test of significance was performed by (left)
One-way ANOVA with Tukey’s multiple comparison test and (right) Student’s t-test. 2 biological replicates.
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We have identified one potential ETV2 binding site in the Myct1 promoter region by analyzing
previously published ETV2 ChIP-Seq data (Figure 3.4A)(118). This binding was validated by
ChIP-qPCR (Figure 3.4B)(116). Only ETV2 and no other ETS factors, such as FLI1 and ERG,
activated different luciferase constructs made with varying sizes of the Myct1 promoter region, all
containing the ETS binding motif. Mutations of the ETS binding motifs reduced luciferase activity,
implying that these sites are critical for ETV2 binding (Figures 3.4C and 3.4D). In vitro
overexpression of Myct1 rescued the tube-like structure formation, sprouting, and migration
defects observed in the Etv2 deficient ECs (Figures 3.4E-H). Finally, Myct1 was downregulated
in the tumor-ECs of the Etv2 conditional knockout (KO) mice (Figure 3.4I) and intra-tumoral
lentiviral Myct1 expression rescued impaired tumor growth and angiogenesis observed in Etv2
deficiency (Figures 3.4J and 3.4K)(164). In this experiment, intra-tumoral lentiviral Myct1
injection resulted in enforced expression of Myct1 in ECs, as well as in tumor cells and
hematopoietic cells (Figure 3.4L). To assess whether the observed phenotypic rescue is from nonendothelial enforced Myct1 expression, we generated Myct1 overexpressing Lewis lung carcinoma
(LLC) tumor cells and found that there is no growth advantage of these Myct1 overexpressing
tumor cells in the wild-type (WT) mice (Figures 3.4M and 3.4N). Additionally, tumor growth
patterns in our bone-marrow chimeric mice suggest that Myct1 expression in hematopoietic cells
does not contribute to tumor growth (as described below; see Figures 3.8A-E). Together, these
results suggest that Myct1 is an ETV2 direct target gene to regulate the angiogenic functionalities
of ECs.
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Figure 3.4: ETV2 direct target gene Myct1 is a novel regulator of angiogenesis. (A) Genomic snapshot illustrating
the ETV2 binding peak to the Myct1 promoter region. (B) ChIP-qPCR analysis of ETV2 binding to the Myct1 promoter
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region. n=7/group. (C,D) Luciferase construct design (C) and normalized reporter activity (D) for ETV2 binding motif
on Myct1. Three different sizes of Myct1 promoter regions, all containing the binding peak, and four different mutated
ETS binding sequences in the -383 bp fragment were cloned into pGL3vector. HEK/293T cells were co-transfected
with pGL3 control vector and wild-type or mutant (mt) Myct1 promoter luciferase reporter constructs, together with
Renilla luciferase vector in the presence or absence of ETV2 (pIRES-FLAG-ETV2), ERG (pIRES-FLAG-ERG), and
FLI1 (pIRES-FLAG-FLI1).n=15/group. (E) Etv2 and Myct1 expression in parental, Etv2 KD (mEKD), Etv2 KD Myct1
overexpressing (mEKD mMOE) MCEC cells. n=3/group. (F-H) Representative images and quantifications from fibrin
gel bead sprouting angiogenesis assay (F), Matrigel tube formation assay (G), and Boyden chamber migration assay
(H) with parental, Etv2 KD, and Etv2 KD Myct1 overexpressing (OE) MCEC cells. Nuclei counter stained with DAPI
(red) (H). Scale bar: 100 µm (F, H) and 250 µm (G). ***p<0.001 compared to the respective values in the absence of
ETV2 (null). (I) Myct1 mRNA expression in CD31+CD45- ECs isolated from the tumors of wild-type and VECCre;Etv2f/f (Etv2 KO)mice at. n=6/group. (J,K) Tumor growth (J) and representative images with quantification for
CD31+ vessel density (K) in PBS (control) and Myct1 lentiviral overexpression construct (intra-tumor) treated wildtype and Etv2 KO mice. CD31 (red), LLC (green), and nuclei (DAPI, blue). Scale bars: 100 µm. *p<0.05 at the end
of the study. (L) Myct1 expression in the ECs (endothelial cells: GFP-CD31+CD45-), HCs (hematopoietic cells: GFPCD45+ CD31-), and tumor cells (GFP+CD31-CD45-) isolated from the tumors of PBS (control) and Myct1 lentiviral
overexpression construct (intra-tumor) treated wild-type and Etv2 KO mice with LLC subcutaneous tumor model.
n=3/group. (M) Myct1 expression in different genetically modified LLC tumors, as indicated. n=3/group. **p<0.01,
n.s. not significant. (N) Tumor growth in WT mice transplanted with different genetically modified LLC tumors, as
indicated. *p<0.05, n.s. not significant. Data is presented as mean with SD. Test of significance was performed by
Student’s t-test (for two groups) or One-way ANOVA with Tukey’s multiple comparison test (for more than two
groups).
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3.5.2 Myct1 is dispensable for vascular development and homeostasis in mice
and zebrafish.
We generated Myct1-/- (Myct1 KO) mice by utilizing the CRISPR/CAS9 technology. Briefly, we
designed gRNA to target the first exon of the Myct1 gene and injected it together with Cas9 mRNA
into fertilized eggs (Figures 3.5A-C). By crossing the candidate knockout founder to wild-type
mice, we generated heterozygous (Myct1+/-) offspring and obtained Myct1 KO mice from the
brother-sister matings. Myct1 expression was undetected in the ECs isolated from the lungs of the
KO animals (Figure 3.5D), confirming the efficient deletion of the gene. Myct1 KO mice were
seemingly normal and exhibited histologically regular vasculature in different organ beds. Vital
cardiovascular parameters (Figures 3.5E), compliance profiles of the ascending aorta and carotid
artery (Figures 3.5F), and clinically relevant cardiac functions (Figures 3.5G) were similar between
the Myct1 KO and littermate control mice. Similarly, myct1 zebrafish morphants showed minimal
defects in vascular development (Figure 3.5H). Together, these observations suggest that Myct1 is
dispensable for vascular development, maintenance, and homeostatic functions.
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Figure 3.5: Myct1 is not required for vascular development and homeostasis. (A) Graphical representation of
gRNA (SM767.Myct1.g1) targeting to sequence very early (14bp down from the first ATG) in the open reading frame
of Myct1 gene. (B) Summary of deep sequencing results showing the allelic frequency and CRISPR/Cas9 out-of-frame
indels that will lead to the knockout of the Myct1 gene. Red dashed box indicates the mosaic pup (with -4bp InDel)
selected to generate founder F1 Myct1 heterozygous pups. (C) Genotyping strategy for Myct1 KO depicting the
different WT and KO forward primer and the common reverse primer. KO sequence has 2bp insertion (green) and
6bp deletion (red). Representative picture from genotypic gel-run is shown. (D) qRT-PCR analysis of mouse Myct1
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gene expression in the lung endothelial cells (EC) isolated from Myct1 KO and littermate wild-type (WT) mice.
n=3/group. (E,F) Vital cardiovascular measurements (E) and pressure-diameter measurements (F) in the Myct1 KO
and WT mice. n=9(KO) and 11(WT). n.s. not significant. (G) Clinically important cardiac functional parameters
measured by Doppler Echocardiogram of Myct1 KO and WT mice. n=3 (WT), 4 (Myct1 KO). n.s. not significant. (H)
Representative images for the zebrafish vascular development at 48 hours post fertilization (hpf) and 72hpf are shown
utilizing flk;GFP expression (green) as a vascular marker. Red arrows indicating the areas where minimal defects
were observed. To generate the KD and to rescue the KD phenotype, indicated amounts of morpholino (MO) and
mRNAs were injected, respectively. Data is presented as mean with SD. Test of significance was performed by
Student’s t-test (for two groups) or One-way ANOVA with Tukey’s multiple comparison test (for > two groups).
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3.5.3 Myct1 is required for efficient tumor growth and tumor vasculature in
multiple mouse models.
Since high Myct1 expression is observed in tumor ECs, we determined whether Myct1 deficiency
has any impact on tumor growth by employing five different (one transgenic, three subcutaneous
transplantation, and one orthotopic transplantation) mouse models of cancer. For the transgenic
model, we developed MMTV-PyMT; Myct1-/- mice as a spontaneous breast cancer model and
tracked the development and progression of the tumor in the mammary gland. For transplantation
models, we subcutaneously transplanted Lewis lung carcinoma (LLC-GFP)(164), B16F10
melanoma, and 1956 sarcoma tumor cells(189) and orthotopically transplanted PyMT-BO1
mammary tumor cells(190) to the mammary fat pad as described previously(164, 177). Compared
to the WT mice, Myct1 KO mice showed retarded tumor growth in all five of the tumor models;
the growth restricted tumors had reduced counts of tumor vessels, which had better pericyte
coverages (Figures 3.6A-J and 3.7A). Moreover, Myct1 KO mice exhibited subsided intra-tumoral
hypoxia (Figure 3.7B), improved vascular perfusion (Figure 3.7C), and reduced vascular leakage
(Figures 3.7D). These data demonstrate that although not essential for vascular development and
maintenance, Myct1 deficiency leads to reduced tumor growth and normalization of tumor vessels.
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Figure 3.6: Myct1 is required for tumor growth and angiogenesis. (A-C) Number of tumors per mouse (A), total
tumor burden (B), and representative images with quantification of CD31+ vessel density (C) in wild-type and Myct1
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KO MMTV-PyMT mice at 21 weeks of age. n=14/group. CD31 (red) and nuclei (DAPI, blue). Scale bars: 100 µm.
***p<0.001. (D,E) LLC tumor growth (D) and representative images with quantification for CD31+ vessel density
(E) in wild-type and Myct1 KO mice. CD31 (red), LLC (green), and nuclei (DAPI, blue). Scale bars: 100 µm.
**p<0.01 at the end of the study. (F,G) 1956-sarcoma tumor growth (F) and representative images with quantification
for CD31+ vessel density (G) in wild-type and Myct1 KO mice. CD31 (red) and nuclei (DAPI, blue). Scale bars: 100
µm. **p<0.001 at the end of the study. (H,I) PyMT-BO1 orthotopic tumor growth (H) and representative images with
quantification for CD31+ vessel density (I) in wild-type and Myct1 KO mice. CD31 (red) and nuclei (DAPI, blue).
Scale bars: 100 µm. **p<0.01. (J) B16F10 melanoma subcutaneous transplant tumor growth in wild-type and Myct1
KO mice. Data is presented as mean with SD. Test of significance was performed by Student’s t-test.

104

Figure 3.7: Myct1 deficient tumor vessels show improved vascular functions. (A) Representative
immunofluorescence images and quantification for pericyte (NG2+) coverage of tumor vessels (CD31+) in wild-type
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and Myct1 KO mice with indicated tumor models. CD31 (red), NG2 (green), and nuclei (DAPI, blue). Scale bars: 50
µm. **p<0.01. (B) Representative immunofluorescence images and quantification for intra-tumoral hypoxia as
measured by the relative abundance of Hypoxyprobe-1 binding to tumor tissue in wild-type and Myct1 KO mice with
1956 sarcoma tumor. CD31 (red), Hypoxyprobe-1 (green), and nuclei (DAPI, blue). Scale bars: 100 µm. **p<0.01.
(C,D) Representative immunofluorescence images and quantification for vascular perfusion (C) and vascular leakage
(D) as measured by the FITC-lectin binding to vessels and FITC-Dextran 70KD spread in the tumor tissue,
respectively, in wild-type and Myct1 KO mice with 1956 sarcoma tumor. FITC-Lectin (green) (C), FITC-Dextran
(Green) (D), CD31 (red), and nuclei (DAPI, blue). Scale bars: 100 µm. **p<0.01. Data is presented as mean with SD.
Test of significance was performed by Student’s t-test.
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3.5.4 Endothelial Myct1 is critical for tumor growth in mice.
While Myct1 expression is mostly restricted to the ECs, Myct1 is also expressed in hematopoietic
stem and progenitor cells (Figure 3.1A. See also Figure 3.3B-D)(165, 166, 191). To evaluate
whether the observed growth restrictive phenotype is dependent on EC-specific Myct1, we
generated two distinct bone marrow chimeras: ‘WT hematopoietic/Myct1 KO background’ and
‘Myct1 KO hematopoietic/WT background’ (Figures 3.8A) mice. ‘WT hematopoietic/Myct1 KO
background’ chimeric mice exhibited impaired tumor growth and vascular network formation, a
phenotype similar to Myct1 KO mice (Figures 3.8B and 3.8C). However, ‘Myct1 KO
hematopoietic/WT background’ chimeric mice exhibited tumor growth comparable to WT mice
(Figures 3.8D and 3.8E). Moreover, endothelial-specific Myct1 deletion in mice (Cdh5-cre
Myct1f/f) recapitulated the global Myct1 KO phenotype of retarded tumor growth and reduced
angiogenesis, together suggesting that hematopoietic Myct1 expression is dispensable for tumor
progression (Figures 3.8F-H).
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Figure 3.8: Endothelial Myct1 expression is relevant for tumor growth and angiogenesis. (A) Stromal and
hematopoietic Myct1 KO bone-marrow chimera mice generation scheme. Lethally irradiated WT and Myct1 KO
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recipient mice (CD45.2) were transplanted with WT donor bone-marrow (CD45.1) to generate the stromal Myct1 KO
mice, whereas lethally irradiated WT recipient mice (CD45.1) were transplanted with WT or Myct1 KO donor bonemarrow (CD45.2) to generate the hematopoietic Myct1 KO mice. Five months after the transplantation, complete
repopulation with the donor bone marrow was confirmed with flow cytometric analysis of CD45.1 (for stromal KO)
or CD45.2 (for hematopoietic KO) in the peripheral blood. n=6/group. n.s. not significant. (B-E) Tumor growths (B,
D) and representative images with quantification for CD31+ vessel density (C, E) in stromal Myct1 KO (B,C) and
hematopoietic Myct1 KO mice (D,E). CD31 (red), LLC (green) and nuclei (DAPI, blue). Scale bars: 100 µm. n.s. not
significant, **p<0.01 at the end of the study. (F) Genotyping strategy for Cdh5-cre Myct1f/f mice. Arrows in the top
panel indicate different PCR primers for the genotyping. TGA: Myct1 stop codon. Green arrows: forward 5’AATCCAGGCTCTGTGAAGTGG-3’, reverse 5’-GTGGCTCCCAAATTCCGCTTA-3’, Purple arrows: forward 5’
GGGCTTCGACTTTCCATCCCTTC-3’, reverse 5’-GGAACCTGTGCCTTATCGGT-3’. Bottom panel shows
representative images of the genotyping gel-run. (G,H) PyMT-BO1 orthotopic tumor growth (G) and representative
images with quantification for CD31+ vessel density (H) in wild-type and Cdh5-cre Myct1f/f mice. CD31 (red) and
nuclei (DAPI, blue). Scale bars: 100 µm. **p<0.01. Data is presented as mean with SD. Test of significance was
performed by Student’s t-test.
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To investigate whether Myct1 plays any role(s) in tumor cells, we assessed Myct1 expression in
the tumor cell lines that we have utilized in the present study and found that Myct1 expression is
not detectable (Figures 3.9A). To investigate whether synthetic Myct1 expression in tumor cells
contributes to the growth, we genetically modified the LLC tumor cells with either Myct1 shRNA
or Myct1 overexpressing lentivirus and the PyMT-BO1 tumor cells with Myct1 siRNA. We found
that either Myct1 siRNA or shRNA treatment or enforced expression of Myct1 in the tumor cells
did not play any role in the tumor growth kinetics (Figures 3.9B-E). Additionally, tumor explants
from neither the WT nor the Myct1 KO MMTV-PyMT mice exhibited any growth defects in the
WT recipient mice. However, explants from both types of mice showed tumor growth defects in
the Myct1 KO recipient mice (Figure 3.9F). Together these data suggest that Myct1 function in the
observed phenotype is tumor cell independent. We also modified a human fibroblast cell line (BJ5ta) that do not express MYCT1 by treating with MYCT1 shRNA or enforcing the expression of
MYCT1 with lentivirus. We found that neither of the modifications impacted the growth kinetics
and the angiogenic sprouting of the fibroblasts (Figures 3.9G-I). Collectively, these series of data
suggest an endothelial-specific role of Myct1 in tumor growth and angiogenesis.
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Figure 3.9: Only endothelial Myct1 is critical for tumor growth. (A) Myct1 expression in the indicated tumor cell
lines utilized in the present study. MCEC cell line data is provided for comparison. n=3/group. (B) Myct1 expression
in different genetically modified LLC tumors, as indicated. n=3/group. **p<0.01, n.s. not significant. (C,D) Tumor
growth in WT and Myct1 KO mice transplanted with different genetically modified LLC tumors, as indicated.
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*p<0.05, n.s. not significant. (E) Myct1 expression (left) and tumor growth in the WT mice (right) of cultured PyMTBO1 tumor cells treated with PBS or scrambled siRNA or Myct1 siRNA nanoparticle. n=3/group. n.s. not significant.
(F) Tumor growth in WT and Myct1 KO mice orthotopically transplanted with the tumor explants from the WT and
Myct1 KO MMTV-PyMT mice. *p<0.05, n.s. not significant. (G, H) Myct1 expression (G) and growth kinetics in
culture (H) for different genetically modified BJ-5ta fibroblast cells, as indicated. n=3/group. ***p<0.001 (I)
Representative images and quantifications of sprouts from the fibrin gel sprouting assay with the parental and Myct1
KD HUVEC cells and the parental, Myct1 KD, and Myct1 overexpressing BJ-5ta cells. n≥6/group. *p<0.05,
**p<0.01, and n.s not significant compared to WT HUVEC+WT BJ-5ta group. Scale bars: 100 µm. Data is presented
as mean with SD. Test of significance was performed by Student’s t-test (for two groups) or One-way ANOVA with
Tukey’s multiple comparison test (for more than two groups).
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3.5.5 Myct1 is also required for vascular regeneration in mice.
To investigate whether Myct1 is required exclusively for tumor angiogenesis, we utilized a
hindlimb ischemia injury model as described previously(131). We found that following the injury,
Myct1 KO mice had a lower blood perfusion recovery and neo-vascularization of the injured area
compared to the WT mice (Figure 3.10A and 3.10B), suggesting that Myct1 requirement is not
exclusive to tumor angiogenesis, rather other forms of neovascularization also require Myct1.

Figure 3.10: Myct1 is required for efficient vascular regeneration. (A) Blood perfusion ratios (left) and
representative images perfusion status (right) of the ischemic limb of the WT and Myct1 KO mice measured at
indicated days after the infliction of hindlimb ischemic injury. n=8/group. Data is presented as mean with SD.
Student’s t-test performed for individual data points. **p<0.01. (B) Representative images and quantifications for
CD31+ vascular density in the adductor muscle surrounding the injured area of the WT and Myct1 KO mice 21 days
after the infliction of hindlimb ischemia injury. CD31 (red) and nuclei (DAPI, blue). Scale bars: 150 µm. Data is
presented as mean with SD. Test of significance was performed by Student’s t-test (for two groups) or One-way
ANOVA with Tukey’s multiple comparison test (for more than two groups).
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3.5.6 MYCT1 interacts with ZO1 and regulates EC motility through actin
cytoskeleton in vitro.
Because very little is known about the cellular function of Myct1, we first assessed the subcellular
localization of MYCT1 in ECs. To this end, we generated mouse cardiac EC lines (MCEC)
expressing either N-terminal HA-tagged or C-terminal FLAG-tagged mouse Myct1 (Figure
3.11A). Flow cytometric analysis revealed that in the intact cells, while the anti-HA antibody
recognized HA-MYCT1, the anti-FLAG antibody did not recognize MYCT1-FLAG. On the
contrary, both the antibodies recognized HA-MYCT1 and MYCT1-FLAG in permeabilized cells
(Figure 3.11A). Immunofluorescence with anti-HA and anti-FLAG antibodies showed that
MYCT1 is indeed present at the plasma membrane, as well as in the cytoplasm, where it was found
colocalized mainly with GM130+ and GIANTIN+ Golgi apparatus (Figures 3.11B-D). Collectively,
these results demonstrate that MYCT1 is a membrane-spanning protein with an extracellular Nterminal and an intracellular C-terminal. This finding is consistent with a previous structural
prediction based on bioinformatic analysis of MYCT1(192).

114

Figure 3.11: MYCT1 is localized at cell membrane. (A) (left) Flow cytometric analysis of HA- and FLAG-tagged
MYCT1 overexpressing MCEC cells. (right) Graphical presentation of the HA- and FLAG-tagged MYCT1 protein
situated at the plasma membrane. (B-D) Representative images of HA-tagged and FLAG-tagged mouse MYCT1
protein overexpressing MCEC cells showing the cell membrane and cytoplasmic localization (B) and Golgi
colocalization (C,D) of MYCT1 protein. Anti-HA (green) (B), Anti-FLAG (green) (B), anti-GIANTIN (red) (C) and
anti-GM130 (red) (D) antibodies were used as described in the methods section. Nucleus was counterstained with
DAPI (blue). Scale bars: 15 µm (B,D) and 10 µm (C).
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We next developed Myct1 knockdown (KD) MCEC cells (Figure 3.12A) and assessed EC
functionalities. We did not observe any proliferative or maintenance disparity compared to the
parental cells, as supported by the similar cell cycle distribution between parental and Myct1 KD
cells (Figure 3.12B). However, Myct1 KD MCEC cells showed defects in tube-like structure
formation in the Matrigel assay (Figure 3.12C) and tumor spheroid/EC co-culture assay (Figures
3.12D). Myct1 KD MCEC cells also displayed defects in sprout formation on the fibrin gel matrix
(Figures 3.12E and 3.12F). Additionally, Myct1 KD MCEC cells lost their migratory
characteristics, as shown in the Boyden chamber tumor-chemotaxis assay (Figures 3.12G) and
wound-closure assay (Figure 3.12H). Together, these findings suggest that while Myct1 is not
required for the steady-state maintenance of ECs, it is essential for ECs responses in the angiogenic
environment.
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Figure 3.12: Myct1 is essential for angiogenic functionalities of endothelial cells. (A) qRT-PCR analysis of mouse
Myct1 gene expression in parental and Myct1 KD MCEC cells. n=3/group. (B) Representative FACS chart and
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quantifications for the BrdU cell proliferation assay with parental and Myct1 KD MCEC cells. n=3/group. (C)
Representative images and quantifications from the Matrigel tube formation assay. n=12/group. **p<0.01. Scale bars:
250µm. (D) Representative images from tumor-spheroid/EC co-culture assay. (E) Representative images and
quantifications of sprouts from the fibrin gel sprouting assay. n≥32/group. **p<0.01. Scale bars: 100 µm. 3 biological
replicates. (F) Representative image and quantification of sprouts from the fibrin gel sprouting assay with 1:1
competitive seeding of parental (red) and Myct1 KD (green) MCEC cells on the beads. Scale bar: 100 µm. *p<0.05.
(G) Schematic representation, representative images, and quantifications of cell migration from the Boyden chamber
assay. Nuclei (DAPI, red). n≥12/group. **p<0.01. Scale bars: 100 µm. (H) Representative images and quantifications
for recovery from the wound closure assay. n≥3/group. *p<0.05. Scale bar: 100µm. Data is presented as mean with
SD. Test of significance was performed by Student’s t-test.
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Different phases of angiogenesis, such as sprouting, migration, and tube-like-structure formation,
require EC alignment and directional movement in response to angiogenic cues(193). To
understand why Myct1 KD ECs show defective migratory properties in the angiogenic
environment, we assessed the downstream effectors of Myct1 in regulating EC motility.
Specifically, we extracted RNA from sprouts formed in the fibrin gel matrix (see Figure 3.12E)
and performed a PCR array for genes that regulate cellular motility (Figure 3.13A). Genes that
regulate actin cytoskeleton dynamics and cell adhesion turnover such as Capn2, Actin, Actinr2 and
3, Cfl1, Rdx, Myl12a, and Wasf1 were downregulated in the Myct1 KD MCEC sprouts (Figure
3.13A). Rhoa and Rhoc, which are required for the formation of actin stress fibers, cell retraction
following protrusions, and overall movement(194), were also downregulated (Figure 3.13A),
implying that Rho GTPase signaling is defective in Myct1 KD cells. Intriguingly, elements of RAC
signaling, such as Rac1, Arhgef7, and Stat3, were upregulated in the Myct1 KD sprouts, suggesting
an unbalanced hyperactivation of RAC signaling, which regulates the formation of leading-edge
protrusion during cell movement(194). Consistent with this idea, Myct1 KD MCEC cells in both
2D culture (Figure 3.13B) and scattered 3D tube structures (Figure 3.13C) formed virtually no
stress fibers, which are critical for cellular contractility-relaxation, adhesion, and migration(195).
Notably, Arhgdia, a Rho GDP dissociation inhibitor that keeps Rho GTPase proteins in their
inactive forms(196), was highly upregulated in the Myct1 KD MCEC sprouts (Figure 3.13A),
again implying a dysregulated Rho GTPase signaling. Congruent with this idea, Arhgdia
knockdown moderately rescued the Myct1 KD MCEC phenotype (Figure 3.13D-F).
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Figure 3.13: MYCT1 regulates actin cytoskeleton dynamics in the angiogenic environment. (A) Qiagen Cell
motility PCR array was performed using RNA obtained from the parental and Myct1 KD MCEC sprouts formed in
the fibrin gel bead sprouting assay at 36 hours. Downregulated and upregulated genes in Myct1 KD sprout, compared
to parental sprouts, are shown in red and green, respectively. (B) Representative immunofluorescence images of actin
filaments in a cultured monolayer of MCEC cells. Phalloidin (green) and nuclei (DAPI, blue). Scale bars: 25 µm (C)
Representative immunofluorescence image of Phalloidin 488 (green) staining of actin filaments in 3D tubes of parental
and Myct1 KD MCEC cells plated on Matrigel. Nuclei counterstained with DAPI (blue). Scale bar: 200 µm (inset 60
µm). (D) qRT-PCR analysis of mouse Arhgdia gene expression in parental, Myct1 KD, and Myct1 KD Arhgdia KD
MCEC cells. n=3/group. **p<0.01. (E,F) Representative images and quantification for Arhgdia KD-mediated rescue
of Myct1 KD MCEC cell sprouting phenotype in fibrin gel bead sprouting angiogenesis assay (E) and migration
phenotype in Boyden chamber assay (F). Nuclei counterstained with DAPI (red) (F). Scale bar: 100µm. Data is
presented as mean with SD. Test of significance was performed by Student’s t-test (for two groups) or One-way
ANOVA with Tukey’s multiple comparison test (for more than two groups).
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Next, we characterized MYCT1 binding partners by taking a target-directed approach. Using
proteomics analysis, we identified ZO1 (Zona Occludens 1, also known as tight junction protein
1) and CKAP4 as potential candidates for binding MYCT1. We confirmed ZO1 and CKAP4 as
binding partners of MYCT1 by utilizing co-immunoprecipitation followed by western blot.
Intriguingly, we found that, although ZO1 and CKAP4 do not bind directly to each other, MYCT1
binds both of them together in a complex (Figures 3.14A and 3.14B). Immunofluorescence
observation also supported the interaction between MYCT1 and ZO1 by co-localization (Figure
3.14C). A similar binding pattern between MYCT1 and CKAP4 in HEK293T cells was also
reported in a previous study(197). Since ZO1 plays a critical role in EC functions such as barrier
formation, tension, and migration(198) and RHOA regulates endothelial tight junction
maintenance and barrier formation in close association with ZO1(199), we investigated whether
there is a functional interplay between MYCT1, ZO1, and RHOA through a series of combined
knockdown and overexpression of these genes in MCEC cells (Figure 3.14D). We found that
similar to Myct1 KD, downregulation of either Zo1 or Rhoa led to impaired sprouting and tube
formation of ECs in the angiogenic environment. These angiogenic defects of Myct1 deficient ECs
could be partially rescued by Zo1 overexpression and, vice versa (Figures 3.14E). We observed
similar, although to a somewhat lesser extent, interplay between Myct1 and Rhoa as well (Figures
3.14E), suggesting that MYCT1-ZO1 complex works in close functional association with RHOA
to control actin cytoskeleton. Intriguingly, both the parental and Myct1 KD cells responded
similarly to VEGF in a fibrin gel sprouting assay, suggesting that Myct1 might regulate ECs
angiogenic functionalities independently of VEGF (Figure 3.14F). Collectively, these data suggest
that MYCT1 regulates directional movement of ECs in the angiogenic environment through
controlling actin cytoskeleton dynamics.
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Figure 3.14: MYCT1 functionally supplement ZO1 and RHOA to regulate endothelial cells characteristics in
the angiogenic environment. (A) Immunoprecipitation followed by western blot (IP-WB) for MYCT1 of total cell
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lysates of the parental and HA-tagged MYCT1 overexpressing (HA-MYCT1) MCEC cells transfected with either
mock (empty vector control) or MYC-tagged ZO1, and FLAG-tagged CKAP4 expression plasmids. Anti-ACTIN
antibody was used as control. (B) IP-WB analysis for CKAP4 of total cell lysates of the parental MCEC cells
transfected with either mock (empty vector control), or MYC-tagged ZO1, or FLAG-tagged CKAP4 expression
plasmids. Anti-ACTIN antibody was used as control. (C) Representative immunofluorescence image of ZO1 (green)
and MYCT1 (anti-FLAG, red) in a confluent monolayer of FLAG-tagged MYCT1 overexpressing MCEC cells.
Nuclei (DAPI, blue). Scale bar: 20 µm (D) qRT-PCR analysis of Myct1, Zo1, and Rhoa expression in parental and
different genetically modified MCEC cells, as indicated. n=3/group. **p<0.01, ***p<0.001 (E) Representative
images and quantifications from the Matrigel tube formation assay and in fibrin gel bead sprouting angiogenesis assay
with different combinations of Myct1, Zo1, and Rhoa KD and overexpressing MCEC cells. “+”, “++”, and “-” denotes
wild-type, overexpression, and knockdown, respectively. n≥6/group. Scale bars: 250 µm and 100 µm. (F)
Representative images from and quantification for VEGF treatment of parental (WT) and Myct1 KD MCEC cells in
fibrin gel bead sprouting angiogenesis assay. Scale bars: 100 µm. Data is presented as mean with SD. Test of
significance was performed by Student’s t-test (for two groups) or One-way ANOVA with Tukey’s multiple
comparison test (for more than two groups).
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3.5.7 Endothelial MYCT1 function is evolutionarily conserved between
human and mouse
Mouse MYCT1 protein shares an 85% sequence identity with the human MYCT1 protein (Figure
3.15A)(192, 197). To determine whether MYCT1 function is conserved between human and
mouse, we knocked-down human MYCT1 in HUVEC (HUVEC hMKD) cells (Figure 3.16A).
Similar to the Myct1 KD MCEC cells, HUVEC hMKD cells displayed severely impaired tubelike-structure generation, sprout formation, and migration capabilities (Figures 3.16B-D).
Importantly, enforced expression of mouse Myct1 could almost completely rescue the human
MYCT1 KD defects and vice-versa in vitro (Figures 3.16B-G). Moreover, both the mouse and
human MYCT1 overexpression rescued the impaired tumor growth and reduced angiogenesis
phenotype of the Myct1 KO mice in a subcutaneous tumor transplantation model (Figures 3.16H
and 3.16I). Again, although the lentiviral treatment induced Myct1 over expression in tumor cells
and hematopoietic cells along with the ECs, as we described above (see Figures 3.9A-I), the
observed rescue of the tumor phenotype in this experiment is most likely from endothelial Myct1
(Figure 3.16J). Together, these data suggest that the MYCT1 function in EC is conserved between
human and mouse.
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Figure 3.15: MYCT1 protein is evolutionarily conserved between human and mouse. (A) Protein sequence
alignment computation for human and mouse MYCT1 using COBALT from NCBI.
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Figure 3.16: Endothelial MYCT1 function is evolutionarily conserved between human and mouse. (A) qRTPCR analysis of the mouse Myct1 and human MYCT1 gene expressions in parental and other different genetically
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modified MCEC and HUVEC cells, as indicated. n=3/group. **p<0.01, ***p<0.001. (B-D) Representative images
and quantifications from the Matrigel tube formation assay (B), Boyden chamber migration assay (C), and fibrin gel
bead sprouting angiogenesis assay (D) with parental, human MYCT1 KD (hMKD), and mouse Myct1 overexpressing
human MYCT1 KD (hMKD mMOE) HUVEC cells. Nuclei counterstained with DAPI (red) (B). Scale bar: 250 µm
(B) and 100 µm (C, D). n≥10/group. *p<0.05, **p<0.01. (E-G) Representative images and quantifications from the
Matrigel tube formation assay (E), Boyden chamber migration assay (F), and fibrin gel sprouting assay (G) with
parental, mouse Myct1 KD (mMKD), and human MYCT1 overexpressing mouse Myct1 KD (mMKD hMOE) MCEC
cells. Nuclei counterstained with DAPI (red) (F). Scale bar: 250µm (E) and 100µm (F,G). n≥10/group. *p<0.05,
**p<0.01. (H,I) Tumor growth (H) and representative immunofluorescence images with quantification for CD31+
vessel density (I) in PBS (control) and either mouse Myct1 or human MYCT1 lentiviral overexpression constructs
(intra-tumor) treated wild-type and Myct1 KO mice. CD31 (red), LLC (green), and nuclei (DAPI, blue). Scale bars:
100 µm. n.s. not significant and *p<0.05 at the end of the study. (J) Mouse Myct1 and human MYCT1 expressions in
the ECs (endothelial cells: GFP-CD31+CD45+), HCs (hematopoietic cells: GFP-CD45+ CD31-), and tumor cells
(GFP+CD31-CD45-) isolated from the tumors of empty vector (control), mouse Myct1 lentiviral overexpression
construct, and human MYCT1 lentiviral overexpression construct treated (intra-tumor) wild-type and Myct1 KO mice
with a LLC subcutaneous tumor model. n=3/group. ***p<0.001. Data is presented as mean with SD. Test of
significance was performed by Student’s t-test (for two groups) or One-way ANOVA with Tukey’s multiple
comparison test (for more than two groups).
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3.5.8 Analysis of mouse tumor endothelial transcriptome reveals Myct1
regulation of angiogenesis and immune responses.
To better understand the tumor endothelial heterogeneity and the potential role(s) of Myct1 in
tumor-ECs, we performed single-cell RNA-sequencing on sorted tumor-ECs from the PyMT-BO1
orthotopic tumor bearing WT and Cdh5-cre Myct1f/f mice using the 10X-genomics platform.
Unsupervised hierarchical and Seurat cell-clustering analysis (using a total of 965 ECs) revealed
heterogeneity in the tumor endothelium. We identified distinct clusters of angiogenic, tip-like,
stalk-like, proliferating, and transitionary ECs (Figures 3.17A and 3.17B). Compared to WT
tumor-ECs, Myct1 KO tumor-ECs had a vastly different transcriptional landscape, as evidenced
by the reduced angiogenic and tip-like cell populations that are enriched for biological processes
related to growth factor activities and invasive vascularization as per GSEA (gene set enrichment
analysis) (Figures 3.17C-H)(188). Whereas, Myct1 KO tumor-ECs had increased stalk-like and
transitionary cell populations that are enriched for biological processes related to leukocyte
transendothelial migration, oxidative phosphorylation, and antigen presentation and processing
(Figures 3.17I-N), collectively reflecting on the Myct1 requirement for aggressive tumor
angiogenesis and tumor immune modulation. We applied SCENIC (Single-cell rEgulatory
Network Inference and Clustering)(187), which scans co-expression of transcription factors and
putative target genes and found that WT and Myct1 KO tumor-ECs were in transcriptionally vastly
different cellular states (Figure 3.17O). While angiogenic transcriptional networks were driving
the gene expressions in WT tumor-ECs, transcription factors for immune responses were among
the prominent transcriptional drivers for gene expressions in Myct1 KO tumor-ECs (Figure 3.17P).
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Figure 3.17: Single cell RNA sequencing of tumor endothelium from WT and Cdh5-cre Myct1f/f mice. (A)
Schematic of tumor endothelium sample collection and processing from wildtype vs Cdh5-cre Myct1f/f mice (n = 5)
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for single cell RNA sequencing. (B) (Left) tSNE projection color-coded for 995 endothelial cells sorted from tumor
mass (PYMT BO1 orthotopic transplantation tumor model). (Right) tSNE projection grouped for different genotypes.
(C-N) Feature plots (C, F, I, L), gene set enrichment analyses (D, G, J, M), and normalized proportion of cells in WT
and Cdh5-cre Myct1f/f group (E, H, K, N) in different endothelial sub-clusters as indicated derived from the
SCTtransform data (normalized). (O,P) tSNE projection (O) and area under the curve (AUC) plots for differentially
enriched transcription factor activity modules (P) in WT and Cdh5-cre Myct1f/f tumor endothelium generated using
SCENIC.
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Additionally, we observed similar patterns of transcriptional activities even in the WT tumor-ECs
grouped as Myct1high and Myct1low expressing cells in one other tumor model. Briefly, we performed
single-cell RNA-sequencing on sorted tumor-ECs from the LLC subcutaneous transplantation
tumor model with only WT mice using the 10X-genomics platform. Unsupervised hierarchical
cell-clustering analysis (using a total of 1977 ECs) revealed a similar heterogeneity and Myct1
expression pattern in the tumor-ECs (Figures 3.18A-D). GSVA (Gene Set Variance Analysis) for
biological activities on the tumor-ECs based on high and low Myct1 expression levels revealed a
similar enrichment pattern as the WT vs Myct1 KO tumor-ECs. As such, Myct1low ECs were
enriched for biological processes related to leukocyte transendothelial migration, whereas
Myct1high ECs were enriched for processes related to active vascularization (Figures 3.18E).
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Figure 3.18: UMAP projection of endothelial cell sub-population in WT mice tumor by scRNAseq. (A) UMAP
scRNAseq projection color-coded for 1977 endothelial cells sorted from tumor mass of WT mice (LLC subcutaneous
transplantation tumor model). (B) DotPlot presentation for expression levels of top cluster-discriminating genes in
different endothelial subpopulation. (C) Feature plots for expression of denoted marker genes. (D) Feature plots
depicting expression levels of Pecam1, Flk1, and Myct1 genes. (E) GSVA (gene set variation analysis) of indicated
biological processes compared between cells grouped as high vs low Myct1 expression levels. Data is presented as
scatter plot with the mean value. Statistical significance was calculated by Mann-Whitney U test. **p<0.01 and
***p<0.001
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3.5.9 Myct1 deficiency leads to increased formation of high endothelial
venules (HEV) in mouse tumors and an overall immunostimulatory tumor
microenvironment.
While Myct1 KO mice exhibited reduced tumor vessel formation, we found that they developed
more intra-tumoral high endothelial venules (HEV) compared to the WT mice (Figure 3.19A-D).
HEVs are specialized vascular structures that mediate large scale lymphocyte extravasation in
lymphoid organs and inflammatory sites. In solid tumors, HEVs preferentially facilitate infiltration
of CD8+ cytotoxic T lymphocytes (CTL) into the tumor, and their presence is correlated with
reduced tumor growth and favorable prognosis in cancer patients(200). The potential role(s) of
Myct1 in leukocyte adhesion and endothelial transmigration (see Figures 3.17I-K and 3.18E) and
HEV formation (Figures 3.19A-D) suggest a possible alteration of tumor immune environment in
the Myct1 KO mice. Indeed, flow cytometric analysis revealed that tumors from Myct1 KO mice
exhibited an increase of CTLs and decrease of immunosuppressive regulatory T cells (Treg), as
evident by the increased ‘CD8-to-Treg ratios’ in all the tumor models (Figures 3.19E-G).
Likewise, tumors from Myct1 KO mice had an increased M1-macrophage population and a
decreased M2-macrophage population; further manifested by the increased ‘M1-to-M2 ratios’ in
all the tumor models (Figures 3.19E and 3.19F). Similar to the Myct1 KO mice, Etv2 conditional
KO mice exhibited normalization of tumor vasculature and an immunostimulatory tumor
microenvironment, as evident by the increased ‘CD8-to-Treg’ and ‘M1-to-M2’ ratios (Figure
3.19H; also see Figures 3.4J and 3.4K). Intriguingly, this anti-tumor immune environment was
reversed to a pro-tumor environment following enforced Myct1 expression (Figure 3.19H).
Moreover, analysis of the TCGA-derived cancer datasets using an immune-cell-deconvolution
algorithm from CIBERSORT revealed similar trends. Tumor samples with low MYCT1 expression
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showed decreased FOXP3 expression, a marker for regulatory T cells, and increased ‘M1-to-M2
ratio’ compared to the high expression group (Figure 3.19I). Additionally, in some cancer types,
tumor samples with low MYCT1 expression also exhibited higher frequencies of activated natural
killer (NK) cells and activated dendritic cells (DC) (Figure 3.19I). Collectively, these observations
suggest that Myct1 deficiency in tumor endothelial cells promotes an anti-tumor immune
microenvironment.
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Figure 3.19: Myct1 deficiency promotes immunostimulatory tumor microenvironment. (A-D) Representative
immunofluorescence images and quantification of MECA79+ high endothelial venules (HEVs) in 1956 sarcoma tumor
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(A), MMTV-PyMT spontaneous breast tumor (B), PyMT-BO1 orthotopic breast tumor (C), and LLC subcutaneous
tumor (D). CD31 (red), MECA79 (green), and nuclei (DAPI, blue). White dotted boxed area from the inset is presented
as zoomed in. Arrows in the inset indicate the MECA79 expressing vessels. Scale bars: 10 µm and 20 µm (inset).
**p<0.01. (E) CTL (CD8+ T cells) and Treg (CD4+FOXP3+ T cells) cells as a percentage of CD3+ T cells and M1
(iNOS+ macrophages) and M2 (CD206+ macrophage) populations as a percentage of F4/80+ cells. n=6/group.
**p<0.01. (F) CD8/Treg and M1/M2 ratios as measures of immunosuppression in the tumor microenvironment of
WT and Myct1 KO mice. n=6/group. *p<0.05, **p<0.01, n.s. not significant. (G) Representative immunofluorescence
images and quantification for the CD8+ T cells in wild-type and Myct1 KO mice with 1956 sarcoma tumor. CD8 (red)
and nuclei (DAPI, blue). Scale bars: 100 µm. **p<0.01. (H) CD8/Treg and M1/M2 ratios as the measures of immune
activation in the tumor microenvironment of WT, VEC-Cre;Etv2 CKO, and VEC-Cre;Etv2 CKO mice rescued with
Myct1 lentiviral overexpression construct in a LLC transplant tumor model. Tumor masses were collected at the end
of transplant studies as indicated in Figure 1. n=4/group. **p<0.01, n.s. not significant. (I) FOXP3 expression in high
vs. low MYCT1 expressing tumors in patients from the TCGA database and M1/M2 population ratios, activated NK
cell, and activated dendritic cell populations in high vs. low MYCT1 expressing tumors obtained by analyzing the
TCGA patient datasets with the CIBERSORT algorithm. Datasets utilized were BC (TCGA-BRCA), LAC (TCGALUAD), TT (TCGA-TGCT), SAC (TCGA-STAD), LSCC (TCGA-LUSC), CAC (TCGA-COAD), HNSCC (TCGAHNSC), OC (TCGA-OV), PC (TCGA-PRAD), PAC (TCGA-PDAC), Sarcoma (TCGA-SARC), CCRCC (TCGAKIRC), PRCC (TCGA-KIRP), and BLC (TCGA-BLCA). Data is presented mean with SD (A-H) or as scatter plot
with the mean value (I). *p<0.05, **p<0.01. Test of significance was performed by Student’s t-test or Mann-Whitney
U test (for two groups) or One-way ANOVA with Tukey’s multiple comparison test (for more than two groups).
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3.5.10

Vascular normalization-mediated tumor growth restriction observed

in Myct1 KO mice is dependent on adaptive immunity.
If, indeed, the increased CTLs in Myct1 KO tumor contributed to the tumor growth restriction, the
ablation of CTLs should restore the tumor growth. To this end, we utilized neutralizing antibodies
to deplete CD4+ and CD8+ T cell compartments in the tumor-bearing Myct1 KO mice and found
that the tumor growth restriction was completely abrogated (Figures 3.20A and 3.20B), suggesting
that presence of the adaptive immunity is essential for the anti-tumor activity of Myct1-mediated
tumor vessel normalization. This crosstalk between tumor vascular control and adaptive immunity
is partly IFNg-mediated. While IFNg neutralizing antibody abrogated tumor growth restriction
phenotype of Myct1 KO mice, mimicking the CD4+ and CD8+ T cell depletion, recombinant IFNg
treatment partially restored the phenotype in CD4+ and CD8+ T cell-depleted Myct1 KO mice
(Figure 3.20C). Together, our data demonstrate that Myct1-mediated tumor vascular control
actively shapes the tumor microenvironment through a close engagement with adaptive immunity.
Notably, we also observed a small but statistically significant (p<0.05) increase in tumor vessels
in the CD4+ and CD8+ T cell-depleted Myct1 KO mice (Figure 3.20D). This observation is similar
in principle to a previous report that depletion of CD8+ T cells was associated with a dramatic
increase in tumor microvascular frequency(201). However, the lack of Myct1 could be the reason
why we observed only a modest increase of tumor vasculature even after T cell depletion.
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Figure 3.20: Tumor restrictive phenotype in Myct1 KO mice is T cell dependent. (A) Representative FACS plots
for CD8+ T cells and CD4+ T cells in the peripheral blood and spleen of the IgG and combined anti-CD4 and anti-CD8
neutralizing antibody treated mice. (B) Tumor growth in either IgG or combined anti-CD4 and anti-CD8 neutralizing
antibody treated Myct1 KO mice. n=5/group. p<0.001 at the end of the study. (C) Tumor growth in either IgG, or antiIFNg neutralizing antibody, or combined anti-CD4 and anti-CD8 neutralizing antibody, or combined anti-CD4 and
anti-CD8 neutralizing antibody with IFNg cytokine treated Myct1 KO mice. ‘p-values’ are calculated at the end of the
study. (D) Representative immunofluorescence images and quantification for the CD8+ T cells in wild-type and Myct1
KO mice with 1956 sarcoma tumor. CD8 (red) and nuclei (DAPI, blue). Scale bars: 100 µm. **p<0.01. Data is
presented mean with SD. Test of significance was performed by Student’s t-test (for two groups) or One-way ANOVA
with Tukey’s multiple comparison test (for more than two groups).
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3.5.11

Myct1 deficient ECs promote T cell trafficking and skew macrophage

polarization in the angiogenic environment.
Since both the Myct1 KO and Myct1low tumor-ECs were enriched for leukocyte adhesion and
transendothelial migration (see Figures 3.17I-K and 3.18E), we first evaluated whether Myct1
deficient ECs support more T cell infiltration. By utilizing a modified T cell transendothelial
migration assay as described previously(202), we found that CD8+ T cells transmigrated through
Myct1 deficient EC barrier more compared to the WT EC barrier (Figure 3.21A). However, Treg
cells did not display any difference in transmigration between the WT or Myct1 deficient ECs
(Figure 3.21B). Mechanistically, Myct1 KO tumor-ECs showed increased expression of
endothelial adhesion molecules E-and P-selectin, ICAM-1, and VCAM-1 (Figures 3.21C and
3.21D). Moreover, Myct1 KO tumor-ECs had increased expression of Rac1 and associated effector
molecules such as Trio, Tiam, and Rhog (Figures 3.21C and 3.21D). This upregulation of the Rac1
mediated pathway is crucial as RAC1 inhibition by NSC23766 abrogated the increased T cell
migration phenotype (Figures 3.21A and 3.21B). Additionally, tumor endothelium is known to
express immune-suppressor molecules, such as PDL1, PDL2, Fas ligand, and TRAIL(203-206).
We found that the expression of Fas ligand (Faslg), which can induce apoptosis of infiltrating
CD8+ T cells by binding to the cognate FAS receptor(206), was downregulated in Myct1 KO
tumor-ECs (Figures 3.21E). We observed a similar trend in the tumor samples with low MYCT1
expression compared to the samples with high MYCT1 expression in some human cancer types
(Figure 3.21F). Finally, we investigated whether Myct1 expression in tumor endothelium had any
direct impact on macrophage polarization. In the presence of respective M1 or M2 polarizing
cytokines, Myct1 deficient ECs promoted more M1-like and less M2-like macrophage polarization
from monocytes (Figure 3.21G). Intriguingly, tumor-ECs in Myct1 KO mice showed reduced
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expression of Nos2 and Nos3 (Figures 3.21H and 3.21I), which have been shown to affect M1and M2-macrophage polarization(207-209), suggesting a potential role for NOS in the observed
anti-tumor macrophage skewing. Together, investigations provide a mechanistic explanation for
the observed anti-tumor T cell and macrophage remodeling phenotype in the Myct1 KO mice.
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Figure 3.21: Myct1 deficiency skews polarization of anti-tumor immune components. (A) Transendothelial
migration (TEM) of CD8+ T cells through parental and Myct1 KD MCEC cell barrier with TNFa and Rac1 inhibitor
NSC23766 pre-treatment. n.s. not significant, *p<0.05, **p<0.01. (B) Relative migration of CD4+FOXP3+ Treg cells
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through parental and Myct1 KD MCEC cell barrier that were or were not pretreated with Rac1 inhibitor NSC23766 in
a leukocyte transendothelial migration assay. **p<0.01, n.s. not significant. (C) mRNA expression of the indicated
genes in CD31+CD45- ECs isolated from the 1956 sarcoma tumors. n=4/group. *p<0.05, **p<0.01. (D) qRT-PCR
analysis of expression of the indicated genes in parental and Myct1 KD MCEC cells pre-treated with TNFa.
n=3/group. *p<0.05, **p<0.01, n.s. not significant. (E) qRT-PCR analysis of Faslg expression in CD31+CD45- ECs
isolated from the 1956 sarcoma tumors. n=4/group. *p<0.05, **p<0.01. (F) FASLG expression profile in high vs. low
MYCT1 expressing tumors in SAC (TCGA-STAD), LSCC (TCGA-LUSC), CAC (TCGA-COAD), OC (TCGA-OV),
PC (TCGA-PRAD), PAC (TCGA-PDAC), Sarcoma (TCGA-SARC), CCRCC (TCGA-KIRC), and PRCC (TCGAKIRP) patients from the TCGA database. *p<0.05, **p<0.01. (G) Polarization of peripheral blood-derived monocytes
to M1 or M2 phenotype with LPS+IFNg or IL4 cytokine treatment, respectively, in a coculture assay with either
parental or Myct1 KD MCEC cells, expressed as a percentage of F4/80+ macrophage population. *p<0.05, **p<0.01.
(H,I) Nos2 and Nos3 mRNA expression in CD31+CD45- ECs isolated from the 1956 sarcoma tumor (H) and in parental
and Myct1 KD MCEC cells pre-treated with TNFa (I). n=3 or more/group. *p<0.05, **p<0.01. Data is presented
mean with SD. Test of significance was performed by Student’s t-test (for two groups) or One-way ANOVA with
Tukey’s multiple comparison test (for more than two groups).
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3.5.12

Targeting of Myct1 improves anti-PD1 immunotherapy outcomes in

mice.
The success of the immune checkpoint blockade-mediated immunotherapeutic approach partially
relies on the presence of CTLs in the tumor microenvironment. Since our data show that Myct1
deficient tumor endothelium promotes CTL infiltration, inclusion of anti-PD1 to prevent CTL
exhaustion might provide a synergistic and superior treatment outcome. As such, we assessed the
efficacy and usefulness of the combined anti-Myct1 and anti-PD1 treatment approaches in both
anti-PD1-responsive and anti-PD1-refractory tumor models. First, we utilized an anti-PD1responsive 1956 sarcoma subcutaneous transplantation tumor model that responds completely to
an early-onset scheme of anti-PD1 treatment, but not to late onset schemes(189). To this end, we
validated different modalities of anti-PD1 therapy in this tumor model and found that a late-onset
treatment starting from 9-days post-tumor transplantation does not result in total regression, but
somewhat slows tumor progression with eventual complete relapse of the tumor in WT mice
(Figure 3.22A). We treated the tumor-bearing Myct1 KO mice with this late-onset anti-PD1
scheme and observed dramatic tumor regression within 12 days of treatment initiation (Figure
3.22B). This short-term regression led to a complete tumor regression in all but one treated mouse
(7 out of 8) (Figure 3.22C). Supporting our observation that endothelial-specific Myct1 regulates
the tumor growth and angiogenesis, Cdh5-cre Myct1f/f mice demonstrated a similar tumor
regression with this late-onset anti-PD1 treatment scheme (Figure 3.22D). To determine whether
a systemic anti-Myct1 approach confers similar anti-tumor activity, we utilized a Myct1 directed
siRNA-peptide nanoparticle treatment approach(144, 164) in WT mice either alone or in
combination with DC101 (a vascular endothelial growth factor receptor 2 (VEGFR2) blocking
antibody) and/or anti-PD1, following a similar late-onset treatment scheme (Figure 3.22E). We
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found that combined anti-PD1 and anti-Myct1 treatment restricted tumor progression in all the
treated mice (Figure 3.22E), with a complete regression in 25% of the mice (2 out of 8) (Figure
3.22F). In comparison, combined anti-PD1 and DC101 treatment also produced significant
(p<0.05), but to a somewhat lesser extent, short-term tumor growth restriction (Figure 3.22E),
with an eventual relapse of tumor growth in all the mice (Figure 3.22F). Remarkably, anti-PD1
treatment with the dual blockade of Myct1 and VEGFR2 resulted in a complete tumor regression
in all of the treated mice (Figure 3.22F). Since combined Myct1 siRNA and anti-PD1 treatment
resulted a complete tumor regression in 2 out of 8 mice (Figure 3.22F), while anti-PD1 treatment
in Myct1 KO mice led to complete tumor regression in 7 out of 8 mice (Figure 3.22C), we assessed
whether this was due to a sub-optimal Myct1siRNA treatment. We utilized an extended anti-Myct1
treatment approach that starts before the onset and continues even after the termination of the antiPD1 treatment. We found that this prolonged anti-Myct1 treatment resulted in the restriction of
tumor progression for a lengthier period, with about 60% mice showing complete tumor regression
(14 out of 24 mice) (Figure 3.22G).
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Figure 3.22: Combined Myct1 targeting improves the outcome of anti-PD1 immunotherapy. (A) Tumor growth
in 1956 sarcoma tumor bearing WT mice treated with anti-PD1 antibody in different schemes. Donut charts displaying
the percentage of subjects undergoing complete regression (green) and relapse (gray). (B) Tumor progression in 1956
sarcoma tumor bearing WT and Myct1 KO mice at 12-days after anti-PD1 treatment initiation. *p<0.05, **p<0.01,
***p<0.001. (C) Tumor growth in 1956 sarcoma tumor bearing WT and Myct1 KO mice treated with the anti-PD1
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antibody. (D) Tumor growth in 1956 sarcoma tumor bearing WT and Cdh5-cre Myct1f/f mice treated with the antiPD1 antibody. (E) Tumor progression in 1956 sarcoma tumor bearing WT mice at 13-days after treatment initiation
as indicated. *p<0.05, **p<0.01, ***p<0.001. (F) Tumor growth in 1956 sarcoma tumor bearing WT mice treated
with different treatments as indicated. (G) Tumor growth in WT mice treated with the anti-PD1 antibody in
combination with an extended anti-Myct1 siRNA-peptide nanoparticle treatment. Data is presented mean with SD.
Test of significance was performed by One-way ANOVA with Tukey’s multiple comparison test.
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Next, we assessed whether Myct1 targeting could sensitize the anti-PD1 refractory tumors. Here,
we utilized an orthotopic breast tumor model with PyMT-BO1 tumors that do not respond to antiPD1 treatment (Figure 3.23A). We treated the tumor bearing WT mice with Myct1 directed
siRNA-peptide nanoparticle either alone or in combination with DC101 and/or anti-PD1. Although
DC101 failed to induce any sensitivity to anti-PD1 treatment, combined anti-Myct1 and anti-PD1
treatment resulted in a substantial short-term tumor regression (Figure 3.23B), with a complete
tumor regression in 43% of the treated mice (3 out of 7) (Figure 3.23C). Intriguingly, similar to
the 1956 sarcoma model, dual blockade of Myct1 and VEGFR2 with anti-PD1 treatment generated
both the maximal short-term tumor restriction and long-term complete tumor regression (7 out of
8 mice) (Figure 3.23B and 3.23C), suggesting that the collective blockade of both the VEGF and
MYCT1 pathways might provide a better and longer-lasting vascular control that improves the
outcome of the anti-PD1 immunotherapy in both the sensitive and refractory tumor models.
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Figure 3.23: Combined Myct1 targeting sensitizes the resistant tumors to anti-PD1 immunotherapy. (A) Tumor
growth in PyMT-BO1 tumor bearing WT mice treated with anti-PD1 antibody in different schemes. Donut charts
displaying the percentage of subjects undergoing complete regression (green) and relapse (gray). (B) Tumor
progression in PyMT-BO1tumor bearing WT mice at 15-days after treatment initiation as indicated. **p<0.01,
***p<0.001, n.s. not significant. (C) Tumor growth in PyMT-BO1 tumor bearing WT mice treated with different
treatments as indicated. Data is presented mean with SD. Test of significance was performed by One-way ANOVA
with Tukey’s multiple comparison test.
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Dormant tumor cells can reinitiate tumor growth after treatment(210-212). To address if dormant
tumor cells still existed in these transplant tumor models after anti-Myct1 and anti-PD1 treatment,
we treated the tumor-regressed mice (pooled from the experiments with 1956 sarcoma tumor
model described in Figures 3.22F and 3.22G) with monoclonal neutralizing antibodies against
CD4, CD8, and IFNg, three major components of adaptive immunity. None of the tumor-regressed
mice developed any tumor mass even after the alleviation of the immune surveillance for a period
of over 90 days (Figure 3.24A), suggesting that the anti-PD1 treatment combined with anti-Myct1
targeting, with or without other anti-angiogenics, not only brought complete tumor regression but
also destroyed any potential dormant tumor(s) residing in the equilibrium phase. Intriguingly, rechallenging both the tumor-regressed mice (pooled from the experiment with PyMT-BO1 tumor
model described in Figure 3.23B) and naïve control mice with the PyMT-BO1 tumor cells resulted
in an unrestrained tumor growth without any statistical difference (Figure 3.24B), suggesting that
anti-Myct1 and anti-PD1 combination treatment did not induce long-lived immunological
memory.
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Figure 3.24: Combined anti-Myct1 and anti-PD1 treatment clears dormant tumor niche. (A) Tumor growth in
1956 sarcoma tumor-regressed WT mice (pooled from experiments described in Figures 7E and 7F) with weekly
treatment anti-CD4, anti-CD8, and anti-IFNg neutralizing antibodies for duration as indicated. (B) Tumor growth in
PyMT-BO1 tumor-regressed WT mice (pooled from experiment described in Figure 7H) re-challenged with PyMTBO1 cells 90 days after primary tumor regression along with naïve mice.
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To further understand how Myct1-directed siRNA-peptide nanoparticle treatment improves the
outcome of the anti-PD1 immunotherapy, we harvested and analyzed the tumor masses seven days
after the treatment initiation in the anti-PD1 refractory PyMT-BO1 tumor model, at a time when
the tumors just started to respond to the combination treatment (Figure 3.25A). Flow cytometric
analysis revealed that anti-Myct1 treatment increased CTLs and M1 macrophages, while reduced
the Treg cells and M2 macrophages. Conversely, anti-PD1 treatment increased the percentage of
Granzyme B+ CTLs, however, did not alter the immune microenvironment. Notably, anti-Myct1
and anti-PD1 combined treatment increased both the influx of CTLs and the percentage of
Granzyme B+ CTLs, suggesting that the combination treatment produces a considerably superior
tumor control due to the additive nature of the individual treatments on CTLs (Figure 3.25B).
Immunofluorescence observations supported this conclusion that anti-Myct1 treatment reduced
angiogenesis, improved vascular normalization, and increased the infiltration of CD8+ T cells
(Figure 3.25C-F). Intriguingly, although siRNA-peptide nanoparticle treatment downregulated
Myct1 expression in both the tumor and non-tumor endothelium (Figure 3.25G), unlike in the
tumor masses, there were no alterations in the immune constituents of the non-tumor tissues
(Figure 3.25H). We observed a similar modification of immune constituents of the tumor masses
in the Myct1 KO mice with the anti-PD1 treatment, supporting the notion of the additive nature of
the treatments (Figures 3.26A and 3.26B).
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Figure 3.25: Anti-Myct1 works synergistically with anti-PD1 to improve the outcome. (A) Tumor growth in
PyMT-BO1 tumor bearing WT mice treated with different treatments as indicated. (B) CTL (CD8+ T cells) and Treg
(CD4+FOXP3+ T cells) cells as a percentage of CD3+ T cells, GranzB+ CTL as % of CTL cells, M1 (iNOS+
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macrophages) and M2 (CD206+ macrophage) populations as a percentage of F4/80+ cells in the tumor of the PyMTBO1 tumor bearing WT mice treated with different combination of treatments, as indicated. n=3-6/group. *p<0.05,
**p<0.01. (C-F) representative images (C-E) and quantifications (F) for CD31+ vascular density (C), pericyte
coverage (D), and CD8+ T cell infiltration (E) in the tumor of PyMT-BO1 tumor bearing WT mice treated with
different combination of treatments, as indicated. n=3-6/group. **p<0.01. (G) Myct1 expression in the ECs
(CD31+CD45-) sorted from the PyMT-BO1 tumors of WT mice treated with different combination of treatments, as
indicated. n=3-6/group. *p<0.05, **p<0.01. (H) CTL (CD8+ T cells) and Treg (CD4+FOXP3+ T cells) cells as a
percentage of CD3+ T cells and F4/80+ macrophages as a percentage of CD45+ cells in the lungs and heart of the
PyMT-BO1 tumor bearing WT mice treated with different combination of treatments, as indicated. n=3-6/group. Data
is presented mean with SD. Test of significance was performed by One-way ANOVA with Tukey’s multiple
comparison test.
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Figure 3.26: Myct1 deficiency acts synergistically with anti-PD1 to improve the outcome. (A) Tumor growth in
PyMT-BO1 tumor bearing WT and Myct1 KO mice treated with anti-PD1. (B) CTL (CD8+ T cells) and Treg
(CD4+FOXP3+ T cells) cells as a percentage of CD3+ T cells, GranzB+ CTL as % of CTL cells, M1 (iNOS+
macrophages) and M2 (CD206+ macrophage) populations as a percentage of F4/80+ cells, and F4/80+ macrophages as
a percentage of CD45+ cells in the tumor, lungs, and heart of the PyMT-BO1 tumor bearing WT and Myct1 KO mice.
n=4/group. *p<0.05, **p<0.01. Data is presented mean with SD. Test of significance was performed by One-way
ANOVA with Tukey’s multiple comparison test.
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Downregulation of Myct1 by the nanoparticles led to the upregulation of several adhesion
molecules, among which Selp and Icam1 reached statistical significance (p<0.05), only in the
tumor endothelium but not in the non-tumor tissues (Figures 3.27A), corroborating with the
observation in the Myct1 KO mice (see Figure 3.21C). Importantly, Myct1-directed siRNA-peptide
nanoparticle treatment largely did not induce any non-specific immune responses in either the
tumor-infiltrating hematopoietic cells or tumor cells (Figures 3.28A and 3.28B). Collectively,
these suggest that Myct1 targeting generates tumor-EC focused changes that allows anti-PD1
treatment to mount more effective anti-tumor responses.
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Figure 3.27: Combined Myct1 and PD1 targeting does not induce off-target effects. (A) Expression of the
indicated genes in the tumor, lung, and heart ECs sorted from the PyMT-BO1 tumors of WT mice treated with different
combination of treatments, as indicated. n=3-6/group. Data is presented as mean with SD. Test of significance was
performed by One-way ANOVA with Tukey’s multiple comparison test. *p<0.05, **p<0.01.
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Figure 3.28: Combined Myct1 and PD1 targeting does not trigger non-specific immune activation. (A)
Expression of the indicated genes in the tumor hematopoietic cells (HC) and tumor cells sorted from the PyMT-BO1
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tumors of WT mice treated with different combination of treatments, as indicated. n=3-6/group. *p<0.05, **p<0.01.
(C) Expression of the indicated genes in the cultured PyMT-BO1 tumor cells treated with PBS or scrambled siRNA
or Myct1 siRNA nanoparticle. n=3/group. Data is presented as mean with SD. Test of significance was performed by
One-way ANOVA with Tukey’s multiple comparison test.
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3.6 Discussion
Herein, we have demonstrated that Myct1 is a regulator of angiogenesis downstream of ETV2.
Myct1 was first identified as a direct target gene of c-MYC in myeloid cells, as well as in laryngeal
squamous cell carcinoma cells, in the context of c-MYC overexpression(213, 214). However,
analysis of published scRNA sequencing datasets from different mouse organs revealed that Myct1
expression is mostly restricted to ECs and hematopoietic stem and progenitor cells. We found that
Myct1 is not required for blood and vascular development, as evidenced by the normal breeding,
development, and cardiovascular functions of Myct1 KO mice. Instead, Myct1 seems to regulate
acute angiogenic demand in pathological conditions such as cancer. We observed that Myct1
expression was upregulated exclusively in tumor-ECs. Myct1 KO mice showed a severe reduction
of tumor angiogenesis and tumor growth, while improving tumor vascular normalization. Notably,
data from human patients with varying MYCT1 expression across multiple different cancer types
also suggest that MYCT1 is positively correlated with the angiogenic status of the cancers.
Importantly, in the mouse models, hematopoietic Myct1 expression deemed non-relevant for tumor
progression. Enforced Myct1 expression or Myct1 shRNA/siRNA treatments in fibroblast or tumor
cells also did not play any role in tumorigenesis, supporting the notion of an endothelial-intrinsic
function.
Complex cellular processes like directional movement and migration require highly
coordinated and localized organization of actin cytoskeleton manifested by continuous initiation,
polarized growth, and turnover of the actin filaments(215). Different aspects of this process are
reported to be regulated by distinct molecular pathways, for instance, protrusion of the leading
edge requires the activity of Rac GTPases, whereas contraction and pulling the cell forward
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requires Rho GTPases(194, 195). We found that Myct1 deficient ECs show reduced expression of
actin skeleton forming and remodeling proteins, reduced actin network and stress fibers, and an
imbalance between the Rho and Rac GTPases, probably contributing to a severe impairment in
angiogenic responses. Notably, Myct1 deficient EC motility was partially rescued by Arhgdia
knock-down, further supporting the notion that Myct1 regulates endothelial motility through Rho
GTPases and the actin cytoskeleton. Tight junction scaffolding proteins, such as ZO1, ZO2, and
ZO3, link tight junction transmembrane proteins such as CLAUDIN and OCCLUDIN to the actin
cytoskeleton to regulate endothelial adhesion, migration, and barrier functions(216). A recent
report also revealed that ZO1 is critical for EC functions such as barrier formation, tension and
migration, and angiogenesis(198). The finding that MYCT1 binds to both the ZO1 and CKAP4
and forms a complex further suggests a regulatory role for Myct1 in the actin cytoskeleton
dynamics for cellular movement. It will be necessary to further delineate the crosstalk among
MYCT1, ZO1, Rho GTPases, and CKAP4 in regulating the actin cytoskeleton and EC motility.
Myct1 deficient tumor vasculature is characterized by having more HEVs, facilitating
CTLs infiltration, and promoting anti-tumor macrophage polarization. Particularly, Myct1
deficient ECs show increased expression of adhesion molecules and manifest hyperactivation of
the Rac1-mediated machinery for enhanced T cell extravasation. Tumor vessels inhibit CTLs
activation and promote apoptosis of the infiltrating immune cells in part by upregulating
immunosuppressive molecules, PDL1, PDL2, Fas ligand, and TRAIL(203-206). We found that
Myct1 deficient ECs downregulate the expression of Fas ligand. We also found a similar trend
with human cancers with reduced MYCT1 expression. The Fas ligand is a pro-apoptotic member
of the tumor necrosis factor (TNF) superfamily that induces apoptosis in activated CTLs(206). Our
data suggest that Myct1 deficient endothelium promotes an immunostimulatory microenvironment
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by enhancing CTLs infiltration and presumably by preventing CTLs apoptosis. Moreover, it has
been reported that inducible-NOS (NOS2) inhibits the M1-macrophage population, whereas
endothelial-NOS (NOS3) promotes the M2-macrophage polarization(207-209). Notably, the
expressions of Nos2 and Nos3 were decreased in Myct1 deficient ECs, suggesting that enhanced
anti-tumor macrophage polarization in Myct1 deficient tumor microenvironments may, in part,
through the regulation of NO production of ECs. These findings collectively provide mechanistic
insights into Myct1 deficient tumor vessels contributing to an immunostimulatory
microenvironment.
Vascular normalization has been implicated to influence local tumor immune
environment(217, 218). However, the molecular targets like VEGF and associated pathways also
impact the immune cells in an endothelial cell-independent manner(219-222), raising a possibility
of synergistic and/or independent effect rather than a sole consequence of vascular normalization
on the tumor immune components. Myct1 targeting in endothelial cells leading to an anti-tumor
microenvironment provides a more definitive evidence for endothelial regulation of tumor
immunity. Notably, the beneficial outcomes of Myct1 targeting in the tumor are dependent on the
presence of functional adaptive immunity as depletion of either CD4+ and CD8+ T cell populations
or neutralization of IFNg abrogated the Myct1 KO phenotype. This data is consistent with the
human cancer datasets that show the increased presence of immunostimulatory components in
tumors with lower MYCT1 expression. Our finding supports the emerging notion that combined
vascular and immune control would provide a synergistic anti-tumor activity(90, 223, 224).
Indeed, our data demonstrate that targeting Myct1 significantly improves the response to suboptimal anti-PD1 therapy in treatment-responsive tumors. More importantly, Myct1 targeting
induces sensitivity to anti-PD1 therapy in treatment-refractory tumors, as evident by the complete
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tumor-regression and long-term survival. Anti-Myct1 treatment works additively with anti-PD1
for an effective CTL response in tumor. Importantly, we observed that combined Myct1 and VEGF
targeting with anti-PD1 treatment produced a superior tumor control, suggesting a potential
synergy between Myct1 and VEGF pathways.
Our study’s limitations include that our data on Myct1 expression in tumor endothelium is
confined to RNA, not including protein, due to the unavailability of antibodies against MYCT1.
Additionally, our data on immune modulation are limited to CTL infiltration and M1 polarization.
Global changes in tumor immunity by endothelial-specific Myct1 deficiency need to be further
elucidated to better understand the crosstalk between angiogenesis and tumor immunity. Lastly,
while siRNA-nanoparticle-mediated Myct1 targeting has provided proof of concept, it would be
valuable to develop and validate an antibody-mediated MYCT1 blocking approach to realize the
therapeutic potential of MYCT1 inhibition.
In summary, we have identified Myct1 as a regulator of tumor angiogenesis. Myct1
deficient ECs display suboptimal angiogenesis, facilitate HEV formation, enhance robust CTL
infiltration, and promote inflammatory M1 macrophage polarization. Anti-PD1 antibody treatment
in the context of Myct1 inhibition augments complete tumor elimination in mouse models of tumor,
presumably by preventing exhaustion of the infiltrating CTLs. We propose that combined Myct1inhibition and immunotherapy might be a superior treatment regimen for cancer patients. The
observation that Myct1 encodes a membrane-spanning protein makes it an attractive target for the
development of small molecule inhibitors and/or blocking antibodies. MYCT1 function in ECs is
conserved between human and mouse, signifying the potential for successful clinical translation
of the findings of the mouse studies.
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Chapter 4: Conclusion and future directions
No other pathological condition, except death, the seemingly inevitable fate for everyone, healthy
and diseased alike, has been as elusive and resistant to human beings' collective efforts as cancer.
With the increase in life expectancies, which is accompanied by sedentary lifestyles, an abundance
of foods, and harmful changes in the environment, comes the associated accelerated increases in
cancer incidence and resulting mortality. The risk cancer poses to our existence is now more than
ever, and this will only be worse unless we are successful in fighting this deadly disease. Although
cancer treatment has not been a success story yet, the progress made through the painstaking and
diligent efforts of more than a century of modern medical research has firmly established our
understanding of cancer biology and identified various therapeutics approaches. The advent of
advanced tools, such as high-throughput deep sequencing techniques, DNA editing tools like
CRISPR, and powerful cloud-based computer technology to efficiently handle big datasets, to
name a few, has now made it possible to build on the progress achieved so far and take cancer
research to a whole new level where we will finally be able to combat this disease successfully.
Normal cells go through a transformation process to become cancerous cells by acquiring
a set of traits commonly referred to as hallmarks of cancer. These hallmark characteristics include
favorable regulation of growth signaling, inactivation of cellular death programs, genomic
instability, altered metabolism tailored for unrelenting growth, sustained angiogenesis, evasion of
immune surveillance, and metastasis. Different aspects of these characteristics have been subjects
of ongoing research and have demonstrated the potentials to be targeted therapeutically in cancer
patients. Unsurprisingly, concomitant targeting of the regulators of different hallmark traits has
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shown to be yet more promising. Investigations are underway towards an even better
understanding of these unique cancer features and more insight into the mechanistic nature of the
combined targeting.
Among the hallmark cancer characteristics, angiogenesis is an essential and rate-limiting
phenomenon for cancer growth and metastasis. Endothelial cells that line the lumen of the vascular
system are among the longest-lived cells of the body and maintain a quiescent state; in response
to certain stressors such as tissue injury, however, they transiently enter into the cell cycle to
generate new vessels from the existing ones in the process that is called angiogenesis. Once the
vascular system is re-established in the injured area, and the tissue repair process is complete,
angiogenesis stops, and endothelial cells revert to their quiescent state. During solid tumor growth,
cancer cells commandeer this process to their advantage to form a tumor vasculature system,
which, unlike in the physiological conditions, never retreats to a quiescent state and keeps
expanding for sustained tumor growth. Targeting this process has long been considered as a highly
potential anti-tumor treatment strategy.
Different angiogenic regulators have been identified, most prominently in the VEGF and
FGF pathways, and tried as a potential anti-angiogenic treatment in the tumor. Although these
targeting approaches achieved reasonable tumor control in pre-clinical mouse models and
somewhat diminished responses in cancer patients in clinics, providing the proof of concept for
the usefulness of anti-angiogenic treatments, they never generated complete and durable tumor
regression in either mouse models or patients(70, 79, 103). This has led current research into
further exploring vascular biology for novel therapeutic targets and finding ways to combine the
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benefits of tumor angiogenic control with other classes of anti-cancer treatments, such as
chemotherapy and immunotherapy.
In this body of work, I, with my colleagues and collaborators, have identified the Etv2Myct1 axis as a novel endothelial-specific regulator of tumor angiogenesis. ETS transcription
factor Etv2 is a master regulator of blood and vascular system development. During the early
embryonic development, Etv2 expression plays an essential and indispensable role in the
specification of hematopoietic and endothelial cells by switching the transcriptions of the ETS
family of transcription factors(111-121, 126-130). After this instructive roleplay, Etv2 expression
gets downregulated, and it stays silent throughout the healthy adult life. Although silent in the
healthy vasculature, our lab previously found that Etv2 expression gets restarted in the angiogenic
endothelial cells of the injured tissue(131). I started my dissertation research work with the leading
question of whether Etv2 expression is relevant to tumor angiogenesis. We found that endothelial
cells began to express Etv2 after the tumor transplantation, and this expression was limited to the
tumor-associated endothelial cells. By utilizing the Tie2-Cre, VEC-Cre, VAV-cre Etv2 conditional
knockout mouse models, we established that this reactivation of Etv2 expression in the tumor
endothelial cells is essential for tumor angiogenesis and tumor growth. Etv2 deficiency reverts
tumor vasculature to a steady-state-like quiescent phenotype, both morphologically as evident by
the decreased tortuousness, branching, and leakiness of the vessels and systematically as evident
by the diminished proliferation and responsiveness to growth factor signaling. We found that
reactive oxygen species trigger Etv2 expression in the endothelial cells. It is known that the tumor
mass is hypoxic in nature(3, 93, 140). The resulted oxidative stress present in the tumor mass could
start Etv2 expression and kickstart the angiogenic switch; reducing this oxidative stress could be a
strategy to control tumor angiogenesis. Such a notion is not novel, and antioxidant therapies were
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previously reported to be reducing tumor progression(139, 141). We, too, found in our mouse
model that treating the tumor-bearing mice with a reactive oxygen species scavenger leads to a
lower Etv2 expression and moderately restricted tumor growth. Therapeutically targeting the Etv2
pathway is beneficial, as we found that siRNA nanoparticle-mediated downregulation of Etv2
restricted tumor angiogenesis and tumor growth. However, as a transcription factor, Etv2 is not
exactly an ideal candidate for drug development, and I aimed to explore the downstream of the
Etv2 pathway that regulates endothelial cells and controls angiogenesis.
At this point, I utilized the Etv2 ChIP-seq and microarray datasets previously published by
our lab to identify Etv2 direct target genes(118). Next, we developed an angiogenic regulatory
gene signature from TCGA cancer patient datasets. Although few such gene signatures exist today,
they only focus on certain cancers(169, 171). In contrast, our developed signature encompassed
thirteen different cancer types to reflect universal tumor angiogenic mechanism irrespective of the
cancer types. We found several of Etv2 direct target genes to be in our developed signature's top
genes, among which Myct1 was a novel gene for angiogenic functionality. Significantly, Myct1 is
expressed almost exclusively in the endothelial cells. Although the quiescent endothelial cells
express Myct1 at a basal level, tumor-associated endothelial cells express very high levels of
Myct1. Myct1 is downregulated in the Etv2 conditional knockout mice and enforced Myct1
expression rescued Etv2 deficiency tumor phenotype, suggesting a potential relaying of Etv2
function by Myct1 in the tumor-associated endothelial cells. Indeed, Myct1 deficient mice,
generated either through global knockout or endothelial-specific Cdh5-cre conditional knockout,
displayed decreased tumor angiogenesis and restricted tumor growth. Like with the Etv2
deficiency, Myct1 deficient tumor vessels were functionally more normalized with increased
pericyte coverage and perfusion efficiency and decreased leakiness and hypoxic environment.
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Although ubiquitously expressed by the endothelial cells, unlike other angiogenic factors, for
example, VEGFs, Myct1 is neither essential for vascular development nor required for homeostatic
maintenance of endothelial cells, which makes it an attractive molecule to target tumor
angiogenesis. Mechanistically, unlike other angiogenic factors or even Etv2, Myct1 deficiency
does not seem to curb endothelial proliferation or responsiveness to growth factor signaling.
However, Myct1 deficiency severely impairs the angiogenic migration of the endothelial cells.
Myct1 physically interacts with tight junction protein ZO1 and functionally interacts with Rho
GTPases to control cellular actin dynamics and directional migration. Similar to Etv2, siRNA
nanoparticle-mediated downregulation of Myct1 reduced tumor angiogenesis and restricted tumor
growth, implying its therapeutic potential as an anti-angiogenic approach. Myct1 protein is
membrane-localized, making antibody-mediated targeting a real possibility that would need to be
explored in future studies.
Although almost exclusively an endothelial gene, Myct1 deficiency leads not only to
vascular control but also a change in the tumor immune microenvironment. We found that Myct1
deficient tumors had more anti-tumor cytotoxic T cells and less pro-tumor regulatory T cell and
M2 macrophages, potentially explaining the observed tumor growth restriction phenotype. This
shift in the immune microenvironment is also trending in human cancer patients stratified by the
relative Myct1 expression. The tumor growth restrictive outcome of Myct1 targeting is likely to be
a combined outcome of both the vascular normalization and enhancement of anti-tumor immunity,
as evident by our immune compartment depletion studies with Myct1 knockout mice. Because the
success of the checkpoint blockade immunotherapy heavily depends on the availability of CTLs
in the tumor and Myct1 deficient mice show increased infiltration of CTLs in the tumor, combined
targeting of Myct1 and immune checkpoint molecules such as PD1 could provide a synergistic
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anti-tumor outcome. Indeed, siRNA nanoparticle-mediated Myct1 and antibody-mediated PD1
combined targeting generated durable complete regression in both the anti-PD1 sensitive and nonsensitive mouse models of the tumor. Recent pre-clinical studies in the last few years have also
reported similar benefits, although of varying degrees, of combining immune checkpoint blockade
therapies with anti-angiogenic treatments(98, 99, 162, 163). Considering these data from our
studies and others, a combination of vascular control and immune checkpoint blockade strategy in
cancer patients seems promising for better clinical responses. Most importantly, several clinical
trials have demonstrated superior clinical outcomes for the combined anti-angiogenic and immune
checkpoint blockade treatments in a few cancer types. The FDA has already approved some of
these combinations for treating specific patients with renal cell carcinoma, non-squamous nonsmall cell lung cancer, and endometrial cancer(85, 98). Our data suggest that Myct1 targeting
mediated tumor endothelial control could offer a better outcome for the combination treatment
strategies.
As I have discussed already, Myct1 deficiency led to an anti-tumor immune
microenvironment. To understand how tumor endothelial control could generate such a response,
we investigated phenotypic and molecular signatures of the tumor vasculature. We found that
Myct1 deficient tumor vasculature, along with the phenotypic vascular normalization, had
increased incidence of HEVs, which are known to act as a gateway for large-scale CTL infiltration
in solid tumors. At the transcriptomic level, Myct1 deficient tumor endothelial cells had
upregulation of CTL endothelial transmigration pathways, which control the tumor infiltration of
CTLs. Together, our data suggest that the anti-tumor immune environment observed in the Myct1
deficient mice is not a mere outcome of reducing the angiogenesis or normalization of the vessels;
instead, the endothelial cells play an active regulatory role in modeling the immune environment.
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Intriguingly, our single-cell transcriptomic level data of the Myct1 deficient tumor endothelial cells
suggested the presence of potential transitionary and immunoregulatory endothelial cell
populations and an overall upregulation of antigen presentation pathways. This raises the
possibility of endothelial cells acting as potential antigen-presenting cells and playing an
instructive role in shaping the tumor immune microenvironment. Very recently, such endothelial
cell populations are also observed by few other groups in both healthy and inflammatory
tissues(225-228). To investigate this potential instructive role of endothelial cells, further studies
focusing on the tumor-infiltrating leukocyte population under Myct1 deficiency-mediated vascular
control at the transcriptomic and epigenetic levels are warranted. Moreover, extensive lineage
tracing studies to delineate the extent and impact of the potential endothelial to immune-cells-like
cell transition or de-differentiation in the context of tumor microenvironment would be of
significant contribution to our understating of cancer biology.
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